 
Official Title:  Phase III, Randomized, Double- Blind, Placebo- Controlled, Multicenter 
Study to Evaluate the Efficacy (Maintenance of Remission) and 
Safety of Etrolizumab Compared With Placebo in Patients With 
Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors  
Study ID: [REMOVED]  
Document  Date : Protocol  Version 7: 27-Aug-2018  
 
 
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2002PROTOCOL AMENDMENT APPROVA L
CONFIDENTIA L
This clinical study is being sponsored globally by F. Hoffmann -La [COMPANY_002] Ltd of Basel, 
Switzerland. However, it may be implemented in individual countries by [CONTACT_26702]’s local affiliates, 
including Genentech, Inc. in the [LOCATION_002].  The information contain ed in this document, especially 
any unpublished data, is the property of F.Hoffmann -La [COMPANY_002] Ltd (or u nder its control) and therefore 
is provided to you in confidence as an investigator, potential investigator, or consultant, for review by 
[CONTACT_10825], your staff , and an applicable Ethics Committee or Institutional Review Board.  It is understood that 
this information will not be disclosed to others without written authorization from [COMPANY_002] except to the 
extent necessary to obtain informed consent from persons to w hom the drug may  be administered.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
Protocol GA29102, Version 7PROTOCOL
TITLE: PHA SE III, RA NDOMIZED, DOUBLE -BLIND, 
PLACEBO -CONTROLLED, MULTICENTER STUDY 
TOEVALUATE THE EFFICA CY (MA INTENA NCE 
OFREMISSION) A ND SA FETY OF ETROLIZUMA B 
COMPA RED WITH PLA CEBO IN P ATIENTS WITH 
MODERA TE TO SEVERE A CTIVE ULCERA TIVE 
COLITIS WHO A RE NAIVE TO TNF INHIBITORS
PROTOCOL NUMBER: GA29102
VERSION NUMBER: [ADDRESS_1073890] NUMBER: 2013 -004280 -31
IND NUMBER: [ADDRESS_1073891]: Etrolizumab (PRO145223, RO5490261)
MEDICA L MONITOR: , M.D., M.S.
SPONSOR: F. Hoffmann -La [COMPANY_002] Ltd
DATE FINA L: Version 1:  20 December 2013
DATES AMENDED: Version 2:  3 April 2014
Version 3:  8 July 2014
Version 4:  [ADDRESS_1073892] 2014
Version 5:  [ADDRESS_1073893] 2015
Version 6 :  [ADDRESS_1073894] 2017
Version 7:   See electronic date stamp below. 
27-Aug-2018 07:34:08Title Approver's Name
[CONTACT_781284] (UTC)

Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2003Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
2/Protocol GA [ZIP_CODE] , Version 7PROTOCOL A MENDMENT, VERSION 7:
RATIONA LE
Protocol GA2 [ADDRESS_1073895] at the site level. The 
changes made to the protocol are as follows:
The primary efficacy endpoint has been changed to remission at Week 62for 
patients who achieve clinical response (rather than remission) at Week 10.  This
change has been made to align with clinical practice standards whereby [CONTACT_781241] a clinical response during treatment induction continue on treatment 
and ar e assessed for remission at a later time point (Sections 2.1, 3.4.1, 6.1, and 
6.4.1, Figure 1 and Figure 3).
To assess the onset of action of etrolizumab, a secondary efficacy endpoint of 
change in Mayo Clinic Score (MCS) rectal bleeding and stool frequenc y subscores 
from baseline to Week 6 has been added (Sections 2.1, 3.4.1, and 6.4.2).
Secondary and exploratory efficacy endpoints have been amended to align with the 
revision of the primary efficacy endpoint (Sections 2.1, 3.4.1 and 6.4.2).
Histologic remi ssion, defined as a Nancy histological index of 1, has been added 
as a secondary efficacy outcome measure. The definition is based on consensus 
guidelines recommending that histologic remission should be defined by [CONTACT_781242] (Section 2.1, 3.4.1, 6.4.2 
Appendix 12 and Table 1 ).
Janus kinase inhibitors have been added to the list of rescue therapi[INVESTIGATOR_760419] ( Sections [IP_ADDRESS], [IP_ADDRESS], and 4.4.2 ).
Exclusion criteria have been amended to include any treatment with tofacitinib 
during screening as this drug has been approved for use in the [LOCATION_002] and 
European Union and is no longer an investigational product ( Section 4.1.2 ).
The exclusion criterion related to eligibility following receipt of investigational 
treatments has been modified to account for current molecules in development for 
the treatment of inflammatory bowel disease.  The allowable time period after 
treatment has been reduced to [ADDRESS_1073896] dose, (whichever is greater) prior to Day 1 of the study ( Section 4.1.2 ).
Derivation of the MCS endoscopic subscore at post -baseline timepoints has been 
amended to be consistent with emerging normative standards of endoscopic 
assessment in clinical trials (Sandborn etal.2017).  The sigmoid colon MCS 
endoscopic subscore will be used (rather than the score from the worst affected 
segment, i.e., rectum, sigmoid colon, or descending colon) if the baseline sigmoid 
colon MCS endoscopic subscore is 2 3. The sigmoid colon MCS endoscopic 
subscore is considered to be more reliable in assessing earlier treatment response 
(Section [IP_ADDRESS] and Appendix 4).
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2004Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
3/Protocol GA [ZIP_CODE] , Version 7Histologic activity on colon biopsies will be measured using the Nancy histological 
index instead of the Geboes scale .  The Geboes scale was designed to characterize 
all types of mucosal inflammation related to ulcerative colitis but was not designed 
to easily compare differences i n histologic activity over time in th e context of a 
clinical trial.  On the other hand, the Nancy histological index was developed and 
validated to capture meaningful changes in key histologic features of ulcerative 
colitis andcan be easily applied in a clinical trial setting ( Sections [IP_ADDRESS] and 
Appendix 12 ).
Procedures for adverse event reporting have been updated to clarify that adverse 
event reports will not be derived from patient -reported outcome (PRO) data and 
safety analyses will not be performed using PRO data .  Sites are not expected to 
review the PRO data for adverse events ( Section [IP_ADDRESS] ).
Language regarding local injection -site reactions has been clarified in Table 5, 
"Guidelines for Managing Specific Adverse Events" (Section 5.1.5).
Information regarding the reporting of adverse events related to medical device 
complaints in individuals other than the study patient is covered in Section 4.3.6 .  
Hence, Section [IP_ADDRESS] has been removed to eliminate redundancy and to ensure 
consistency with c urrent standard protocol language.
Text differentiating immunosuppressant use for p atients recruited from U.S. and 
Canadian sites, which had been eliminated in Version [ADDRESS_1073897] been made to improve clarity and consistency. 
Substantive new information appears in italics. This amendment represents cumulative 
changes to the original protocol. 
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2005Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
4/Protocol GA29102, Version 7TABLE OF CONTENTS
PROTOCOL AMENDMENT A CCEPTANCE FORM .......................................... 11
PROTOCOL SYNOPSIS .................................................................................... 12
1. BACKGROUND .......................................................................................... 26
1.1 Background on Ulcerative Colitis ................................
........... 26
1.2 Background on Etrolizumab ................................................... 27
1.3 Study Rationale and Benefit -Risk Assessment ...................... 29
2. OBJECTIVES .............................................................................................. 30
2.1 Efficacy Objectives ................................................................ 30
2.2 Safety Objectives ................................................................... 33
2.3 Pharmacokinetic Objectives .................................................. 33
2.4 Exploratory Pharmacodynamic and Diagnostic 
Objectives .............................................................................. 33
3. STUDY DESIGN ......................................................................................... 34
3.1 Description of Study .............................................................. 34
3.1.1 Overview of Study Design ..................................................... 34
[IP_ADDRESS] Definition of Clinical Relapse ................................................. 37
[IP_ADDRESS] Rescue Therapy .................................................................... 37
[IP_ADDRESS] Number of Patients ................................................................ [ADDRESS_1073898] Dosage ........................................ 41
3.3.2 Rationale for Patient Population ............................................ 43
3.3.3 Rationale for Control Group ................................................... 43
3.3.4 Rationale for Biomarker Assessments ................................... 43
3.4 Outcome Measures ............................................................... 44
3.4.1 Efficacy Outcome Measures .................................................. 44
3.4.2 Safety Outcome Measures .................................................... 45
3.4.3 Pharmacokinetic Outcome Measures .................................... 46
3.4.4 Exploratory Biomarker Outcome Measures ........................... 46
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2006Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
5/Protocol GA29102, Version 74. MATERIALS AND METHOD S.................................................................... 46
4.1 Patients.................................................................................. 46
4.1.1 Inclusion Criteria ................................
.................................... 46
4.1.2 Exclusion Criteria ................................................................... 49
4.2 Method of Treatment Assignment and Blinding ..................... 52
4.3 Study Treatments .................................................................. 55
4.3.1 Formulation, Packaging, and Handlin g.................................. 56
[IP_ADDRESS] Etrolizumab and Placebo ....................................................... 56
[IP_ADDRESS] Concomitant Backgroun d Treatment for 
Ulcerative Colitis .................................................................... 57
4.3.2 Dosage, Administration, and Compliance .............................. 57
[IP_ADDRESS] Etrolizumab and Placebo ....................................................... 57
[IP_ADDRESS] Concomitant Background Treatment and Rescue 
Therapy ................................................................................. [ADDRESS_1073899] .................................................................................. 63
4.3.6 Reporting of Prefilled Syringe Complaints/Events ................. 63
4.4 Concomitant Therapy ............................................................ 64
4.4.1 Permitted Therapy ................................................................ .64
4.4.2 Prohibited Therapy ................................................................ 64
4.4.3 Definition of Clinical Relapse ................................................. 64
4.5 Study Assessments ............................................................... 65
4.5.1 Description of Study Assessments ........................................ 65
[IP_ADDRESS] Medical History and Demographic Data ................................ 65
[IP_ADDRESS] Physical Examinations ........................................................... 65
[IP_ADDRESS] Vital Signs .............................................................................. 65
[IP_ADDRESS] Ulcerative Colitis Disease Activity Assessments ................... 65
[IP_ADDRESS] Laboratory Assessments ....................................................... 69
[IP_ADDRESS] Chest X -Ray.......................................................................... 72
[IP_ADDRESS] Electrocardiograms ................................................................ 72
[IP_ADDRESS] Patient -Reported Outcomes .................................................. 73
[IP_ADDRESS] Medication Use and Compliance ........................................... 74
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2007Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
6/Protocol GA29102, Version [IP_ADDRESS] Samples for [COMPANY_002] Clinical Repository .................................. 74
4.5.2 Timing of Study Assessments ............................................... 77
[IP_ADDRESS] Screening and Pretreatment Assessments ............................ 77
[IP_ADDRESS] Assessments during Tr eatment ............................................. 80
[IP_ADDRESS] Assessments at Study Completion/Early 
Withdrawal from Treatment Visit ............................................ 81
[IP_ADDRESS] Safety Follow -Up Assessments ............................................. 85
[IP_ADDRESS] Assessments at Unscheduled Visits ................................
......85
4.6 Patient, Study, and Site Discontinuation ................................ 86
4.6.1 Patient Discontinuation .......................................................... 86
[IP_ADDRESS] Discontinuation from Study Drug ........................................... 86
[IP_ADDRESS] Withdrawal from Study ........................................................... 87
4.6.2 Study and Site Discontinuation .............................................. 87
5. ASSESSMENT OF SA FETY ....................................................................... 87
5.1 Safety Plan ............................................................................ 87
5.1.1 Potential Risks for Etrolizumab .............................................. 88
5.1.2 Progressive Multifocal Leukoencephalopathy ........................ 88
[IP_ADDRESS] Scree ning and Patient Selection ............................................ 88
[IP_ADDRESS] Monitoring and Management ................................................. 89
5.1.3 Monitoring for Other Serious Infections ................................ .90
5.1.4 Monitoring for Hypersensitivity Reactions .............................. 90
5.1.5 Management of Specific Adverse Events .............................. 91
5.2 Safety Parameters and Definitions ........................................ 95
5.2.1 Adverse Events ..................................................................... 95
5.2.2 Serious Adverse Events (Immediately Reportable 
tothe Sponsor) ...................................................................... [ADDRESS_1073900] (Immediately 
Reportable to the Sponsor) .................................................... 96
5.3 Methods and Timing for Capturing and 
Assessing Safety Parameters ................................................ 97
5.3.1 Adverse Event Reporting Period ........................................... 97
5.3.2 Eliciting Adverse Event Information ....................................... 97
5.3.3 Assessment of Severity of Adverse Events ........................... 98
5.3.4 Assessment of Causality of Adverse Events ......................... 98
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2008Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
7/Protocol GA29102, Version 75.3.5 Procedures for Recording Adverse Events ............................ 99
[IP_ADDRESS] Diagnosis versus Signs and Symptoms ................................ .99
[IP_ADDRESS] Adverse Events Occurring Secondary to Other 
Events.................................................................................. 100
[IP_ADDRESS] Persistent or Recurrent Adverse Events .............................. 100
[IP_ADDRESS] Abnormal Laboratory Values ............................................... 101
[IP_ADDRESS] Abnormal Vital Sign Values ................................
................. 101
[IP_ADDRESS] Abnormal Liver Function Tests ............................................ 102
[IP_ADDRESS] Deaths ................................
................................................. 102
[IP_ADDRESS] Preexisting Medical Conditions ............................................ 103
[IP_ADDRESS] Lack of Efficacy or W orsening of Ulcerative 
Colitis ................................................................................... 103
[IP_ADDRESS] Hospi[INVESTIGATOR_26589] ........................ 103
[IP_ADDRESS] Adverse Events Associated with an Overdose or 
Error in Drug Administration ................................................ 104
[IP_ADDRESS] Patient -Reported Outcome Data ......................................... [ADDRESS_1073901] ................... 105
5.4.3 Reporting Requirements for Pregnancies ............................ 106
[IP_ADDRESS] Pregnancies in Female Patients .......................................... 106
[IP_ADDRESS] Pregnancies in Female Partners of Male Patients ............... 106
[IP_ADDRESS] Abortions ............................................................................. 107
[IP_ADDRESS] Congenital Anomalies/Birth Defect s.................................... [ADDRESS_1073902]- Study Adverse Events ................................................. 108
5.7 Expedited Reporting to Health Authorities, 
Investigators, I nstitutional Review Boards, and 
Ethics Committees ............................................................... 108
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2009Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
8/Protocol GA29102, Version 76. STATISTICAL CONSIDER ATIONS AND ANALYSIS PLAN ..................... [ADDRESS_1073903] or Ethics Committee .................. 118
8.4 Confide ntiality ...................................................................... 118
8.5 Financial Disclosure ............................................................ 119
9. STUDY DOCUMENTATION, MONITORING, AND 
ADMINISTRATION ................................................................................... 119
9.1 Study Documentation .......................................................... 119
9.2 Protocol Deviations .............................................................. 119
9.3 Site Inspections ................................................................... 119
9.4 Administrative Structure ....................................................... 120
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2010Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
9/Protocol GA29102, Version 79.5 Publication of Data and Prote ction of Trade 
Secrets ................................................................................ 120
9.6 Protocol Amendments ......................................................... 121
10. REFERENCES ......................................................................................... 122
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2012Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
11/Protocol GA29102, Version 7PROTOCOL A MENDMENT A CCEPTA NCE F ORM
TITLE: PHA SE III, RA NDOMIZED, DOUBLE -BLIND, 
PLACEBO -CONTROLLED, MULTICENTER STUDY 
TO EVA LUATE THE EFFICA CY (MA INTENA NCE 
OF REMISSION) A ND SA FETY OF ETROLIZUMA B 
COMPA RED WITH PLA CEBO IN P ATIENTS WITH 
MODERA TE TO SEVERE A CTIVE ULCERA TIVE 
COLITIS WHO A RE NA IVE TO TNF INHIBITORS 
PROTOCOL NUMBER: GA29102
VERS ION NUMBER: [ADDRESS_1073904] NUMBER: 2013 -004280 -31
IND NUMBER: [ADDRESS_1073905]: Etrolizumab (PRO145223, RO5490261)
MEDICA L MONITOR: , M.D., M.S.
SPONSOR: F. Hoffmann -La [COMPANY_002] Ltd
I agree to conduct the study in accordance with the current protocol.
Principal Investigator’s Name  (print)
Principal Investigator’s Signature [CONTACT_335604] a Sponsor representative .  Please retain 
a copy for your study files.

Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2013Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
12/Protocol GA29102, Version 7PROTOCOL SYNOPSIS
TITLE: PHASE III, R ANDOMIZED, DOUBLE -BLIND, 
PLACEBO -CONTROLLED, MULTICENTER STUDY TO EVA LUATE 
THE EFFICA CY (M AINTENA NCE OF REMISSION) A ND SA FETY 
OF ETROLIZUM AB COMPA RED WITH PLA CEBO IN PA TIENTS 
WITH MODERA TE TO SEVERE A CTIVE ULCERA TIVE COLITIS
WHO A RE NA IVE TO TNF INHIBITORS
PROTOCOL NUMBER: GA29102
VERSION NUMBER: [ADDRESS_1073906] NUMBER: 2013- 004280 -31
IND NUMBER: [ADDRESS_1073907]: Etrolizumab (PRO145223, RO5490261)
PHASE: III
INDIC ATION: Ulcerative colitis
SPONSOR: F. Hoffmann -La [COMPANY_002] Ltd
Objectives
Efficacy Objectives
The primary  efficacy  objective for this study is as follows:
To evaluate the efficacy  of etrolizumab (105 mg subcutaneous [SC] ever y 4 weeks [Q4 W]) 
compared with placebo remission at Week 62 among patients with a clinical response at 
Week 10 , as determined by [CONTACT_335503] (MCS)
The secondary efficacy  objectives for this study are as follows:
To evaluate maintenance of clinical remission at Week 62 for patients in clinical remission 
at Week 10
To evaluate clinical remission at Week 62
To evaluate remission at Week 62 among patients in remission at Week 10
To evaluate improvement in endoscopic appearance of the mucosa at Week 62
To evaluate endoscopic remission at W eek 62
To evaluate histologic remission at Week 62
To evaluate onset of action, defined as change from baseline in rectal bleed subscore at 
Week 6
To evaluate onset of action, defined as change from baseline in stool frequency subscore at 
Week 6
To evaluate corticosteroid -free clinical remission at Week 62 (off corticosteroids for at least 
24weeks prior to Week 62) in patients who were receiving corticosteroids at baseline
To evaluate corticosteroid -free remission at W eek 62 (off corticosteroids for at least 
24weeks prior to Week 62) in patients w ho were receiving corticosteroids at baseline
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2014Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
13/Protocol GA29102, Version 7To evaluate change from baseline to W eek 62 in UC bowel movement signs and 
symptoms, as assessed by [CONTACT_335504] -Reported Outcome Signs and 
Symptoms (UC -PRO/SS) measure
To evaluate change from baseline to W eek 62 in UC abdominal s ymptoms, as assessed by 
[CONTACT_335505] -PRO/SS measure
To evaluate change from baseline to W eek 62 in patient -reported health -related QOL, as 
assessed by [CONTACT_335530] (IBDQ)
The exploratory efficacy  objectives for this study are as follows:
To evaluate clinical response at Week 62 among patients with a clinical response at 
Week 10 
To evaluate remission achieved at Week 62 among patients in clinical remission at 
Week 10
To evaluate corticoste roid-free clinical remission at W eek 62 (off corticosteroids for at least 
12 weeks prior to Week 62) in patients who were receiving corticosteroids at baseline
To evaluate change in histologic disease activity from baseline to Week 10 and Week 62
To evaluate improvement in histologic and/or endoscopic disease activity
To evaluate change in health utilities, as assessed by [CONTACT_760464] -Dimension 
Questionnaire (EQ -5D), from Week 10 to W eek 62
To evaluate improvement in endoscopic appearance of mucos a at W eek 10
To evaluate endoscopic remission at W eek 10
To evaluate the frequenc y and duration of hospi[INVESTIGATOR_760420] 10 to W eek62
To evaluate response, remission, and corticosteroid -free endpoints, as determined by [CONTACT_781243]:
To evaluate the overall safety and tolerability of etrolizumab over a period of 62 weeks
To evaluate the incidence and severity of infection -related adverse events
To evaluate the incidence of malignancies
To evaluate the incidence and severity of hypersensitivity reactions
To evaluate the incidence and the clinical significance of anti -therapeutic antibodies (ATAs)
Pharmacokinetic Objectives
The pharmacokinetic (PK) assessment will be performed in all pati ents during the 
Induction Phase and in all patients who were randomized into the Maintenance Phase.
The PK objectives for this study are as follows:
To evaluate etrolizumab serum concentration at the time of primary endpoint evaluation 
(Week62) and predos e concentration at the steady state during the maintenance 
dosing period
To evaluate the interindividual variability and potential covariate effects on etrolizumab 
serum exposure
Exploratory Pharmacodynamic and Diagnostic Objectives
The exploratory pharma codynamics (PD) and diagnostic objectives for this study are as follows:
To evaluate the relationship between baseline colonic mucosal biomarkers and/or 
peripheral blood and response to study drug, including ,but not limited to ,the Eintegrin
To evaluate the levels of biomarkers in colonic tissue and/or peripheral blood at baseline 
and during the treatment period, including, but not limited to, the E integrin
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2015Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
14/Protocol GA29102, Version 7To evaluate the PD effects on biomarkers in colonic tissue and/or peripheral blood following 
study treatment or placebo
To evaluate biomarkers in stool at baseline and during the treatment period through 
assessments that may include, but are not limited to, analyses of the microbiota and 
bacterial cultures
Study Design
Description of Study
This is a multicenter, Phase III, randomized, double -blind, parallel -group study to evaluate the 
safety, efficacy , and tolerability of etrolizumab (105 mg SC Q4W ) com pared with placebo in the 
treatment of UC.  Safety and efficacy  of continued etrolizumab treatment will be evaluated in 
patients achieving a clinical response after 10 weeks.
Patients enrolled in this study may be eligible to participate in an open -label extension and 
safety monitoring (OLE -SM) study (GA28951), which consists of two parts: Part 1 (designated 
OLE [open -label extension]) and Part 2 (designated SM [safety monitoring]).
Disease severity will be measured using the MCS, which is the current outcome measure 
accepted by [CONTACT_335511].  The target population is 
patients with moderately to severely active UC (defined as MCS 612, endoscopy subscore of 
2 as determined by [CONTACT_335517] ,a rectal bleeding 
subscore 1, and a stool frequency subscore  1)and involvem ent that extends a minimum of 
20 cm from the anal verge.
All patients are to be naive to tumor necrosis factor (TNF) inhibitors.
Patients must have had an inadequate response, loss of response, or intolerance to prior 
immunosuppressant and/or corticosteroi d treatment.
Patients who are on background immunosuppressant therapy (6 -MP, AZA, MTX) may be 
enrolled if they have received a stable dose for at least 8 weeks prior to Day 1.  Such patients 
should continue on stable doses of their background immunosuppres sant therapy during the 
study unless dose reduction or discontinuation is required due to toxicity.
Generally accepted criteria for discontinuation of immunosuppressants due to toxicity include ,
but are not limited to ,acute pancreatitis, severe leukopenia, severe thrombocy topenia, or 
clinically significant elevations of the liver -associated enzy mes from baseline, especially in the 
presence of an elevated total bilirubin.  The ultimate decision to reduce dose or discontinue 
immunosuppressants due to toxicit y rem ains at the discretion of the investigator.
Patients on o ral corticosteroid therapy (prednisone at a stable dose of 30 mg, or equivalent) 
may be enrolled according to the following criteria:
If corticosteroid therapy is ongoing or has recently been initiated, the dose has to be stable 
for at least 4 weeks immediately prior to Day 1
If corti costeroids are being tapered, the dose has to be stable for at least 2weeks 
immediately prior to Day 1
Such patients should continue stable doses of their backgro und corticosteroid until Week 10, 
at which point a corticosteroid taper will be initiated.
Initiation of corticosteroid or an increase in corticosteroid dose above the patients’ entry dose 
(up to a maximum of 30 mg/day prednisone [or equivalent] ) will not be permitted during 
screening.  Use of budesonide will be allowed at stable doses ( 9mg) provided that the dose 
has been stable for 4weeks prior to Day 1.  Oral 5 -ASA treatment and probiotics for the 
treatment of UC may  be continued at a stable dose as long as the dose(s) had been stable for 
4weeks and 2weeks, respectively, prior to Day 1.  Certain concomitant treatments are 
prohibited (see the protocol for li st of all prohibited concomitant treatments).
A total of approximately 350 patients will be recruited (see the protocol) from approximately 
125sites.  The study will be divided into:
Screening period of up to 35 day s
Open -label etrolizumab treatment perio d of 10 weeks (Induction Phase)
Double -blind treatment period of 52 weeks (Maintenance Phase)
Safety follow -up period of 12 weeks.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2016Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
15/Protocol GA29102, Version 7All patients entering the study will receive induction treatment with open-l abel etrolizumab 
(105 mg SC Q4W) for 10 weeks.  Eligibility for entry into the Maintenance Phase will be 
determined between Weeks 10 and 12.  Patients who achieved a clinical response at Week 10 
(see the protocol for definition of clinical response) will be randomized in a 1:1 ratio by [CONTACT_781244] 12 
into the Maintenance Phase and will receive either etrolizumab (1 05 mg S C Q4W) or placebo 
(n≈105 for each arm).  Randomization will be stratified by [CONTACT_781245] 10, 
concomitant treatment with corticosteroids (including budesonide) at baseline, concomitant 
treatment with immunosuppressants after Week 10, and disease activity measured during 
screening (MCS 9/MCS 10).
Patients not achieving clinical response at Week  10 and patients completing the Maintenance 
Phase at Week 62 should enroll in Part 1 (OLE) of Study GA28951, if eligible, where they will 
receive o pen-l abel etrolizumab.  If they do not enroll in Part 1 (OLE) of Study GA28951, they 
will enter the 12-w eek safety follow-u p period of this study and then be requested to enroll in 
Part 2 (SM) of Study GA28951  for 92 weeks of extended for progressive multifocal 
leukoencephalopathy (PML) monitoring.
Number of Patients
Approximately 350 patients are to be enrolled for this study.  Following 10 weeks of open-l abel 
induction with etrolizumab, it is estimated that approximately 60% of patients will achieve clinical 
response, which will provide approximately [ADDRESS_1073908] meet the following criteria for study entry:
Able and willing to provide written informed consent
1880 years of age, inclusive
Diagnosis of UC established at least 3 months prior to Day 1 by [CONTACT_781246].  This diagnosis should be corroborated by [CONTACT_781247] a histopathology report.  (Note that histopathology
may be performed at screening if no prior report is readily available.)
Moderately to severely active UC as determined by [CONTACT_335516] 6 12 with an endoscopic
subscore 2as determined by [CONTACT_781248], a rectal bleeding subscore 1,
and a stool frequency subscore 1 during the screening period (prior to Day 1)
Evidence of UC extending a minimum of 20 cm from the anal verge as determined by
[CONTACT_335543] (flexible sigmoidoscopy or colonoscopy ) performed during screening,
416 days prior to Day 1.  See protocol for additional information regarding the time
window.
Naive to treatment with TNF inhibitors
Patients must have had an inadequate response, loss of response, or intolerance to prior
immunosuppressant and/or corticosteroid treatment.
Inadequate response to, los s of response to, or intolerance to prior immunosuppressant
treatment is defined as one or more of the following:
Persistent signs and sy mptoms of active disease despi[INVESTIGATOR_040] a history of at least one 
12-week regimen of oral AZA ( 1.5 mg/kg) or 6 -MP ( 0.75 mg/kg) and/or
MTX (15mg/week) within the previous 5 years
Persistent signs and sy mptoms of active disease despi[INVESTIGATOR_040] a 6 -TG level of 
230 pm ol/8108RBCs during at least one 12 -week regimen of oral AZA or 6 -MP at a 
stable or increasing dose within the p revious 5 years
History of intolerance to AZA, 6 -MP, or MTX (including ,but not limited to ,
nausea/vomiting, abdominal pain, pancreatitis, LFT abnormalities, ly mphopenia, TPMT 
genetic mutation, infection) within the previous 5 years
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2017Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
16/Protocol GA29102, Version 7Inadequate response, loss of response, or intolerance to corticosteroid treatment is defined 
as one or more of the following: 
Steroid refractory :  persistent sy mptoms of active disease despi[INVESTIGATOR_168013] 4 -week induction regimen that included a dose of 30 mg prednisone (oral) 
daily (or equivalent) for at least [ADDRESS_1073909] 1 week within the 
previous 5 years
Steroid dependent:  two failed attempts to taper steroids below a dose equivalent to 
10mg prednisone (oral) daily
Steroid intolerant :  history of intolerance to corticosteroids (including ,but not limited to ,
Cushing’s syndrome, osteopenia/osteoporosis, hyperglycemia, insomnia, infection) 
within the previous 5 years
Any ongoing UC therapy must be at stable doses:
May be receiving oral 5 -ASA compounds provided that the dose has been stable for 
4 weeks immediately prior to Day 1
May be receiving oral corticosteroid therapy (prednisone at a stable dose of 30 mg a 
day, or equivalent steroid).
If corticosteroid therapy is ongoing or has recently been initiated , the dose has to 
be stable for at least [ADDRESS_1073910] 2 weeks immediately prior to 
Day 1.
May be receiving budesonide therapy at a stable dose of up to 9 mg a day for 
4weeks prior to Day 1
May be receiving probiotics (e.g., Culturelle, Saccharomy ces boulardii), provided 
thatthe dose has been stable for 2 weeks immediately prior to Day 1
May be receiving AZA, 6 -MP, or MTX, provided that the dose has been stable for 
8weeks immediately prior to Day 1
For women who are not postmenopausal (at least 12 months of non therapy -induced 
amenorrhea) or surgically sterile (e.g., absence of ovaries and/or uterus):  agreeme nt to 
remain abstinent or use a highly effective method of contraception during the treatment 
period and for at least [ADDRESS_1073911] dose of study drug . 
The reliability of sexual abstinence should be evaluated in relation to the duration of 
the c linical trial and the preferred and usual lifestyle of the patient.   Periodic abstinence 
(e.g., calendar, ovulation, sy mptothermal, or postovulation methods) and withdrawal 
are not acceptable methods of contraception.
For men:  agreement to remain abstinen t (refrain from heterosexual intercourse) or use 
contraceptive measures, and agreement to refrain from donating sperm, as defined below:
With female partners of childbearing potential or pregnant female partners, men must 
remain abstinent or use a condom d uring the treatment period and for at least 
24weeks after the last dose of study drug to avoid exposing the embryo to study drug.  
Men must refrain from donating sperm during this same period.  
The reliability of sexual abstinence should be evaluated in relation to the duration of 
the clinical trial and the preferred and usual lifestyle of the patient. Periodic 
abstinence (e.g., calendar, ovulation, sy mptothermal, or postovulation methods) and 
withdrawal are not acceptable methods of contraception.
Must have received a colonoscopy within the past year or be willing to undergo a 
colonoscopy in lieu of a flexible sigmoidoscopy at screening.  This colonoscopy must:
Confirm disease extent (defined as 1) left- sided colitis [up to the splenic flexure], 
2)exten sive colitis [beyond the splenic flexure but not involving the entire colon], and 
3) pancolitis; see the protocol) 
Include removal of any adenomatous polyps 
Document evidence of surveillance for dysplasia for all patients with left -sided colitis 
of12years’ duration and total/extensive colitis of 8 years duration 
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2018Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
17/Protocol GA29102, Version 7Patients who meet any of the following criteria will be excluded from study entry:
Exclusion Criteria Related to Inflammatory Bowel Disease
Prior extensive colonic resection, subtotal or t otal colectom y, or planned surger y for UC
Past or present ileostom y or colostom y
Diagnosis of indeterminate colitis 
Suspi[INVESTIGATOR_335456], radiation colitis, or microscopic colitis
Diagnosis of toxic megacolon within 12 months of initial screening visit 
Any diagnosis of Crohn’s disease
Past or present fistula or abdominal abscess
A history or current evidence of colonic mucosal dysplasia
Patients with any stricture (stenosis) of the colon
Patients with history or evidence of adenomatous colonic polyps that have not 
been removed
Exclusion Criteria Related to Prior or Concomitant Therapy
Any prior treatment with etrolizumab or other anti -integrin agents (including natalizumab, 
vedolizumab, and efalizumab)
Any prior treatment with anti -adhesion mol ecules (e.g., anti -MAdCAM -1)
Any prior treatment with rituximab
Any treatment with tofacitinib during screening
Use of intravenous (IV) steroids within 30 days prior to screening with the exception of a 
single administration of IV steroid
Use of agents tha t deplete B or T cells (e.g., alemtuzumab or visilizumab) within 12 months 
prior to Day 1, with the exception of AZA and 6 -MP
Use of cy closporine, tacrolimus, sirolimus, or my cophenolate mofetil (MMF) within 4 weeks 
prior to Day 1
Chronic nonsteroidal anti -inflammatory  drug (NSAID) use (Note: occasional use of NSAIDs 
and acetaminophen [e.g., headache, arthritis, m yalgias, or menstrual cramps] and aspi[INVESTIGATOR_760425] 325 mg daily is permitted.)
Patients who are currently using anticoagulants including ,but not lim ited to ,warfarin, 
heparin, enoxaparin, dabigatran, api[INVESTIGATOR_3822], rivaroxaban.  (Note that antiplatelet agents such 
as aspi[INVESTIGATOR_155752] 325 mg daily or clopi[INVESTIGATOR_335457].)
Patients who have received treatment with corticosteroid enemas/suppositories and/o r 
topi[INVESTIGATOR_2855] (rectal) 5 -ASA preparations within 2 weeks prior to Day 1
Apheresis (i.e., Adacolumn apheresis) within 2 weeks prior to Day 1
Received any investigational treatment including investigational vaccines within [ADDRESS_1073912] dose , whichever is greater , prior to 
Day 1
History of moderate or severe allergic or anaphylactic/anaphylactoid reactions to chimeric, 
human, or humanized antibodies, fusion proteins, or murine proteins or hypersensitivity to 
etrolizumab (active drug substance) or any of the excipi[INVESTIGATOR_840] (L- histidine, L -arginine, 
succinic acid, poly sorbate 20)
Patients administered tube feeding, defined formula diets, or parenteral 
alimentation/nutrition who have not discontinued these treatm ents 3 weeks prior to Day 1
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2019Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
18/Protocol GA29102, Version 7Exclusion Criteria Related to General Safety
Pregnant or lactating
Lack of peripheral venous access
Hospi[INVESTIGATOR_057] (other than for elective reasons) during the screening period
Inability to comply with study protocol, in the op inion of the investigator
Significant uncontrolled comorbidity, such as cardiac (e.g., moderate to severe heart failure 
[LOCATION_001] Heart Association [NYHA] Class III/IV), pulmonary , renal, hepatic, endocrine, or 
gastrointestinal disorders (excluding UC)
Neurological conditions or diseases that may interfere with monitoring for PML
History of dem yelinating disease
Clinically significant abnormalities on screening neurologic examination (PML Objective 
Checklist)
Clinically significant abnormalities on the s creening PML Subjective Checklist
History of alcohol, drug, or chemical abuse 6 months prior to screening
Conditions other than UC that could require treatment with 10 mg/day of prednisone 
(orequivalent) during the course of the study
History of cance r, including hematologic malignancy, solid tumors, and carcinoma in situ, 
within 5 years before screening with the following exceptions:
Local basal or squamous cell carcinoma of the skin that has been excised and is 
considered cured is not exclusionar y.
Ahistory of chronic m yelogenous leukemia, hair y cell leukemia, melanoma, renal cell 
carcinoma, or Kaposi sarcoma is exclusionary, irrespective of the duration of time 
before screening.
History of a cervical smear indicating the presence of adenocarcinoma i n situ (AIS), 
high-grade squamous intraepi[INVESTIGATOR_12184] (HSIL), or cervical intraepi[INVESTIGATOR_28601] 
(CIN) of Grade 1 is exclusionar y, irrespective of the duration of time before screening.
Exclusion Criteria Related to Infection Risk
Congenital or a cquired immune deficienc y
Patients must undergo screening for HIV and test positive for preliminary and confirmatory 
tests
Positive hepatitis C virus (HCV) antibody test result, unless the patient (1) has undetectable 
HCV RNA levels for 6 months after co mpleting a successful course of HCV anti -viral 
treatment and an undetectable HCV RNA at screening or (2) has a known histor y of HCV 
antibody positivity with a history of undetectable HCV RNA and undetectable HCV RNA at 
screening in the absence of histor y of HCV anti -viral treatment.
Patients must undergo screening for hepatitis B virus (HBV).  This includes testing for 
HBsAg (HBV surface antigen), anti -HBc total (HBV core antibody total), and HBV DNA 
(patients who test negative for these tests are eligible for this study):
Patients who test positive for surface antigen (HBsAg )are not eligible for this study, 
regardless of the results of other hepatitis B tests.
Patients who test positive only for core antibody (anti -HBc ) must undergo further 
testing for hepatitis B DNA (HBV DNA test).
If the HBV DNA test is positive, the patient is not eligible for this study.
In the event the HBV DNA test cannot be performed, the patient is not eligible for 
this study. 
If the HBV DNA test is negative, the patient is eligible for this study).  These 
patients will undergo periodic monitoring for HBV DNA during the study.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2020Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
19/Protocol GA29102, Version 7Evidence of or treatment for Clostridium difficile (as assessed by C. difficile toxin testing) 
within 60 days prior to Day 1 or other intestinal pathog ens (as assessed by [CONTACT_781249]) within 30 days prior to Day 1
Evidence of or treatment for clinically significant cytomegalovirus (CMV) colitis (based on 
the investigator’s judgment) within 60 day s prior to Day 1.  Labora tory confirmation of CMV 
from colon biopsy sample is required during screening evaluation only if clinical suspi[INVESTIGATOR_781222]
History of active or latent treated tuberculosis (TB), regardless of treatment history
(see protocol)
Patients with a histor y of active or latent TB (based on a positive screening assay, 
either purified protein derivative [[COMPANY_003]] skin test or QuantiFERONTB Gold test), are 
not eligible for this study.
Patients with a chest X -ray (posteroanteri or [PA] and lateral) within 3 months of Day 1 
suspi[INVESTIGATOR_760428].
History of recurrent opportunistic infections and/or history of se vere di ssemi nated viral
infections (e.g., herpes)
Any serious opportunistic infection within the last 6 months
Any current or recent signs or sy mptoms (within 4 weeks before screening and during 
screening) of infection, except for the following:
Minor infections (e.g., common cold) that have, in the investigator’s judgment, 
completely resolved prior to Day 1
Fungal infections of the nail beds
Oral or vaginal candidiasis that has resolved with or without treatment prior to Day 1
Any major epi[INVESTIGATOR_760443] 8 weeks prior to 
screening or oral antibiotics within 4weeks prior to screening
Treatment with antibiotics as adjunctive therapy for UC in the absence of documented 
infection is not exclusionary .
Received a live attenuated vaccine within 4 weeks prior to Day 1
History of organ transplant
Exclusion Criteria Related to Laboratory Values (at Screening)
Serum creatinine 2 times upper limit of normal (ULN)
ALT or AST 3ULN, or alkaline phosphatase 3ULN, ortotal bilirubin 2.5ULN 
(unconjugated hyperbilirubinemia that is associated with known Gilbert's syndrome is not an 
exclusion criterion)
Platelet count 100,000/ L
Hemoglobin  8 g/dL
Absolute neutrophil count 1500/ L
Absolute ly mphocyte count 500/L
Length of Study
The total length of the treatment period will be [ADDRESS_1073913] clinical relapse during the Maintenance Phase, 
patients who receive defined rescue treatment (see protocol), and patients who complete 
62weeks of the study may be gi ven the option of enrolling in Part 1 (OLE) of Study GA28951 , 
where they will receive open -label etrolizumab treatment.  Those who do not enroll in Part 1 
(OLE) of Study GA28951 will continue to 12 weeks of safety follow -up in this study, and then be 
reque sted to enroll in Part 2(SM) of Study GA28951 for [ADDRESS_1073914] patient enrolled in to Study GA28951 
(OLE -SM), whichever is later.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2021Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
20/Protocol GA29102, Version 7End of Study
The end of the study is defined as the last patient last safety follow -up visit in this protocol or 
last patient in this protocol enrolled into Study GA28951 (OLE -SM), whichever is later.
Efficacy Outcome Measures
The efficacy  outcome measures for this study are as follows:
Primary Outcome Measure
Remission at W eek 62 among patients with a clinical response at Week 10, as determined 
by [CONTACT_781250]
Clinical remission at W eek 62 among patients in clinical remission at W eek 10
Clinical remission at W eek 62
Remission at Week 62 among patients in remission at Week 10
Improvement in endoscopic appearance of the mucosa at Week 62
Endoscopic remission at W eek 62
Histologic remission at Week 62
Change from baseline in rectal bleed subscore at Week 6
Change from baseline in stool frequency subscore at Week 6
Corticosteroid -free clinical remission at Week 62 (off corticosteroids for at least 24 weeks 
prior to Week 62) in patients who are receiving corticosteroids at baseline
Corticosteroid -free remission at W eek 62 (off corticosteroids for at least 24 weeks prior to 
Week 62) in patients who are receiving corticosteroids at baseline
Change from baseline to Week 62 in UC bowel movement sign s and sy mptoms as 
assessed by [CONTACT_335505] -PRO/SS measure
Change from baseline to Week 62 in UC abdominal symptoms as assessed by [CONTACT_335519]-PRO/SS measure
Change from baseline to Week 62 in patients’ health- related QOL as assessed by [CONTACT_335520] y Efficacy Outcome Measures 
Clinical response at Week 62 among patients with a clinical response at Week 10
Remission at Week 62 among patients in clinical remission at Week 10
Corticosteroid -free clinical remission at Week 62 (off corticosteroi ds for at least 12 weeks 
prior to Week 62) in patients who are receiving corticosteroids at baseline
Histologic disease activity change from baseline to Week 10 and Week 62
Improvement in histologic and/or endoscopic disease activity
Change in health utilities, as assessed by [CONTACT_20367] -5D, from baseline to W eeks10and 62
Improvement in endoscopic appearance of the mucosa at Week 10
Endoscopic remission at W eek 10
Frequenc y and duration of hospi[INVESTIGATOR_760420] 10 to W eek 62
Response, remission and c orticosteroid -free endpoints as determined by [CONTACT_781251]: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2022Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
21/Protocol GA29102, Version 7Safety Outcome Measures
The safety  outcome measures for this study are as follows:
Incidence and severity of adverse events
Incidence of serious adverse events
Incidence and severity of infection -related adverse events
Incidence of serious infection- related adverse events
Incidence and severity of injection -site reactions 
Incidence of adverse events leading to study drug discontinuation
Incidence of laboratory abnormalities
Incidence of malignancies
Incidence of ATAs to etrolizumab
Incidence and severity of hypersensitivity reaction events
Pharmacokinetic Outcome Measures
The PK outcome measures for this study are as follows:
Serum trough concentration at steady state during the dosing period from Week 12 to 
Week62
Serum concentration at primary  endpoint time (W eek 62)
Exploratory Biomarker Outcome Measures
The exploratory biomarker outcome measures for this study are as follows:
Remission at W eek 10 and maintenance of remission at Week 62 in pati ents according to 
baseline levels of colonic tissue biomarkers and/or peripheral blood, including ,but not 
limited to ,E integrin
Changes in levels of exploratory colonic tissue and/or peripheral blood biomarkers during 
the Induction and Maintenance Phases
Changes in stool biomarkers, which may include, but are not limited to, those in the 
microbiota and bacterial cultures, during the Induction and Maintenance Phases
Investigational Medicinal Products
Test Product
Etrolizumab prefilled s yringe (PFS):  containing SC formulation, 10 5mg given as 0.7 mL of a 
150-mg/mL solution will be administered by [CONTACT_10530] Q4 W.
Comparator
Placebo PFS:  etrolizumab SC matching placebo given in the amount of 0.7- mL solution will be 
administered by [CONTACT_10530] Q4 W.
Non-Investigational Medicinal Products
Patients are to continue on their baseline dose of corticosteroid (including budesonide) to the 
end of the Induction Phase (W eek 10).  Tapering of corticosteroid (including budesonide) is to 
be attempted during the Ma intenance Phase.
All patients are to continue on their baseline dose of immunosuppressants (AZA, 6 -MP, MTX) to 
the end of Induction Phase (W eek 10), unless dose reduction or discontinuation is required due 
to toxicity.  
Probiotics and oral 5 -ASA may be co ntinued at a stable dose throughout the study.
Occasional use of NSAIDs and acetaminophen (e.g., headache, arthritis, m yalgias, and 
menstrual cramps) and aspi[INVESTIGATOR_155752] 325 mg daily are permitted throughout the study.
Antidiarrheals (e.g., loperamide, diphe noxy late with atropi[INVESTIGATOR_050]) for control of chronic diarrhea are 
permitted throughout the study.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2023Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
22/Protocol GA29102, Version 7Statistical Methods
Primary A nalysis
The analysis of data from the [ADDRESS_1073915] been cleaned and verified.
Whereas Sponsor personnel will be unblinded to treatment assignment to perform the primary 
Week 62 analyses, patients and study site personnel will remain blinded to individual treatment 
assignment during the Maintenance Phase until after the study is completed (after all patients 
have either completed the safety follow -up period or discontinued early from the study ) and the 
database is locked.
Detailed specifications of the statistical methods will be described in the Statistical Analysis Plan.
Determination of Sample Size  
The study sample size was selected so that sufficient patients are enrolled to evaluate the 
primary  endpoint in the Maintenance Phase.  Approximately 350 patients will be enrolled in the 
open- label Induction Phase. 
Under the assumption of clinical response at Week 10 of approximately 60% (based on the 
Phase II W eek 10 response results for the TNF -naive subgroup), the planned size of 
350patients in the open -label Induction Phase would provide approx imately 210patient s 
randomized in tothe Maintenance Phase.   A sample size of approximately 105 patients per arm 
is required in the Maintenance Phase to achieve 90% power to detect a 25% absolute 
difference in remission rates between the etrolizumab and placebo arms, for a 2test at the 
two-sided 5% significance level, under the assumption of a placebo true remission rate of 
30%45%.  If clinical response rates at Week 10 are lower than projected, the total enrollment 
in the open -label induction cohort may  be increased to ensure that a sufficient number of 
Week-10 clinical responders are randomized into the Maintenance Phase.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2024Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
23/Protocol GA29102, Version 7LIST OF A BBREVI ATIONS AND DEFINITIONS OF TERMS
Abbreviation Definition
5-ASA 5-aminosalicylate
6-MP 6-mercaptopurine
AIS adenocarcinoma in situ
ATA anti-therapeutic antibody
AZA azathioprine
BCG bacille Calmette -Guérin 
CD Crohn’s disease
CHO Chinese hamster ovary
CIN cervical intraepi[INVESTIGATOR_781223] C-reactive protein
CSF cerebrospi[INVESTIGATOR_781224]- Reported Outcomes
EQ-5D EuroQoL Five -Dimension Questionnaire
FDA U.S. Food and Drug Administration
HBcAb hepatitis B core antibody
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HCP health care professional
HCV hepatitis C virus
HIPAA U.S. Health Insurance Portability and 
Accountability Act
HSIL high-grade squamous intraepi[INVESTIGATOR_781225] (Application )
IRB Institutional Review Board
IV intravenous
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2025Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
24/Protocol GA29102, Version 7Abbreviation Definition
IxRS interactive voice/ Web-based response s ystem  
JAK Janus kinase 
JCV John Cunningham virus
LD loading dose
LFT liver function test
MAb monoclonal antibody
MAdCAM -Fc mucosal addressin cell adhesion molecule 
fragment cry stallizable region
MCS Mayo Clinic Score
mMCS modified Mayo Clinic Score
MMF mycophenolate mofetil
MP mercaptopurine
MRI magnetic resonance imaging
MTX methotrexate
NCI CTCAE National Cancer Institute Common Terminology 
Criteria for Adverse Events
NSAID nonsteroidal anti -inflammatory drug 
OLE open- label extension
OLE-SM open- label extension and safety monitoring
PA posteroanterior
PCR polymerase chain reaction
PD pharmacodynamic
PEG polyethylene gly col
PFS prefilled syringes 
PGA Physician’s Global Assessment
PK pharmacokinetic
pMCS partial Mayo Clinic Score
PML progressive multifocal leukoencephalopathy
[COMPANY_003] purified protein derivative 
PRO patient -reported outcome
Q4W every 4 weeks
QOL qualit y of life 
qPCR quantitative poly merase chain reaction
RCR [COMPANY_002] Clinical Repository
SAP Statistical Analysis Plan
SC subcutaneous
SM safety monitoring
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2026Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
25/Protocol GA29102, Version 7Abbreviation Definition
SmPC Summary  of Product Characteristics
S[LOCATION_003]R Suspected Unexpected Serious Adverse 
Reaction
TB tuberculosis
TNF tumor necrosis factor
TNF- tumor necrosis factor -alpha
TNF-IR inadequate response to anti -tumor necrosis factor
UC ulcerative colitis
UC-PRO/SS Ulcerative Colitis Patient- Reported Outcome 
Signs and Sy mptoms
ULN upper limit of normal
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2027Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
26/Protocol GA29102, Version 71. BACKGROUND
1.1 BACKGROUND ON ULCERA TIVE COLITIS
Ulcerative colitis (UC) is an idiopathic inflammatory bowel disease (IBD) that affects the 
colon in a diffuse, continuous, and superficial pattern.  Approximately 40%50% of 
patients have disease limited to the rectum and rectosigmoid colon, 30% 40% have 
disease extending beyond the sigmoid but not involving the whole colon, and 20% have 
a total colitis.  Proximal spread occurs in continuity without areas of uninvol ved mucosa.  
When the whole colon is involved, the inflammation extends 2 3 cm into the terminal 
ileum in 10% 20% of patients.
UC is characterized by [CONTACT_335523], rectal bleeding, diarrhea, and abdominal pain 
and may be complicated by [CONTACT_335524], requiring 
major and sometimes urgent surgery.  UC represents dysregulation of the mucosal 
immune system in genetically susceptible individuals in response to commensal 
microbiota and other environmental triggers.  The overall incidence of UC ranges from 
6.3to24.[ADDRESS_1073916] estimates in European and 
Northern American populations ( Molodecky etal.2012 ).  Although the i ncidence and 
prevalence vary between regions of the world, both have been increasing in some 
regions, which may be due in part to better detection and diagnosis, as well as 
environmental factors such as improved hygiene and W estern diet.  The disease can 
affect any age group, but occurrence peaks between the ages of 15 and 35 years.
The goals of treatment are to induce and maintain remission, decrease corticosteroid 
use (as measured by [CONTACT_77897] -free remission), induce mucosal healing, reduce 
hospi[INVESTIGATOR_236622], improve health -related quality of life (QOL), and avoid 
disability.  For mildly to moderately active UC, oral and rectal preparations o f
5-aminosalicylate (5 -ASA) medications are used either alone or together and result in 
remission in approxi mately 50% of patients.  Patients whose UC fails to respond to 
5-ASA drugs or who have moderately to severely active UC often receive conventional 
therapy, including corticosteroids and immunomodulator therapy (e.g., azathioprine 
[AZA], 6 -mercaptopurine [6-MP], and methotrexate [MTX]).  Corticosteroids achieve 
remission in about 70% of patients, but approximately 20% become steroid dependent 
and only half maintain steroid -free remission ( Faubion et al. 2001
).  Corticosteroids are 
also associated with significant side effects, such as infections, osteopenia, glucose 
intolerance, and adrenal suppression.  Immunomodulators, such as [ADDRESS_1073917] ( Lobel et al. 2004 ; Chebli et al. 2010; 
Mañosa etal.2011 ;Khan et al. 2013 ).  In addition, these medications are 
associated with significant side effects, including hepatotoxicity, pancreatitis, and bone 
marrow suppression.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2028Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
27/Protocol GA29102, Version 7Monoclonal antibodi es (MAbs) targeting tumor necrosis factor -alpha (TNF -), such as 
infliximab and adalimumab, have been used to induce and maintain remission in patients 
whose immunomodulatory therapy fails, are steroid dependent or refractory, and have 
moderately to severely active UC.  These biologic agents induce remission in up to 40% 
of patients, but sustained remission is seen in only 10% 20% of patients over 1 year 
(Rutgeerts etal.2005 ; Sandborn et al. 2013).  Importantly, TNF inhibitor therapi[INVESTIGATOR_781226], such as bacterial infection, including 
tuberculosis (TB), disseminated fungal infections, lymphoma, and demyelination 
(Chang andLichtenstein 2006 ).  In fulminant steroid- unresponsive colitis, infliximab and 
(less commonly) cyclosporine are utilized as bridging agents to avoid urgent colectomy.  
With either therapy, however, treatment failure occurs in approximately 55% 60% of 
patients ( Laharie et al. 2012 ).
In short, a large proportion of patients with moderately to severely active UC do not 
maintain a durable response to therapy.  Available therapi[INVESTIGATOR_760434] 10% 30% of 
patients with IBD who have chronic disease ( Hanauer et al. 2002 ; Sandborn et al. 2005).  
Patients whose disease fails to respond to medical therapy may be treated with total 
proctocolectomy with an ileal pouch -anal anastomosis.  Although surgical intervention 
may be curative, complications such as chronic pouchitis, fecal incontinen ce, or 
decreased female fertility can occur ( Bradley andOliva -Hemker 2012 ).  The current 
treatments are associated with significant adverse events, resulting in low rates of 
sustained remission, or are highly invasive.
Consequently, there continues to be a high unmet medical need in moderately to 
severely active UC.  Targeted therapy with an improved safety profile and ability to 
sustain remission and prevent long -term complications would provide a valuable 
therapeutic option for these patients.
1.[ADDRESS_1073918] shown evidence of efficacy for these agents, inclu ding natalizumab 
(anti-4) for Crohn’s disease (CD) ( Sandborn et al. 2005 ) and vedolizumab (anti -47) 
for UC and CD ( Feagan et al. 2005 , 2008 ); both agents have been approved for their 
respective indications.  Natalizumab and vedolizumab require IV admini stration, but 
only vedolizumab is gut -selective.  Natalizumab is not gut -selective and is associated 
with the risk of progressive multifocal leukoencephalopathy (PML).   Etrolizumab 
distinguishes itself from these molecules by [CONTACT_781252] 7 subunit, 
found in both 47 (Holzmann et al. 1989 ; Hu etal. 1992 ) and E7 (Cepek et al. 1993), 
which regulate trafficking and retention of leukocyte/lymphocyte subsets, respectively, in 
the intestinal mucosa.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2029Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
28/Protocol GA29102, Version 7It is important to note that etrolizum ab does not bind to 41 (target for natalizumab), 
which regulates trafficking to both mucosal and non -mucosal tissues, including the CNS.  
Etrolizumab, therefore, represents a novel gut mucosal selective anti-trafficking agent 
whose selectivity may enhance efficacy in UC and eliminate generalized 
immunosuppression by [CONTACT_781253].  Data from multiple nonclinical toxicology studies of up to 6 months’ 
duration in adult animals demonstrated no adverse effects in any organ system 
(including the CNS, hematologic, and cardiovascular systems).  No adverse events were 
observed in the embryo- fetal developmental toxicity studies.
Etrolizumab is a humanized MAb based on the human IgG1 sub group -IIIVH, 
subgroup -[ADDRESS_1073919] 
recombinant DNA techniques.  This recombinant antibody consists of two heavy chains 
(446 residues) and two light chains (214 residues) and is produced in Chinese hamster 
ovary (CHO) cells that have been genetically engineered to synthesize the antibody.  
The protein is manufactured in bioreactors and purified using a series of harvest, 
purification, and formulation steps.  The potency of etrolizumab is determined by [CONTACT_335527] 47
-expressing cells to 
mucosal addressin cell adhesion molecule fragment crystallizable region (MAdCAM -Fc).
Safety assessments for etrolizumab have been completed in the adult Phase I, Phase II, 
and Phase II open- label extension (OLE) studies without significant safety concerns.
The following is a summary of the etrolizumab safety experience to date:
There were no observed significant adverse effects in multiple nonclinical toxicity 
studies of up to 6 months’ duration in adult animals or in embryo -fetal 
developmental toxicity studies.  No adverse effects were seen in any organ system 
(including the CNS, hematologic, and cardiovascular systems), no effects were 
seen in embryo -fetal development, and ther e was no evidence of increased rates 
ofinfection.
No significant adverse safety signal, including any evidence of increased rates of 
serious or opportunistic infections, was associated with etrolizumab treatment in the 
Phase I or Phase II trials in adult patients with moderately to severely active UC who 
received either single or multiple doses of intravenous (IV) or subcutaneous (SC) 
etrolizumab.
No events of PML have been reported in etrolizumab -treated patients.
See the most recent Etrolizumab Investig ator's Brochure for details on nonclinical and 
clinical studies.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2030Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
29/Protocol GA29102, Version 71.3 STUDY RA TIONA LE A ND BENEFIT -RISK A SSESSM ENT
Although there are therapeutic options including TNF inhibitors , a significant proportion of 
patients with UC will not experience a durable clinical benefit with those treatment 
options.  Furthermore, adverse events associated with TNF inhibitors include elevated 
rates of serious bacterial infection, including TB, and (more rarely) lymphoma and 
demyelination (Chang and Lichtenstein 2006
).  No currently available therapy , including 
approved anti-i ntegrins (natalizumab for CD and vedolizumab for UC and CD), 
achieves sustained remission in more than 10%30% of patients with IBD who have 
chronic disease (Hanauer et al. 2002; Sandborn et al. 2005; Feagan et al. 2013).  As 
noted above, etrolizumab distinguishes itself from other anti-i ntegrins on the basis of gut 
selectivity combined with a potential dual mechanism of action.  It binds E7 in addition 
to 47 and so regulates retention as well as trafficking leukocyte/lymphocyte in the 
intestinal mucosa.
No clinically significant safety signals have been detected on administration of 
etrolizumab to patients with moderate to severe UC across a dose range of 0.310.0 mg/
kg IV/SC in the single ascending dose stage and of 0.53.0 mg/kg SC and 4 mg/kg IV 
monthly for three doses in the multidose stage of the Phase I study.
A global, Phase II, multicenter study (Study ABS4986g; EUCALYPTUS) designed to 
determine the exposure-response relationship and to further characterize the safety and 
tolerability of etrolizumab in treatment of adult patients with moderately to severely active 
UC has been completed.  Patients were randomized in a 1:1:1 ratio to receive 100 mg 
etrolizumab SC (0.7 mL of 150 mg/mL solution via vial and syringe, with an intended 
nominal dose of 100 mg) at Weeks 0, 4, and 8 or 420 mg SC at Week 0 (loading dose 
[LD]) followed by 300 mg SC (three injections of 0.7 mL of 150 mg/mL solution via vial 
and syringe, with an intended nominal dose of 300 mg) at Week s 2, 4, and 8 (40 patients 
per dose arm) versus matching placebo SC (40 patients per arm).  The primary objective 
of the study was to obtain evidence of clinical efficacy of etrolizumab as measured by 
[CONTACT_760481] (Mayo Clinic Score [MCS] 2 and no individual subscore 
1)at Week 10 (2 weeks after the final dose).
In EUCALYPTUS, etrolizumab showed clinically meaningful efficacy for both doses 
relative to placebo for the primary endpoint :  the proportion of patients in clinical 
remission at Week 10 was 20.5% in the 100 -mg dose group and 10.3% in 
the300-mgLD group versus 0% in the placebo group (p 0.004 and p 0.048, 
respectively) .  In the TNF -naive subgroup, clinical remission at W eek 10 was observed 
in 43.8% versus 0 % of patients in the 100- mg etrolizumab versus placebo group, and 
in25% of 300 -mgLD group.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2031Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
30/Protocol GA29102, Version 7In summary, favorable safety (see Section 1.2) and efficacy data were observed in the 
Phase II EUCALYPTUS study and in the OLE study (SPRUCE).  Overall, e trolizumab 
showed compelling efficacy compared with placebo and there were no clinically 
significant safety signals.  Additionally, etrolizumab distinguishes itself from vedolizumab 
by [CONTACT_47506] E7 in addition to 47, which is involved in lymphocyte retention and may 
contribute to its efficacy and/or safety prof ile.  Etrolizumab is a gut -selective
anti-trafficking agent and does not bind to 41 (target for natalizumab), which regulates 
trafficking to both mucosal and non -mucosal tissues, including the CNS.  Although 
natalizumab has been associated with an increa sed risk of PML, no events of PML to 
date have been reported during [ADDRESS_1073920] recent Etrolizumab Investigator’s Brochure for additional details on 
clinical and nonclinical studies.
2. OBJECTIVES
2.1 EFFICA CY OBJECTIVES
The primary efficacy objective for this study is as follows:
To evaluate the efficacy of etrolizumab (105 mg SC every 4 weeks [Q4 W]) 
compared with placebo for remission at Week 62 among patients with a clinical 
response at Week 10, as determined by [CONTACT_781254]:
To evaluate maintenance of clinical remission at W eek 62 for patients in clinical 
remission at Week 10
To evaluate clinical remission a t Week 62
 To evaluate remission at Week 62 among patients in remission at Week 10 
To evaluate improvement in endoscopic appearance of the mucosa at W eek 62
To evaluate endoscopic remission at Week 62
To evaluate histologic remission at Week 62
 To evaluate onset of action, defined as change from baseline in rectal bleed subscore 
at Week 6
 To evaluate onset of action, defined as change from baseline in stool frequency 
subscore at Week 6  
To evaluate corticosteroid -free clinical remission at Week 62 (off cor ticosteroids for 
at least 24 weeks prior to W eek 62) in patients who were receiving corticosteroids at 
baseline
To evaluate corticosteroid -free remission at Week 62 (off corticosteroids for at least 
24weeks prior to Week 62) in patients who were receiving corticosteroids at 
baseline
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2032Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
31/Protocol GA29102, Version 7To evaluate change from baseline to Week 62 in UC bowel movement signs and 
symptoms, as assessed by [CONTACT_335504] -Reported Outcome Signs 
and Symptoms (UC -PRO/SS) measure
To evaluate change from baseline to Week62 in UC abdominal symptoms, as 
assessed by [CONTACT_335505] -PRO/SS measure
To evaluate change from baseline to Week 62 in patient -reported health- related 
QOL, as assessed by [CONTACT_335530] (IBDQ)
The exploratory efficacy objectives for this study are as follows:
 To evaluate clinical response at Week 62 among patients with a clinical response at 
Week 10 
 To evaluate remission achieved at Week 62 among patient s in clinical remission at 
Week 10
To evaluate corticosteroid -free clinical r emission at Week 62 (off corticosteroids for 
at least 12 weeks prior to W eek 62) in patients who were receiving corticosteroids at 
baseline
 To evaluate change in histologic disease activity from baseline to Week 10 and 
Week 62
 To evaluate improvement in histologic and/or endoscopic disease activity
To evaluate change in health utilities, as assessed by [CONTACT_760464] -Dimension 
Questionnaire (EQ -5D), from W eek 10 to Week 62
To evaluate improvement in endoscopic appearance of mucosa at Week 10
To evaluate endoscopic remission at Week 10
To evaluate the frequency and duration of hospi[INVESTIGATOR_368396] W eek 10 to 
Week62
 To evaluate response, remission, and corticosteroid -free endpoints ,as determined 
by [CONTACT_781255] i n Table 1.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number [PHONE_16298]
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
32/Protocol GA29102, Version 7Table 1Efficacy  Outcomes Definitions
Outcome Measure Outcome Measure Defini tion
Mayo Clinic Score MCS is a composite of 4 assessments, each rated from 0 3:  stool frequency, rectal bleeding, endoscopy, 
and physician’s global assessment
Partial MCS pMCS is a composite of 3 assessments of the MCS , each rated from 0 3:  stool frequency, rectal 
bleeding, and physician’s global assessment
Modified MCS mMCS is a composite of 3 assessments of the MCS, each rated from 0 3:  stool frequency, 
rectal bleeding, and endoscopy
Remission MCS 2 with individual subscores 1 and a rectal bleeding subscore of 0
Maintained remission Remission achieved at the start of the Maintenance Phase (W eek 10) and maintained at the end of the 
Maintenance Phase ( Week 62).
Clinical remission MCS 2 with individual subscores 1
Maintained clinical remission Clinical remission achieved at the start of the Maintenance Phase (W eek 10) and maintained at the end 
ofthe Maintenance Phase (Week 62)
Clinical response MCS with 3-point decrease and 30% reduction from baseline as well as 1-point decrease in rectal 
bleeding subscore or an absolute rectal bleeding score of 0 or 1
Corticosteroid -free clinical remission Clinical remission with no corticosteroid use for 24 weeks prior to W eek 62
Corticosteroid -free remission Remission with no corticosteroid use for 24 weeks prior to Week 62
Improvement in endoscopic appearance of 
the mucosaEndoscopic subscore 1
Endoscopic remission Endoscopic subscore 0
Histologic remission NHI 1a
MCS Mayo Clinic Score; mMCS modified Mayo Clinic Score ; pMCS partial Mayo Clinic Score ; NHI Nancy histological index.
aSee Appendix 12
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2034Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
33/Protocol GA29102, Version 72.2 SAFETY OBJECTIVES
The safety objectives for this study are as follows:
To evaluate the overall safety and tolerability of etrolizumab over a period of 
62weeks
To evaluate the incidence and severity of infection -related adverse events
To evaluate the incidence of malignancies
To evaluate the incidence and severity of hypersensitivity reactions 
To evaluate the incidence and the clinical significance of anti -therapeutic 
antibodies (ATAs)
2.3 PHA RMA COKINETIC OBJECTIVES
The pharmacokinetic (PK) assessment will be performed in all patients during the 
Induction Phase and in all patients who were randomized into the Maintenance Phase.
The PK objectives for this study are as follows:
To evaluate etrolizumab serum c oncentration at the time of primary endpoint 
evaluation (W eek62) and predose concentration at the steady state during the 
maintenance dosing period
To evaluate the interindividual variability and potential covariate effects on 
etrolizumab serum exposure
2.[ADDRESS_1073921] IC 
OBJECTIVES
The exploratory pharmacodynamics (PD) and diagnostic objectives for this study are as 
follows:
To evaluate the relationship between baseline colonic mucosal biomarkers and/or 
peripheral blood and respon se to study drug, including ,but not limited to ,the 
Eintegrin
To evaluate the levels of biomarkers in colonic tissue and/or peripheral blood at 
baseline and during the treatment period, including, but not limited to ,the E 
integrin 
To evaluate the PD effects on biomarkers in colonic tissue and/or peripheral blood 
following study treatment or placebo
To evaluat e biomarkers in stool at baseline and during the treatment period through
assessments that may include, but are not limited to, analyses of the microbiota and 
bacterial cultures
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2035Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
34/Protocol GA29102, Version 73. STUDY DESIGN
3.1 DESCRIPTION OF STUDY
3.1.1 Overview  of Study  Design
This is a multicenter, Phase III, randomized, double- blind, parallel -group study to 
evaluate the safety, efficacy, and tolerability of etrolizumab (105 mg SC Q4 W) compared 
with placebo in the treatment of UC.  Safety and efficacy of continued etrolizumab 
treatment will be evaluated in patients achieving a clinical response after 10 weeks.
Patients enrolled in this study may be eligible to participate in an open -label extension
and safety monitoring (OLE -SM) study (GA28951), which consists of two parts: Part 1 
(designated OLE [open -label extension]) and Part 2 (designated SM [safety 
monitoring]).
Disease severity will be measured using the MCS ( Appendix 4), which is the current 
outcome measure accepted by [CONTACT_335511].  The 
target population is patients with moder ately to severely active UC (defined as 
MCS 612, endoscopy subscore of 2 as determined by [CONTACT_335542] [IP_ADDRESS], a rectal bleeding subscore 1, and a stool frequency 
subscore 1)and involvement that extends a minimum of 20 cm from the anal verge.
All patients are to be naive to tumor necrosis factor (TNF) inhibitors .
Patients must have had an inadequate response, loss of response, or intolerance to 
prior immunosuppressant and/or corticosteroid treatment. 
Patients who are on background immunosuppressant therapy (6 -MP, AZA, MTX) may 
be enrolled if they have received a stable dose for at least 8 weeks prior to Day 1.  
Such patients should continue on stable doses of their background immunosuppressant 
therapy during the study unless dose reduction or discontinuatio n is required due
totoxicity.
Generally accepted criteria for discontinuation of immunosuppressants due to toxicity 
include ,but are not limited to ,acute pancreatitis, severe leukopenia, severe 
thrombocytopenia, or clinically significant elevations of the liver -associate d enzymes 
from baseline, especially in the presence of an elevated total bilirubin.  The ultimate 
decision to reduce dose or discontinue immunosuppressants due to toxicity remains at 
the discretion of the investigator.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2036Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
35/Protocol GA29102, Version 7Patients on o ral corticosteroid thera py (prednisone at a stable dose of 30 mg, or 
equivalent) may be enrolled according to the following criteria:
If corticosteroid therapy is ongoing or has recently been initiated , the dose has to be
stable for at least 4 weeks immediately prior to Day 1
If corti costeroids are being tapered, the dose has to be stable for at least 2weeks 
immediately prior to Day [ADDRESS_1073922] eroid taper will be initiated.
Initiation of corticosteroid or an increase in corticosteroid dose above the patients’ entry 
dose (up to a maximum of 30 mg/day prednisone [or equivalent ])will not be permitted 
during screening.  Use of budesonide will be allowed at stable dose s (9 mg) provided 
that the dose has been stable for 4weeks prior to Day 1.  Oral 5 -ASA treatment and 
probiotics for the treatment of UC may be continued at a stable dose as long as the 
dose(s) had been stable for 4weeks and 2weeks, respectively, prior to Day 1.  
Certain concomitant treatments are prohibited (see Section 4.1.[ADDRESS_1073923] of all prohibited 
concomitant treatments).
A total of approximately 350 patients will be recruited (see Figure 1) from approximately 
125sites.  The study will be divided into:
Screening period of up to 35 days (for details see Section [IP_ADDRESS])
Open -label etrolizumab treatment period of 10 weeks (Induction Pha se)
Double -blind treatment period of 52 weeks (Maintenance Phase)
Safety follow -up period of 12 weeks
All patients entering the study will receive induction treatment with open -label 
etrolizumab (105 mg SC Q4 W) for 10 weeks.  Eligibility for entry into the Maintenance 
Phase will be determined between W eeks 10 and 12.  Patients who achieved a clinical 
response at Week 10 (see Table 1 for definition of clinical response) will be randomized 
in a 1:1 ratio by W eek 12 into the Maintenance Phase and will receive either etrolizumab 
(105 mg SC Q4 W)or placebo (n ≈105 for each arm).  Randomization will be stratified by 
[CONTACT_781256] a t Week 10, concomitant treatment with cortic osteroids (including 
budesonide ) at baseline, concomitant treatment with immunosuppressants after 
Week10, and disease activity measured during screening (MCS 9/MCS 10).
Patients not achieving clinical response at Week 10 and patients completing the 
Maintenance Phase at W eek 62 should enroll in Part 1 (OLE) of Study GA28951, if 
eligible, where they will receive open -label etrolizumab.  If they do not enroll in 
Part 1(OLE) of Study GA28951 , they will enter the 12- week safety follow -up period of 
this study and then will be requested to enroll in Part 2 (SM) of Study GA28951 for 
92weeks of extended PML monitoring .
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2037Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
36/Protocol GA29102, Version 7Study Drug Administration
The first two doses of study medication will be administered via a prefilled syringe (PFS) 
by a health care professional (HCP) in the clinic.  The subsequent two doses will be 
self-administered by [CONTACT_781257] H CP.  If deemed appropriate by [CONTACT_82275], the remaining doses of study 
drug, starting at W eek 16, will be self -administered by [CONTACT_781258] Q4 W (action to be taken as a result of a hypersensitivity 
reaction is pr ovided in Section 5.1.5 ).  The administration of the study medication at 
home by [CONTACT_781259].  If necessary, patients or their HCPs may choose to continue 
administration of study medication in the clinic.  The details of study medication 
administration are provided in Section 4.3.2 .
Oral Corticosteroids during the Study
During the Induction Phase, patients are to maintain their stable, baseline corticosteroid 
dose.  Corticosteroids ar e to be tapered starting from W eek 10 for patients entering the 
Maintenance Phase.  Patients receiving prednisone at a dose of 10 mg/day (or 
equivalent) are to have their dose reduced at a rate of 5 mg per week until a 10 mg/day 
dose is achieved.  Patien ts receiving prednisone at doses 10mg/day (or equivalent), or 
once a 10 mg/day dose (or equivalent) is achieved by [CONTACT_39782], are to have their dose 
reduced at a rate of 2.5 mg/week until discontinuation.  Beginning at W eek 10, patients 
receiving budesonide should taper their dose of 9 mg every day to 9 mg every other day 
for 2 weeks and then discontinue budesonide treatment .  For patients who cannot 
tolerate the corticosteroid taper without recurrence of clinical symptoms of either UC or 
steroid withdraw al, corticosteroid dose may be increased (up to the dose at study entry if 
required), but tapering must begin again within 2 weeks.
Immunosuppressants during the Study
Patients should continue stable doses of immunosuppressants throughout the 
study .
Patients should remain on their stable baseline doses of immunosuppressants (AZA, 
6-MP, MTX) throughout the study unless dose reduction or discontinuation is required 
because of a toxicity related to the medication.  Generally accepted criteria for 
discont inuation of immunosuppressants due to toxicity include ,but are not limited to ,
acute pancreatitis, severe leukopenia, severe thrombocytopenia, or clinically significant 
elevations of the liver -associated enzymes from baseline, especially in the presence o f 
an elevated total bilirubin.  The ultimate decision to reduce dose or discontinue 
immunosuppressants due to toxicity remains at the discretion of the investigator.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2038Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
37/Protocol GA29102, Version [IP_ADDRESS] Definition of Clinical Relapse
Clinical relapse is defined as an:
Increase in partial Mayo Clinic Score (pMCS) 3 points compared with induction 
timepoint (W eek 10) AND absolute pMCS 5 AND endoscopic subscore 2
If a patient meets criteria for clinical relapse during the Maintenance Phase of the study, 
he or she may withdraw from this stud y and enroll in Part 1 (OLE) of Study GA28951 to 
receive open- label etrolizumab treatment, if eligible.
[IP_ADDRESS] Rescue Therapy
Rescue Therapy  that Can Be Given w ith Study Medication for the Treatment 
of UC
During the Induction Phase (Prior to Week 10):
Patients ar e required to maintain stable doses of their concomitant medications 
(oral 5-ASA, corticosteroids, immunosuppressants) for UC.
In the Induction Phase, any patient who requires initiation of an immunosuppressant 
(AZA, 6 -MP, or MTX), corticosteroid, or oral or topi[INVESTIGATOR_2855] 5- ASA, or who requires an
increase in dose over baseline levels for treatment of worsening disease symptoms 
should stay in the study until Week 10, at which time the patient can enroll in Part 1 
(OLE) of Study GA28951 to receive open- label et rolizumab, if eligible, or enter the 
12
-week safety follow -up in this study and then enroll in Part 2 (SM) of Study GA28951
for extended PML monitoring.  These patients will be classified as non -responders at 
Week10 and may not continue into the Maintenan ce Phase of the study.
During the Maintenance Phase:
Initiation or escalation of oral 5- ASA should be avoided but is permitted if deemed 
clinically necessary by [CONTACT_093].  Patients who initiate or escalate oral 5 -ASA 
therapy may continue blinded tr eatment.
Use of topi[INVESTIGATOR_781227] 5 -ASA is not desired as concomitant 
medication.  If these are used to treat clinical symptoms of UC, the patient may remain in 
the blinded study or may enroll in Part 1 (OLE) of Study GA28951, if eligible, based on 
the investigator’s discretion.  Patients who leave the treatment phase early to enroll in 
Part 1 (OLE) of Study GA28951 should complete the early withdrawal from treatment 
visit prior to enrollment.
Patients must begin the specified cortico steroid taper at Week 10 during the 
Maintenance Phase.  For patients who cannot tolerate the corticosteroid taper without 
recurrence of clinical symptoms of UC or symptoms of steroid withdrawal, corticosteroids 
may be increased (up to the baseline dose, on ly if required).  In such cases, the tapering 
regimen must be reinitiated within 2 weeks.  An increase in corticosteroid dose back to 
baseline is not considered rescue medication if it occurs during the corticosteroid taper.  
These patients should remain i n the blinded study.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2039Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
38/Protocol GA29102, Version 7Patients who were not receiving corticosteroids at baseline and patients who have 
completed the steroid taper who subsequently require oral corticosteroids at a dose 
greater than 10 mg for 5 days or longer for the treatment of worsening UC symptoms or 
steroid withdrawal may remain in the blinded study or may enroll in to Part 1(OLE) of 
Study GA28951, if eligible, based on the investigator’s discretion.  Patients who leave 
the treatment phase early to enroll in Part 1 (OLE) of Study GA28951 should complete 
the early withdrawal from treatment visit prior to enrollment in Study GA28951 .
Endoscopy to document disease activity for patients exiting the treatment period early 
for any reason is strongly recommended.
Immunosuppressants (AZA, 6 -MP, or MTX):  Patients are to remain on their stable, 
baseline dose of immunosuppressant therapy throughout the study unless dose 
reduction or discontinuation is required due to toxicity.  Generally accepted criteria for 
disconti nuation of immunosuppressants due to toxicity include ,but are not limited to ,
acute pancreatitis, severe leukopenia, severe thrombocytopenia, or clinically significant 
elevations of the liver -associated enzymes from baseline, especially in the presence of 
an elevated total bilirubin.  The ultimate decision to reduce dose or discontinue 
immunosuppressants due to toxicity remains at the discretion of the investigator.  
Patients who do initiate or escalate immunosuppressant therapy may remain in the 
blinded study or may be given the option to enroll in Part 1 (OLE) Study GA28951 , if 
eligible, based on the investigator’s discretion.  Patients who leave the treatment phase 
early to enroll in Part 1 ( OLE) Study GA28951 should complete the early withdrawal from 
treatment visit prior to enrollment in Study GA28951 .
Endoscopy to document disease activity for patients exiting the treatment period early 
for any reason is strongly recommended.
Rescue Therapy that Cannot Be Given w ith Study  Medication for the 
Treatment of UC
At ANY time during the conduct of the study, use of other immunosuppressive agents 
including ,but not limited to, anti-integrins, T -or B-cell depleters (except AZA and 6- MP), 
TNF inhibito rs(including TNF inhibitor biosimilar s),anti-adhesion molecules ,Janus 
kinase (JAK) inhibitors, cyclosporine, tacrolimus, or investigational agents are 
prohibited.  Patients who receive such therapi[INVESTIGATOR_760437] -label treatment and will be required to enter the 12 -week safety 
follow -up period of this study (see Appendix 2).  These patients will al so subsequently be 
requested to enroll in Part 2 (SM) of Study GA28951 protocol for [ADDRESS_1073924] of study visits and assessments can be found in the Schedule of 
Assessments (see Appendix 1). 
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number [PHONE_16299]
Etrolizumab —F.Hoffmann -La [COMPANY_002] Ltd
39/Protocol GA29102, Version 7Figure 1Study  Schema
6-MP6-mercaptopurine; AZA azathioprine; d day; CS corticosteroid; MTX methotrexate; OLE open -label extension; 
OLE-SMopen -label extension and safety monitoring; Q4 Wevery 4 weeks; QOD every other day; SC subcutaneous; SM safety monitoring;
TNF tumor necrosis factor; UC ulcerative colitis; wk week. 
aStable budesonide at 9 mg/day.  Taper from W eek 10 to QOD for 2 weeks andthen discontinue .

Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2041Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
40/Protocol GA29102, Version [IP_ADDRESS] Number of Patients
Approximately 350 patients are to be enrolled for this study.  Following 10 weeks of 
open -label induction with etrolizumab, it is estimated that approximately 60% of patients 
will achieve clinical response, which will provide approximately 105 patients in each 
treatment arm for the Maintenance Phase.  Additional patients may be enrolled in the 
Induction Phase if needed to meet sample size requirements for the Maintenance Phase.
3.1.2 Data Monitoring Committee
An independent Data Monitoring Committee (iDMC) will monitor safety and study
conduct on an ongoing basis.  Members of the iDMC will be external to the Sponsor and 
will follow a charter that outlines the iDMC roles and responsibilities.  The iDMC will 
meet approximately every 6 months (frequency adjustable as required) to review 
unblinded safety and study conduct data prepared by [CONTACT_760491] (IDCC).  If the iDMC deems a benefit -risk assessment necessary, the iDMC may 
also review unblinded efficacy data.  The iDMC may recommend stoppi[INVESTIGATOR_760438].  However, the iDMC may not recommend stoppi[INVESTIGATOR_760439].
3.[ADDRESS_1073925] clinical relapse during the Maintenance 
Phase, patients who receive defined rescue treatment (see Section [IP_ADDRESS]), and 
patients who complete 62 weeks of the study may be given the option of enrolling in 
Part 1 (OLE) of Study GA28951 , wher e they will receive open -label etrolizumab
treatment.  Those who do not enroll in Part 1 (OLE) of Study GA28951 will continue to 
12 weeks of safety follow -up in this study and then be requested to enroll in Part 2 (SM) 
of Study GA28951 for [ADDRESS_1073926] patient enrolled into 
Study GA28951 (OLE -SM), whichever is later.
End of Study
The end of the study is defined as the last patient last safety follow -up visit in this 
protocol or last patient in this protocol enrolled into Study GA28951 (OLE -SM), 
whichever is later.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2042Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
41/Protocol GA29102, Version 73.[ADDRESS_1073927] Dosage
Data from Phase I (Study ABS4262g) and Phase II (Study ABS4986g; EUCALYPTUS) 
indicated that the 100 -mg Q4 W regimen is sufficient to maintain 7 receptor occupancy 
both in blood and in colonic tissue, is well tolerated, and results in meaningful clinical 
efficacy, and theref ore, will be evaluated further in this Phase III study.  The rationale for 
proposing a 105 -mg Q4W  SC regimen is discussed below.
The Phase II 100 -mg Q4W  SC dose (0.7 mL of 150 mg/mL solution via vial and 
syringe, with an intended nominal dose of 100 mg ) showed clinically meaningful 
efficacy without clinically meaningful safety imbalances (see Section 1.2).  The 
Phase III formulation is a PFS containing 0.7 mL of 150 mg/mL etrolizumab solution, 
corresponding to delivering a dose of 105 mg etrolizumab per injection.
In the Phase II EUCALYPTUS study, the 100 -mg SC Q4 W dose resulted in an 
increased clinical remission rate in TNF -naive pat ients (43.8%; p0.007), as 
well as in the combined TNF -naive and inadequate response to anti- tumor 
necrosis factor (TNF -IR) group (20.5%; p0.004) at Week 10 as compared with 
the clinical remission rate in placebo patients (0%).  These data suggest tha t 
the 100 -mg SC Q4W  dose regimen is efficacious in patients with moderately 
and severely active UC.
Up to a 4 5-fold higher exposure did not result in a greater PD effect or an increase 
in clinical benefit.
A higher dose (420 mg SC at Week 0 followed by 30 0 mg at Weeks 2, 4, and 8) 
was also tested in the EUCALYPTUS study without any major safety concerns.  
However, there was no clear distinction in observed pharmacological effects 
(including clinical efficacy outcome and PD response, such as 7 receptor 
occupancy) between high -dose and the 100- mg dose cohorts.  Although the 
study was not powered to enable a formal comparison of the two active arms, 
the data suggest that the observed clinical remission rate at Week 10 in the 
low-dose cohort was not further im proved in the high -dose cohort. 
Preliminary concentration quartile
-response analysis was conducted, for the 
data pooled from both low -and high -dose cohorts, to see whether patients in 
the higher concentration quartiles had better remission rate.  The res ults did not 
show any exposure response relationship.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2043Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
42/Protocol GA29102, Version 7Exposure lower than 100 mg Q4 W is likely not sufficient to maintain 7 integrin 
receptor occupancy.
In the Phase I study (Study ABS4262g), the etrolizumab PK profile appears 
nonlinear at a dose level of 1 mg/kg IV.  The duration of 7 receptor 
occupancy is dose dependent.  A single dose of0.3 mg/kg IV maintained 
7receptor occupancy for only approximately 2 weeks, which is likely 
insufficient to ensure maximal 7 receptor occupancy at all times withi n a 
Q4Wdosing interval.
On the basis of data from the Phase II EUCALYPTUS study, it is assumed that 
maximal/near maximal occupancy of 7 receptors both in the blood and in 
colonic tissue is minimally necessary for etrolizumab’s clinical activity.  Per thi s 
assumption, population PK simulations were performed and results showed that 
a 100 -mg SC Q4 W regimen can provide steady -state serum trough 
concentration (C trough,ss ) of at least 1.7 g/mL (the minimum serum concentration 
observed that maintained colonic tissue 7occupancy) in 84% of patients, 
whereas a dose lower than the 100 -mgSC Q4 W regimen (e.g., 50 mg Q4W SC) 
is likely not sufficient for maintaining 7receptor occupancy at all times during 
the Q4 W dosing interval, since only 56% of patients were predicted to reach a 
1.7g/mL level in their C trough,ss (see Table 2 ).
Lower doses are also anticipated to result in etrolizumab serum level falling into 
the nonlinear PK concentration range and hence are likely to increase variability 
in exposure.
Table 2Population Pharmacokinetic Modeling Predicted Percentage of 
Patients A chiev ing 1.7 -g/mL Steady -State Trough Concentration 
under Different Dosing Scenarios
Q4W SC Dosing
[ADDRESS_1073928] C trough,ss 1.7g/mL98 84 56
Ctrough,ss steady -state trough concentrations; PK pharmacokinetic; 
Q4Wevery 4 weeks; SC subcutaneous.
Note:  1.7 g/mL is the minimum serum concentration observed in the 
Phase II study that maintained 7 occupancy in the colonic tissue.
In conclusion, on the basis of available etrolizumab efficacy, PK, PD, and safety data 
(see Section 6.6), a PFS delivering a dose of [ADDRESS_1073929] 
appropriate dosing regimen for this Phase III study.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2044Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
43/Protocol GA29102, Version 73.3.2 Rationale for Patient Population 
There is a high unmet medical need in moderately to severely active UC due to current 
treatments being associated with significant adverse events, low rates of sustained 
remission, or being highly invasive (i.e., colectomy) (see Sectio n1.1for details).  
The Phase II EUCALYPTUS trial of etrolizumab versus placebo provided evidence of 
efficacy, including induction of remission at W eek 10, in patients with moderately to 
severely active UC refractory to or intolerant of conventional and/or TNF inhibitor
thera pi[INVESTIGATOR_014].  Results from this trial showed that in the TNF- naive subgroup, clinical 
remission (defined as MCS 2 and all subscores 1)at Week 10 was observed in 
43.8% versus 0 % of patients in the [ADDRESS_1073930] the 
efficacy and safety of etrolizumab in this patient population. 
3.3.3 Rationale for Control Group
A placebo- treated control group will be used in this study in the Maintenance Phase to 
assess the differences i n efficacy, safety, and tolerability in patients who receive 
etrolizumab plus background UC therapy compared with patients who receive placebo 
plus background UC therapy.  The use of a control group during the maintenance period 
is necessary given the inherent variability in disease flares and the use of subjective 
assessments, such as the patient -reported outcomes (PROs) .  Patients in the control 
group will undergo the same study assessments as the etrolizumab -treated patients.
3.3.[ADDRESS_1073931] an increased chance of response to therapy would be 
valuable to patients and treating physicians to aid in guiding treatment decisions.  
Etrolizumab binds to the 7 integrin and blocks 47:MAdCAM and E7:E-cadherin 
binding.  In exploratory analyses from the Phase II EUCALYPTUS study, patients with 
higher baseline biopsy E gene expression by [CONTACT_137414] 
(qPCR) and E+cell counts by [CONTACT_9064] (IHC) had a higher rate of 
remission at Week 10 (see Figure 2).  The baseline levels of E and other biomarkers 
will be evaluated in this Phase III study to further assess whether they may function as 
predictive response biomarkers.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2045Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
44/Protocol GA29102, Version 7Figure 2 Effects of High and Low Baseline Expression of the E Biomarker in 
Colon on the Remission Status of Patients with Ulcerative Colitis 
Treated with Etrolizu mab in EUCA LYPTUS (Observed Data)
LDloading dose; SC subcutaneous.
All patients enrolled in the current study will have mandatory colonic mucosal sampling 
at the screening visit to analyze the relationship of E levels (and potentially other 
biomarkers) with response to treatment.  In addition, samples will be collected at 
Weeks10 and 62 for potential exploratory biomarker analyses that include ,but are not 
limited to, E expression.
3.4 OUTCOME MEA SURES 
3.4.1 Efficacy  Outcome Measures
Primary Outcome Measure
Remission at W eek 62 among patients w ith a clinical response at Week 10 ,as 
determined by [CONTACT_781260]
Clinical remission at Week 62 among patients in clinical remission at W eek 10
Clinical remission at Week 62
 Remission at Week 62 among patients in remission at Week 10
Improvement in endoscopic appearance of the mucosa at W eek 62
Endoscopic remission at W eek 62
Histologic remission at W eek 62
 Change from baseline in rectal bleed subscore at Week 6
 Change from baseline in sto ol frequency subscore at Week 6
Corticosteroid -free clinical remission at W eek 62 (off corticosteroids for at least 
24weeks prior to Week 62) in patients who are receiving corticosteroids at baseline
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2046Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
45/Protocol GA29102, Version 7Corticosteroid -free remission at Week 62 (off corticost eroids for at least 24 weeks 
prior to Week 62) in patients who are receiving corticosteroids at baseline
Change from baseline to Week 62 in UC bowel movement signs and symptoms as 
assessed by [CONTACT_335505] -PRO/SS measure 
Change from baseline to Week 62 in UC abdominal symptoms as assessed by [CONTACT_335519]-PRO/SS measure 
Change from baseline to Week 62 in patients’ health -related QOL as assessed by 
[CONTACT_335536] 
 Clinical response at Week 62 among patients with a clinical response at Week 10
 Remission at Week 62 among patients in clinical remission at Week 10 
Corticosteroid -free clinical remission at W eek 62 (off corticosteroids for at least 
12weeks prior to Week 62) in patients who are receiving corticosteroids at baseline
 Histologic disease activity change from baseline to Week 10 and Week 62
 Improvement in histologic and/or endoscopic disease activity
Change in health utilities, as assessed by [CONTACT_20367] -5D, from baseline to 
Weeks10and 62
Improvement in endoscopic appearance of the mucosa at W eek 10
Endoscopic remission at W eek 10
Frequency and duration of hospi[INVESTIGATOR_368396] W eek 10 to W eek 62
 Response, remission and corticosteroid -free endpoints as determined by [CONTACT_335538]
3.4.2 Safety  Outcome Measures
The saf ety outcome measures for this study are as follows:
Incidence and severity of adverse events
Incidence of serious adverse events
Incidence and severity of infection -related adverse events
Incidence of serious infection -related adverse events
Incidence and severity of injection- site reactions 
Incidence of adverse events leading to study drug discontinuation
Incidence of laboratory abnormalities
Incidence of malignancies
Incidence of ATAs to etrolizumab
Incidence and severity of hypersensitivity reaction e vents
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2047Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
46/Protocol GA29102, Version 73.4.3 Pharmacokinetic Outcome Measures
The PK outcome measures for this study are as follows:
Serum trough concentration at steady state during the dosing period from W eek 12 
to Week 62
Serum concentration at primary endpoint time (W eek 62)
3.4.4 Exploratory  Biomarker Outcome Measures
The exploratory biomarker outcome measures for this study are as follows:
Remission at W eek 10 and maintenance of remission at Week 62 in patients 
according to baseline levels of colonic tissue biomarkers and/or peripheral blood,
including ,but not limited to, E integrin
Changes in levels of exploratory colonic tissue and/or peripheral blood biomarkers 
during the Induction and Maintenance Phases
Changes in stool biomarkers, which may include, but are not limited to , those in the 
microbiota and bacterial cultures ,during the Induction and Maintenance Phases
4. MATERI ALS AND METHOD S
4.1 PATIENTS
The target population is patients who are naive to TNF inhibitors with moderately to 
severely active UC (defined as MCS of 6 12, endoscopy subscore of 2 as determined 
by [CONTACT_335566] [IP_ADDRESS], a rectal bleeding subscore 
1, a stool frequency subscore 1,and colonic involvement extending a minimum of 
20cm from the anal verge) .
4.1.[ADDRESS_1073932] meet the follo wing criteria for study  entry :
Able and willing to provide written informed consent
1880 years of age, inclusive
Diagnosis of UC established at least 3 months prior to Day 1 by [CONTACT_335514].  This diagnosis should be corroborated by [CONTACT_781261] a histopathology 
report.  (Note that histopathology may be performed at screening if no prior report is 
readily available.)
Moderately to severely active UC as determined by [CONTACT_335516] 6 12 with an 
endoscopic subscore 2as determined by [CONTACT_781262] [IP_ADDRESS], a rectal bleeding subscore 1,and a stool frequency subscore 
1 during the screening period (prior to Day 1).  See also Section [IP_ADDRESS] for 
additional information regarding the time window
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2048Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
47/Protocol GA29102, Version 7Evidence of UC extending a minimum of 20 cm from the anal verge as determined 
by [CONTACT_335543] (flexible sigmoidoscopy or colonoscopy) performed during 
screening, 4 16 days prior to Day 1.   See also Section [IP_ADDRESS] for additional 
information regarding the time window
Naive to treatment with TNF inhibitors
Patients must have had an inadequate response, loss of response, or intolerance to 
prior immunosuppressant and/or corticosteroid treatment 
Inadequate response to, loss of response to, or intolerance to prior 
immunosuppressant treatment ,is defined as one or more of the following: 
Persistent signs and symptoms of active disease despi[INVESTIGATOR_040] a history of at least 
one 12- week regimen of oral AZA ( 1.5 mg/kg) or 6
-MP (0.75 mg/kg )and/or 
MTX (15mg/week) within the previous 5 years
Persistent signs and symptoms of active disease despi[INVESTIGATOR_040] a 6 -TG level of 
230pmol/8 108RBCs during at least one 12 -week regimen of oral AZA or 6 -
MP at a stable or increasing dose within the previous 5 years
History of intolerance to AZA, 6 -MP, or MTX (including ,but not limited to ,
nausea/vomiting, abdominal pain, pancreatitis, LFT abnormalities, 
lymphopenia, TPMT genetic mutation, infection) within t he previous 5 years
Inadequate response, loss of response, or intolerance to corticosteroid treatment is 
defined as one or more of the following: 
Steroid refractory :  persistent symptoms of active disease despi[INVESTIGATOR_335470] 4 -week inducti on regimen that included a dose of 30 mg 
prednisone (oral) daily (or equivalent )for at least [ADDRESS_1073933] 1 week within the previous 5 years
Steroid dependent :  two failed attempts to taper steroids below a dose 
equivalent to 10 mg prednisone (oral) daily
Steroid intolerant :  history of intolerance to corticosteroids (including ,but not 
limited to, Cushing’s syndrome, osteopenia/osteoporosis, hyperglycemia, 
insomnia, infection) within the previous 5 years
Any ongoing UC therapy must be at stable doses:
May be receiving oral 5 -ASA compounds provided that the dose has been 
stable for 4 weeks immediately prior to Day 1
May be receiving oral corticosteroid therapy (prednisone at a stable dose 
of30 mg a day, or equivalent steroid)
If corticosteroid therapy is ongoing or has recently been initiated , the dose 
has to be stable for at least [ADDRESS_1073934] 
2weeks immediately prior to Day 1.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2049Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
48/Protocol GA29102, Version 7May be receiving budesonide therapy at a stable dose of up to 9 mg a day for 
4 weeks prior to Day 1
May be receiving probiotics (e.g., Culturelle, Saccharomyces boulardii), 
provided that the dose has been stable for 2 weeks immediately prior to Day 1
May be receiving AZA, 6 -MP, or MTX, provided that the dose has been stable 
for 8weeks immediately prior to Day 1
For women who are not postmenopausal (at least 12 months of
non therapy -induced amenorrhea) or surgically sterile (e.g., absence of ovari es 
and/or uterus): agreement to remain abstinent or use a highly ef fective method of 
contraception during the treatment period and for at least [ADDRESS_1073935] 
dose of study drug (seeAppendix 3).
The reliability of sexual abstinence should be evaluated in relation to the 
duration of the clinical trial and the preferred and usual lifestyle of the patient.   
Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation 
methods) and withdrawal are not acceptable methods of contraception.
For men:  agreement to remain abstinent (refrain from heterosexual intercourse) or 
use contraceptive measures, and agreement to refrain from donating sperm, as 
defined below: 
With female partners of childbearing potential or pregnant female partners, men 
must remai n abstinent or use a condom during the treatment period and for at 
least [ADDRESS_1073936] refrain from donating sperm during this same period.  
The reliability of sexual absti nence should be evaluated in relation to the 
duration of the clinical trial and the preferred and usual lifestyle of the 
patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or 
postovulation methods) and withdrawal are not acceptable me thods of 
contraception.
Must have received a colonoscopy within the past year or be willing to undergo a 
colonoscopy in lieu of a flexible sigmoidoscopy at screening.  This colonoscopy 
must:
Confirm disease extent (defined as 1) left -sided colitis [up to t he 
splenic flexure], 2) extensive colitis [beyond the splenic flexure but not involving 
the entire colon], and 3) pancolitis; see Section [IP_ADDRESS] ) 
Include removal of any adenomatous polyps 
Document evidence of surveillance for dysplasia for all patients with left -sided 
colitis of 12years’ duration and total/extensive colitis of 8 years duration 
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2050Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
49/Protocol GA29102, Version 74.1.2 Exclusion Criteria
Patients who meet any of the following criteria will be excluded from study entry:
Exclusion Criteria Related to Inflammatory  Bowel Disease
Prior extensive colonic resection, subtotal or total colectomy, or planned surgery 
forUC
Past or present ileostomy or colostomy
Diagnosis of indeterminate colitis 
Suspi[INVESTIGATOR_335456], radiation colitis, or microscopic colitis
Diagnosis of toxic megacolon within 12 months of initial screening visit 
Any diagnosis of Crohn’s disease
Past or present fistula or abdominal abs cess
A history or current evidence of colonic mucosal dysplasia
Patients with any stricture (stenosis) of the colon
Patients with history or evidence of adenomatous colonic polyps that have not 
been removed
Exclusion Criteria Related to Prior or Concomitant Therapy
Any prior treatment with etrolizumab or other anti -integrin agents (including 
natalizumab, vedolizumab, and efalizumab)
Any prior treatment with anti -adhesion molecules (e.g., anti -MAdCAM -1)
Any prior treatment with rituximab
 Any treatm ent with tofacitinib during screening
Use of IV steroids within 30 days prior to screening with the exception of a single 
administration of IV steroid
Use of agents that deplete B or T cells (e.g., alemtuzumab or visilizumab) within 
12months prior to Day 1, with the exception of AZA and 6- MP
Use of cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil (MMF) within 
4weeks prior to Day 1
Chronic nonsteroidal anti -inflammatory drug (NSAID) use.  (Note: occasional use of 
NSAIDs and acetaminophen [e.g. , headache, arthritis, myalgias, or menstrual 
cramps] and aspi[INVESTIGATOR_155752] 325 mg daily is permitted.)
Patients who are currently using anticoagulants including ,but not limited to ,
warfarin, heparin, enoxaparin, dabigatran, api[INVESTIGATOR_3822], rivaroxaban.  (Note that 
antiplatelet agents such as aspi[INVESTIGATOR_155752] 325 mg daily or clopi[INVESTIGATOR_335457].)
Patients who have received treatment with corticosteroid enemas/suppositories 
and/or topi[INVESTIGATOR_19529] l (rectal) 5 -ASA preparations within 2weeks prior to Day 1
Apheresis (i.e., Adacolumn apheresis) within 2 weeks prior to Day 1
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2051Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
50/Protocol GA29102, Version 7Received any investigational treatment including investigational vaccines within 
5half-lives of the investigational product or [ADDRESS_1073937] dose , whichever is 
greater , prior to Day 1
History of moderate or severe allergic or anaphylactic/anaphylactoid reactions to 
chimeric, human, or humanized antibodies, fusion proteins, or murine proteins or 
hypersensitivity to etroliz umab (active drug substance) or any of the excipi[INVESTIGATOR_840] 
(L-histidine, L- arginine, succinic acid, polysorbate 20)
Patients administered tube feeding, defined formula diets, or parenteral 
alimentation/nutrition who have not discontinued these treatments 3 we eks prior 
toDay1
Exclusion Criteria Related to General Safety
Pregnant or lactating
Lack of peripheral venous access
Hospi[INVESTIGATOR_057] (other than for elective reasons) during the screening period
Inability to comply with study protocol, in the opi[INVESTIGATOR_8598] e investigator
Significant uncontrolled comorbidity, such as cardiac (e.g., moderate to severe heart 
failure [LOCATION_001] Heart Association [NYHA] Class III/IV), pulmonary, renal, hepatic, 
endocrine, or gastrointestinal disorders (excluding UC)
Neurological conditions or diseases that may interfere with monitoring for PML
History of demyelinating disease
Clinically significant abnormalities on screening neurologic examination (PML 
Objective Checklist)
Clinically significant abnormalities on the screening PML Subjective Checklist
History of alcohol, drug, or chemical abuse 6 months prior to screening
Conditions other than UC that could require treatment with 10 mg/day of 
prednisone (or equivalent) during the course of the study
History of cancer, including hematologic malignancy, solid tumors, and carcinoma 
insitu, within 5 years before screening with the following exceptions :
Local basal or squamous cell carcinoma of the skin that has been excised and 
is considered cured is not exclusionary.
A history of chronic myelogenous leukemia, hairy cell leukemia, melanoma, 
renal cell carcinoma, or Kaposi sarcoma is exclusionary, irrespective of the 
duration of time before screening.
History of a cervical smear indicating the presence of adenocarcinoma in situ 
(AIS), high -grade squamous intraepi[INVESTIGATOR_12184] (HSIL), or cervical 
intraepi[INVESTIGATOR_28601] (CIN) of Grade 1 is exclusionary, irrespective of the 
duration of time before screening.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2052Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
51/Protocol GA29102, Version 7Exclusion Criteria Related to Infection Risk
Congenital or acquired immune deficiency
Patients must undergo screening for HIV and test positive for preliminary and 
confirmatory tests
Positive hepatitis C virus (HCV) antibody test result, unless the patient (1) has 
undetectable HCV RNA levels for 6 months after completing a s uccessful course 
of HCV anti -viral treatment and an undetectable HCV RNA at screening or (2) has 
aknown history of HCV antibody positivity with a history of undetectable HCV RNA 
and undetectable HCV RNA at screening in the absence of history of HCV anti -viral 
treatment.
Patients must undergo screening for hepatitis B virus (HBV).  This includes testing 
for HBsAg (HBV surface antigen), anti -HBc total (HBV core antibody total), and 
HBV DNA (patients who test negative for these tests are eligible for this stu dy):
Patients who test positive for surface antigen (HBsAg )are not eligible for this 
study, regardless of the results of other hepatitis B tests.
Patients who test positive only for core antibody (anti -HBc ) must undergo 
further testing for hepatitis B DNA (HBV DNA test). 
If the HBV DNA test is positive, the patient is not eligible for this study.
In the event the HBV DNA test cannot be performed, the patient is not 
eligible for this study. 
If the HBV DNA test is negative, the patient is eligible for this study.  These 
patients will undergo periodic monitoring for HBV DNA during the study.
Evidence of or treatment for Clostridium difficile (as assessed by C. difficile toxin 
testing) within 60 days prior to Day 1 or other intestinal pathogens (as assessed by 
[CONTACT_760498]) within 30 days prior to Day 1
Evidence of or treatment for clinically significant cytomegalovirus (CMV) colitis 
(based on the investigator’s judgment) within 60 days prior to Day 1.  Laboratory 
confirmation of CMV from colon biopsy sample is required during screening 
evaluation only if clinical suspi[INVESTIGATOR_781228].
History of active or latent TB, regardless of treatmen t history (see Section [IP_ADDRESS] )
Patients with a history of active or latent TB (based on a positive screening 
assay, either purified p rotein derivative [[COMPANY_003]] skin test or QuantiFERON-TB 
Gold test ), are not eligible for this study.
Patients with a c hest X -ray (posteroanterior [PA] and lateral) within 3 months of 
Day 1 suspi[INVESTIGATOR_335459].
History of recurrent opportunistic infections and/or history of se vere d issemi nated 
viral infections (e.g., herpes)
Any serious opportunistic infection within the last 6 months
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2053Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
52/Protocol GA29102, Version 7Any current or recent signs or symptoms (within 4 weeks before screening and 
during scr eening) of infection, except for the following:
Minor infections (e.g., common cold) that have, in the investigator’s judgment, 
completely resolved prior to Day 1
Fungal infections of the nail beds
Oral or vaginal candidiasis that has resolved with or with out treatment prior 
toDay 1
Any major epi[INVESTIGATOR_760443] 8 weeks 
prior to screening or oral antibiotics within 4weeks prior to screening
Treatment with antibiotics as adju nctive therapy for UC in the absence of 
documented infection is not exclusionary.
Received a live attenuated vaccine within 4 weeks prior to Day 1
History of organ transplant
Exclusion Criteria Related to Laboratory  Values (at Screening)
Serum creatinine 2 times upper limit of norm al (ULN)
ALT or AST 3ULN, or alkaline phosphatase 3ULN, or total bilirubin 
2.5ULN (unconjugated hyperbilirubinemia that is associated with known 
Gilbert's syndrome is not an exclusion criterion)
Platelet count 100,000/ L
Hemoglobin 8 g/dL
Absolute neutrophil count 1500/ L
Absolute lymphocyte count 500/L
4.2 METHOD OF TREA TMENT ASSIGNMENT A ND BLIND ING 
After written informed consent has been obtained, all patients will receive a screening 
number, which will be assigned by [CONTACT_26772]/W eb-based response system 
(IxRS).  Following completion of the screening period and after all patient eligibility
requirements are confirmed, patients will be assigned an identification number (a 
different number from the screening number ) on Day 1 and will receive treatment with 
open -label etrolizumab for 10 weeks in the Induction Phase.  Patients achieving a 
clinic al response at W eek 10 (see Table 1 for definition of clinical response) will undergo 
randomization in a 1:1 ratio to either 105 mg etrolizumab SC or placebo (Maintenance 
Phase), stratified by [CONTACT_781263] W eek 10, conco mitant treatment with 
corticosteroids (yes/no), concomitant treatment with immunosuppressants after Week 10 
(yes/no), and disease activity measured during screening (MCS 9/MCS 10). In order 
to facilitate Maintenance Phase sensitivity analyses of outco mes for patients who 
achieved remission in the Induction Phase using alternative remission definitions 
(i.e., not including the Physician’s Global Assessment [PGA] subscore of the MCS 
among remission criteria), the W eek 10 remission status stratification v ariable will 
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2054Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
53/Protocol GA29102, Version 7consist of three levels according to whether remission was achieved with or without 
inclusion of the PGA criteria described in Table 1 .
A permuted blocks randomization method will be used to obtain an approximately 
1:1ratio between the treatment and placebo arms within each stratum. Patients will 
receive either etrolizumab (105 mg SC Q4 W) or placebo in a 1:1 ratio in a blinded 
manner until Week62 (see Figure 3for details of study drug administration schedule).
During the 52- week maintenance double -blind treatment period, the IxRS will make 
etrolizumab/etrolizumab placebo study treatment kit assignments.  Each kit will consist 
of one prefilled 1 -mL syringe (0.7 mL no minal volume).   At each dosing visit (occurring 
every 4 weeks) during the blinded treatment period, one study drug kit will be assigned 
for administration to each patient.  The placebo and active kits are filled and packaged to 
look identical.  Patients perf orming study drug administration at home may receive two 
or three kits at a time beginning at W eek 24 in order to allow sufficient supply until their 
next in- clinic visit.
Patients, all study site personnel, and the Sponsor and its agents will be blinded to 
treatment assignment throughout the 52 -week maintenance double -blind treatment 
period.  The IxRS service provider and personnel responsible for performing PK assays 
(in order to identify appropriate dilutions of PK samples to be analyzed) will be unbli nded 
to patients’ randomized treatment assignments.  As described in Section 6, treatment 
assignment will be unblinded to the Sponsor personnel performing the analysis when all 
data through W eek [ADDRESS_1073938] been cleaned and verified.  
However, patients and all study site personnel will remain blinded to individual treatment 
assignment until after the study is completed (after all patients have either completed the 
treatment and safety follow -up period or discontinued early from the study) and the 
database is locked.
If unblinding is necessary for patient management (in the case of a serious adverse 
event), the investigator will be able to break the treatment code by [CONTACT_123517].  
Treatment codes should not be broken except in emergency situations.  If the 
investigator wishes to know the identity of the study drug for any other reason, he or she 
should c ontact the Medical Monitor.  The investigator should document and provide an 
explanation for any premature unblinding (e.g., accidental unblinding, unblinding due to 
a serious adverse event per health authority reporting requirements).  The 
Sponsor Safety Reporting Department (independent from the study team) will break the 
treatment code for all unexpected serious adverse events (see Section 5.2.2 ) that are 
considered by [CONTACT_335547]. The study team will remain blinded to study treatment .
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number [PHONE_16300]
Etrolizumab —F.Hoffmann -La [COMPANY_002] Ltd
54/Protocol GA29102, Version 7Figure 3Schedule of Study  Drug A dministration
CScorticosteroids ; dday; HCP health care professional; IS immunosuppressant ;OLE-SMopen -label extension and safety monitoring study; 
QOD once every other day; TC telephone call; wkweek.

Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number [PHONE_16301]
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
55/Protocol GA29102, Version 74.3 STUDY TRE ATMENTS
Table 3Treatment/Concomitant Background Treatments
Treatment/Concomitant Background Treatment
Investigational medicinal product Etrolizumab, 105 mg SC every 4 weeks
Placebo SC every 4 weeks
Non-investigational medicinal products
Induction Phase Continuation of stable baseline doses of the following:
oral 5-ASA; AZA; 6-MP ; MTX
Corticosteroids up to 30 mg/day of prednisone (or equivalent)
Budesonide up to 9 mg/day
Maintenance Phase Responders who enter the Maintenance Phase should continue immunosuppressants (AZA, 6 -MP, MTX) at a 
stable dose unless dose reduction or discontinuation is required due to immunosuppressant -related toxicity. 
Generally accepted criteria for discontinuation of immunosuppressants due to toxicity include ,but are not limited to ,
acute pancreatitis, severe leukopenia, severe thrombocytopenia, or clinically significant elevations of the liver-
associated enzymes from baseline, especially in the presence of an elevated total bilirubin.  The ul
timate decision 
to reduce dose or discont inue immunosuppressants due to toxicity remains at the discretion of the investigator.
During the Maintenance Phase, patients receiving prednisone at a dose of 10mg/day (or equivalent) are to have 
their dose reduced at a rate of 5 mg per week until a 10 mg/day dose is achieved.  Patients receiving prednisone at 
doses 10 mg/day (or equivalent), or once a 10 mg/day dose (or equivalent) is achieved by [CONTACT_39782], are to have 
their dose reduced at a rate of 2.5 mg/week until discontinuation.  Patients receiv ing budesonide at study entry are 
to taper their dose starting from W eek10 from 9 mg QD to 9 mg QOD for 2 weeks, and then discontinue.  For 
patients who cannot tolerate the corticosteroid taper without recurrence of clinical symptoms of either ulcerative 
colitis or steroid withdrawal, corticosteroid dose may be increased (up to the dose at study entry if required), but 
tapering must begin again within 2 weeks.
Throughout study Probiotics and oral 5 -ASA may be continued at a stable dose throughout.
Occasional use of NSAIDs and acetaminophen (e.g., headache, arthritis, myalgias, and menstrual cramps) and 
aspi[INVESTIGATOR_155752] 325 mg daily are permitted throughout the study.
Antidiarrheals (e.g., loperamide, diphenoxylate with atropi[INVESTIGATOR_050]) for control of chronic diarrhea are permitted.
5-ASA 5-aminosalicylic acid; 6 -MP6-mercaptopurine; AZAazathioprine; MTXmethotrexate; NSAID nonsteroidal anti-inflammatory drug; QD once a day; 
QOD once every other day; SCsubcutaneous.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2058Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
57/Protocol GA29102, Version [IP_ADDRESS] Concomitant Background Treatment for Ulcerative Colitis
For concomitant background treatment for UC see Table [ADDRESS_1073939] Characteristics (SmPCs) or 
product label, local prescribing dosage, administration, and compliance information for 
the formulation, packaging, and handling details of agents prescribed as concomitant 
background treatment for UC.
4.3.2 Dosage, A dministration, and Compliance
[IP_ADDRESS] Etrolizumab and Placebo
Allpatients willreceiveone 0.7-mLinjection with use of a PFS device once Q4 W.  The
device isa 1mL lo ng glass syringe with a staked -instainless steelneedle. 
 
 
A part of the needle cap of the PFS may contain natural rubber latex that may cause 
allergic reactions in latex -sensitive individuals.
Study site HCPs will be trained on the use of the PFS device and SC administration of 
study medication into the thigh, abdo men, or upper arm.  Patients will in turn be trained 
in the use of the device by [CONTACT_760500] “Information for Use” leaflet.   In the event that 
a caregiver will ultimately administer study drug to the patient in the home setting, the 
caregiver is to be tr ained.   The upper arm site is to be used for caregiver and not patient 
administration of study treatment.
For the initial four dose administrations, study medication is to be administered under 
close supervision of the HCP in a setting where medications an d resuscitation facilities 
are available.  The first two treatments (each 0.7 mL delivered via PFS; Week 0 [Day 1] 
and W eek4) will be administered by [CONTACT_760501] (and/or 
caregiver).  The following two treatments ( Week 8 and Week 12) will be administered by 
[CONTACT_102] (or caregiver) and observed by [CONTACT_760502].   Following the 
first four study treatment administrations, patients will be monitored for acute 
hypersensitivity reactions for at least [ADDRESS_1073940] and treat such reactions.
Patients with severe hypersensitivity reactions (e.g., stridor, angioedema, life -threatening 
change in vital signs) must be withdrawn from s tudy treatment.  These patients will not 
be eligible to receive open -label etrolizumab in Part 1 (OLE) of Study GA28951 but are 
to enter the 12
-week safety follow -up in this study followed by [CONTACT_781264] 2(SM) of Study GA28951 .

Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number [ADDRESS_1073941] 
be informed as soon as is practical (see the Study Manual for contact [CONTACT_3031]).
Following completion of this first 3 -month period training in a clinical setting, study drug 
administration ( Week [ADDRESS_1073942]) will be continued in the home setting, 
by [CONTACT_76409] a caregiver, if considered appropriate by [CONTACT_093].  Study 
medication will be administered in the patients’ home after return from the clinic visit.  
Patients and/or the caregiver will be provided
 with contact [CONTACT_781265]-administration between visits .  Competence of the patient or caregiver to 
administer at home will be documented.  Compliance in the home setting is to be 
monitored  using an e-diary to record drug administration and return of used and unused 
medication syringes (see Appendix 7).  Patients and/or the caregiver will be provided 
with alert cards for themselves and a partner/caregiver, which they will be requested to 
carry at all times.  These will include guidance on
 recognizing
allergic/anaphyl actic/anaphylactoid reacti ons and how to obtain emergency care in the 
event such a reaction occurs and information regarding recognition of symptoms of PML.
If the HCP/ patient cannot administer study medication on the scheduled dosing day, 
study medication is to be administered within a window of +3 days from the scheduled 
dosing date.  If the patient experiences a minor illness (e.g., minor infection), at the 
discretion of the investigator, study medication may be delayed for a maximum period of 
[ADDRESS_1073943].  The injection sites will be inspected by [CONTACT_760506].  Any 
injection- site reactions (including those following an injection in the home setting) 
(see Section 5.1.5 ) should be documented on the appropriate adverse event electronic 
Case Report Form ( eCRF ) page .  Patients administering at home should be taught to 
report any injection-site reactions as adverse events (e.g., redness and/or swelling). 
Guidelines for treatment interruption or discontinuation are provided in Sections  [IP_ADDRESS]  
and 5.1.
Etrolizumab —F.
 Hoffmann -La [COMPANY_002] Ltd
58/Protocol GA29102, Version 7
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2060Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
59/Protocol GA29102, Version [IP_ADDRESS] Concomitant Background Treatment and Rescue Therapy
Patients must have had an inadequate response, loss of response, or intolerance to 
prior immunosuppressant and/or corticosteroid treatment, as described in Section 4.1.1
and as described below.
All patients are to be defined as refractory, dependent, or intolerant in the eCRF, if 
appropriate, irrespective of whether corticosteroid inadequate response forms part of the 
eligibility criteria.
Inadequate response to, loss of response to, or intolerance to prior immunosuppressant 
treatment is defined as one or more of the following: 
Persistent signs and symptoms of active disease despi[INVESTIGATOR_040] a history of at least one 
12-week regimen of oral AZA ( 1.5 mg/kg) or 6 -MP ( 0.75 mg/kg) and/or 
MTX (15mg/week) within the previous 5 years
Persistent signs and symptoms of active disease despi[INVESTIGATOR_040] a 6-TG level of 
230pmol/8 108RBCs during at least one 12 -week regimen of oral AZA or 6 -MP 
at a stable or increasing dose within the previous 5 years
History of intolerance to AZA, 6 -MP, or MTX (including ,but not limited to ,
nausea/vomiting, abdominal pain, pancreatitis, LFT abnormalities, lymphopenia, 
TPMT genetic mutation, infection) within the previous 5 years
Inadequate response, loss of response, or intolerance to corticosteroid treatment is 
defined as one or more of the following:
Steroid refractory :  persistent symptoms of active disease despi[INVESTIGATOR_168013] 4- week induction regimen tha t included a dose of 30 mg prednisone 
(oral) daily (or equivalent) for at least [ADDRESS_1073944] 1 week 
within the previous 5 years
Steroid dependent:  two failed attempts to taper steroids below a dose equivalent to 
10mg prednisone (oral) daily
Steroid intolerant :  history of intolerance to corticosteroids (including ,but not limited 
to,Cushing’s syndrome, osteopenia/osteoporosis, hyperglycemia, insomnia, 
infection) within the previous 5 years
Management of Concomitant Medications during the Study  
During Induction Phase (Prior to Week 10)
Patients are required to maintain stable doses of their concomitant medications 
(oral 5-ASA, corticosteroids, immunosuppressants) for UC.
During Maintenance Phase (after Week 10)
Corticosteroids
Corticosteroids are to be tapered starting from Week 10 in patients who achieve a 
clinical response (patients not achieving clinical response will be allowed to enroll in 
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2061Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
60/Protocol GA29102, Version 7Part 1 (OLE) of Study GA28951).  Patients receiving prednisone at a dose of 
10mg/d ay (or equivalent) are to have their dose reduced at a rate of 5 mg per week 
until a 10mg/day dose is achieved.  Patients receiving prednisone at doses 10 mg/day 
(orequivalent), or once a 10 mg/day dose (or equivalent) is achieved by [CONTACT_39782], are to 
have their dose reduced at a rate of 2.5 mg/week until discontinuation.  Patients 
receiving budesonide at study entry should taper their dose of 9 mg every day to 9 mg 
every other day for 2 weeks and then discontinue budesonide treatment .  For patients 
who cannot tolerate the corticosteroid taper without recurrence of clinical symptoms of 
either UC or steroid withdrawal, corticosteroid dose may be increased (up to the dose at 
study entry, if required), but tapering must begin again within 2 weeks.
Immunosuppressants
Patients should remain on their stable baseline doses of immunosuppressants (AZA, 
6-MP, MTX) throughout the study unless dose reduction or discontinuation is required 
due to a toxicity related to the medication (see Section 3.1.1 for symptoms of toxicity to 
AZA, 6 -MP, or MTX).
Rescue Therapy  that Can B e Given w ith Study Medication for the Treatment 
of Ulc erative Colitis
Induction Phase
In the Induction Phase, any patient who requires initiation of an immunosuppressant, 
oralortopi[INVESTIGATOR_2855] 5-ASA, orcorticosteroid ,or increase in dose over baseline levels for 
treatment of worsening disease symptoms should stay in the study until Week 10, at 
which time he or she should enroll in Part 1 (OLE) of Study GA28951 to receive 
open -label etrolizumab, if eligible, or enter th e 12-week safety follow -up.  These patients 
may not continue into the Maintenance Phase of the study .
Maintenance Phase (after Week 10)
Initiation or escalation of oral 5- ASA should be avoided but is permitted if deemed 
clinically necessary by [CONTACT_31691].  Patients who initiate or escalate oral 5- ASA 
therapy should continue blinded treatment.
Use of topi[INVESTIGATOR_760422] 5 -ASA should also be avoided as 
concomitant medications.  However, if these are clinically required to treat symp toms of 
UC, then the patient may either remain in this blinded phase of the study or may be 
given the option to enroll in Part 1 (OLE) of Study GA28951 , if eligible, based on the 
investigator’s discretion.  Patients who leave the treatment phase early to e nroll in Part 1 
(OLE) of Study GA28951 should complete the early withdrawal from treatment visit prior 
to enrollment in Study GA28951.
Patients who were not receiving corticosteroids at baseline and patients who have 
completed the steroid taper who subsequ ently receive oral corticosteroids at a dose 
greater than 10 mg for 5 days or longer for the treatment of clinical symptoms of either 
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2062Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
61/Protocol GA29102, Version 7UC or steroid withdrawal may either remain in this blinded phase of the study or may be 
given the option to enroll in Part 1 (OLE) of Study GA28951 , if eligible, based on the 
investigator’s discretion .  Patients who leave the treatment phase early to enroll in 
Part 1(OLE) of Study GA28951 should complete the early withdrawal from treatment 
visit prior to enrollment in Study [ZIP_CODE] .
Endoscopy to document disease activity for all patients exiting the treatment period early 
is strongly recommended.
Immunosuppressants (AZA, 6 -MP, or MTX) 
Patients are to remain on their stable baseline dose of immunosuppressant therapy 
throughout the study unless dose reduction or discontinuation is required because of 
toxicity .  Generally accepted criteria for discontinuation of immunosuppressants due to 
toxicity include ,but are not limited to ,acute pancreatitis, severe leukopenia, severe 
thromb ocytopenia, or clinically significant elevations of the liver -associated enzymes 
from baseline, especially in the presence of an elevated total bilirubin.  The ultimate 
decision to reduce dose or discontinue immunosuppressants due to toxicity remains at 
the discretion of the investigator.   However, patients who do initiate or escalate 
immunosuppressant therapy may remain in this blinded phase of the study or may be 
given the option to enroll in Part 1 (OLE) of Study GA28951 , if eligible, based on the 
invest igator’s discretion.  Patients who leave the treatment phase early to enroll in 
Part 1(OLE) of Study GA28951 should complete the early withdrawal from treatment 
visit prior to enrollment in the Study GA28951 .
Endoscopy to document disease activity for pat ients exiting the treatment period early 
for any reason is strongly recommended.
Rescue Therapy  that Cannot Be Given w ith Study  Medication for the 
Treatment of UC
At ANY time during the conduct of the study, use of other immunosuppressive agents 
including ,but not limited to, anti-integrins, T -or B-cell depleters (except for AZA and 
6-MP), TNF inhibitors (including TNF inhibitor biosimilars) , cyclosporine, tacrolimus, 
anti-adhesion molecules, JAK inhibitors, or investigational agents are prohibited.  
Patients who receive such therapi[INVESTIGATOR_760447] -label treatment, and will be required to enter 12 weeks of safety follow -up in this 
study (see Appendix 2).  After completion of safety follow -up, these patients will be 
asked to enroll in Part 2 (SM) of Study GA28951 for [ADDRESS_1073945] A ccountability
All investigational medicinal products (IMPs) required for completion of this study, 
namely, etrolizumab and etrolizumab placebo, will be provided by [CONTACT_1034].  The 
investigator is responsible for the control of the drugs under investigation.  The 
investigational site will acknowledge receipt of IMP (e.g., drug receipt record) and 
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2063Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
62/Protocol GA29102, Version 7disposition (e.g., drug dispensing log).  Accountability will be assessed by [CONTACT_781266].  IxRS will be used to confirm the shipm ent 
condition and content.  Any damaged shipments will be replaced.
Accurate records must be kept for all study drug provided by [CONTACT_1034].
These records must contain the following:
Documentation of drug shipments received from the Sponsor (date received and 
quantity)
Disposition of unused study drug not dispensed to patients 
Drug Dispensing Log must be kept current and should contain the following 
information:
Identification of the patient to whom the study medication was dispensed
Date(s) and quantity of the study medication dispensed tothe patient
Date(s) and quantity of the unused study medication returned by[CONTACT_781267]. 
4.3.4 Assessment of Compliance
Patient compliance will be assessed by [CONTACT_760509], the 
patient e -diary, and return records.
Home -injection:  An e- diary will be provided to patients to record home injections.  
Patients will be asked to return all unused PFSs in the provided boxes at each visit as a 
measure of drug accountability and patient compliance.  Site personnel will monitor the 
medication records from the e -diary via an online portal.  Patients should also bring their 
e-diary to the clinic d uring visit.
Sharps containers for any used PFS will be provided to patients for home usage.  After 
home injections, the used syringes must be placed into the sharps containers 
immediately.  The sharps containers should be returned to sites.  Sharps contai ners will 
be discarded by [CONTACT_760510].
A Drug Dispensing Log must be kept as described in Section 4.3.[ADDRESS_1073946] be clearly documented and approved by [CONTACT_093].   
When the study is completed, the investigator will r eturn all completed Drug Dispensing 
Logs to the Monitors.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2064Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
63/Protocol GA29102, Version 7Any unused study drug and Drug Return Records should be returned to the Monitor, 
unless alternate destruction has been authorized by [CONTACT_335557] (Section 4.3.3 ).  The investigator's copy of the Drug Return 
Record(s) must accurately document the return of all study drug supplies to Spons or.
4.3.[ADDRESS_1073947] contain the following:
Identity (batch numbers or subject numbers) of IMP(s) destroyed
Quantity of IMP(s) destroyed
Date of destruction
Method of destruction
Name [CONTACT_369057] r esponsible person who destroyed investigational product(s)
In case of device failure or if there are any issues with the drug, the PFS should not be 
destroyed, and instead should be returned to the investigator site in the packaging 
provided for this purpose.  The device is to be sent from the investigator site to the 
appropriate [COMPANY_002] clinical trial supplies department for further assessment (see 
Section 4.3.6 ).
4.3.6 Reporting of Prefilled Sy ringe Complaints/Events
The investigator should report all medical device complaints to the Sponsor.  The 
investigator must document as much information as possible on the PD103 IMP 
Deviation Form , including product batch number and expi[INVESTIGATOR_320], and forward the 
complaint form to the Sponsor within 24 hours of the investigator becoming aware of the 
event.  PD103 IMP Deviation Form , together with pi[INVESTIGATOR_335475], should 
be sent to kaisera [EMAIL_14906].
Where possible, the investigator will retrieve the PFS unit(s) involved in the complaint 
and attempt to return it to the Sponsor for further assessment.
If the medical device complaint results in an adverse event, an Adverse Event eCRF 
must be completed and submitted through the electronic data capture (EDC) system 
immediately (i.e., no more than 24 hours after learning of the event).  If the event is 
serious, the Adverse Event eCRF must be completed and submitted through the EDC 
immediately (i.e., no more than 24 hours after learning of the event), as outlined in 
Section 5.4.2 .
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2065Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
64/Protocol GA29102, Version 7If the medical device complaint results in an adverse event to an individual other than 
the study patient (e.g. nurse at the site or relative/care giver during a home 
administration) , the device complaint must be reported on the PD103 IMP Deviation 
Form . The adverse event must be reported as a spontaneous adverse event to the 
Sponsor (see Section 5.3.5 ).
4.4 CONCOMITA NT THERA PY
4.4.1 Permitted Therapy  
Concomitant therapy includes any medication (e.g., prescription drugs, over -the-counter 
drugs, herbal/homeopathic remedies, preventative vaccines, vi tamins, nutritional 
supplements) used by a patient from 8weeks prior to Day 1 to the study 
completion/early termination visit.   All concomitant medications should be reported to the 
investigator and recorded on the Concomitant Medications eCRF.
Patients w ho use oral contraceptives or maintenance therapy for comorbidities should 
continue their use. 
For concomitant therapy for UC and rescue treatment see Section [IP_ADDRESS] .
4.4.2 Prohibited Therapy
Use of the following therapi[INVESTIGATOR_27789]:
Any investigational treatment including investigational vaccines
Use of lymphocyte depleting agents, (e.g., alemtuzumab or visilizumab), e xcept for 
AZA and 6 -MP  
Use of cyclosporine, tacrolimus, sirolimus, or MMF
Use of natalizumab, vedolizumab, efalizumab, or rituximab
Use of TNF inhibitors (including TNF inhibitor biosimilars)
Use of anti -adhesion molecules
 Use of JAK inhibitors
Patients who receive these specified rescue therapi[INVESTIGATOR_760437] -label treatment and are to be withdrawn into safety follow -up.
4.4.3 Definition of Clinical Relapse
Clinical relapse is defined as an:
Increase in pMCS 3 points compared with induction timepoint ( Week 10) AND 
absolute pMCS 5 AND endoscopic subscore 2
If a patient meets criteria for clinical relapse during the Maintenance Phase of the study, 
he or she may withdraw from this study and enroll in Part 1 (OL E) of Study GA28951 for 
open -label etrolizumab treatment, if eligible.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2066Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
65/Protocol GA29102, Version 74.5 STUDY ASSESSMENTS 
4.5.1 Description of Study  Assessments
[IP_ADDRESS] Medical History  and Demographic Data
Medical history includes clinically significant diseases, procedures, and all medication 
taken in the 8 weeks prior to Day 1 (including prescription, over -the-counter, and 
herbal/homeopathic remedies and therapi[INVESTIGATOR_014]).  A detailed history of medication used for 
UC is required for the 5 years prior to screening.
Demographic data , including age, sex, whether the patient is a fraternal or identical twin,
and self-reported race/ethnicity , will be collected during screening .
[IP_ADDRESS] Physical Examinations
A complete physical examination should include the evaluation of head, eye, ear, nose, 
and throat and cardiovascular, dermatological, musculoskeletal, respi[INVESTIGATOR_696], GI, and 
neurological systems, including administration of the PML Subjective Checklist and the 
PML Objective Checklist by [CONTACT_093] (see Appendix 5for PML assessment 
details and Appendix 6for PML algorithm).  New or worsened abnormalities from 
screening should be recorded as adverse events if appropriate.  In addition, a 
symptom -driven examination should be conducted as indica ted in the Schedule of 
Assessments (see Appendix 1).
[IP_ADDRESS] Vital Signs
Vital signs will include measurements of heart rate and systolic and di astolic blood 
pressure, after the patient has been in a seated position for 5 minutes, and are to be 
recorded at the indicated timepoints in the Schedule of Assessments (see Appendix 1) 
before study drug administration at clinic visits only.
[IP_ADDRESS] Ulcerative Colitis Disease A ctivity  Assessments
Extent and duration of patient’s disease is to be recorded on the eCRF from the patient 
medical records and should include therapi[INVESTIGATOR_760448] 5 years.  Extent of disease 
should be defined as follows:  1) left -sided colitis (up to the splenic flexure), 2) extensive 
colitis (beyond the splenic flexure but not involving the entire colon), and 3) pancolit is.
All measurable disease must be documented at screening and re -assessed at each 
subsequent evaluation.  Responses will be assessed by [CONTACT_760512].  The MCS has a range of 0 12, whereas pMCS has a 
range of 0 9, with higher scores indicating more severe disease.  The MCS is a 
composite of four assessments, each rated from 0 3:  stool frequency, rectal bleeding, 
endoscopy, and PGA.  The pMCS is a composite of three assessments, each rated from 
03:  stool freque ncy, rectal bleeding, and PGA.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2067Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
66/Protocol GA29102, Version 7During screening, patients will be instructed on how to appropriately use and complete 
questions on the e- diary.  The patients’ normal number of stools is to be recorded.  This 
is defined as the number of stools passed when a patient is in remission, not in flare.  
This is to be taken from the most recent available data in the patient’s medical notes or 
taken during patient interview at screening. 
One of the components of the MCS is the endoscopic subscore.  The time window for 
performing endoscopy during the screening is 416 days prior to Day 1 (i.e., Day 16to 
Day 4).  Medical Monitor approval is not requ ired for endoscopi[INVESTIGATOR_760449]. Under no circumstances will an endoscopy be accepted more than 16 
days or less than 4 days prior to Day 1 .  Note that the total screening period is up to 35 
days (see Section [IP_ADDRESS]).
The symptoms of UC must be recorded throughout the study, including the screening 
period.  The e -diary entries will be reviewed by [CONTACT_335560] (prior to 
dosing, if applicable) and during study visits ,including the early withdrawal from 
treatment visit and any unscheduled visit sdue to disease exacerbation.  Because the 
colonoscopy/flexible sigmoidoscopy and bowel cleansing preparations can interfere with 
the assessment of patient -reported symptoms , e-diary entries used to calculate the 
complete MCS should not correspond to days of bowel preparation or endoscopy or the 
day following the endoscopy .  Further details and examples of stool frequency and rectal 
bleeding subscore derivation are provided in Appendix 4.
Colonoscopy /Flexible Sigmoidoscopy  with Colonic Biopsies
Patients are to pre pare their bowel prior to the colonoscopy/flexible sigmoidoscopy 
procedures.  Medications used for bowel preparation should be recorded on concomitant 
medications pages of eCRF.
Stool samples for analysis of fecal calprotectin and other exploratory biomarkers (such 
as analyses of the microbiota and bacterial cultures) are to be collected prior to bowel 
preparation (polyethylene glycol [ PEG] based preparation or enema).
Full colonoscopy within a year of screening is required to e nsure against enrollment of 
patients with colonic carcinoma and dysplasia.  If full colonoscopy has not been 
performed within the year before screening, it should be conducted in place of the 
flexible sigmoidoscopy at screening.  For patients not requiring a colonoscopy, a flexible 
sigmoidoscopy will be performed on all patients for inclusion in the study.  Endoscopy 
will be performed during screening 416 days prior to Day 1.
Endoscopy will be also performed at Weeks 10 and 62 and/or at withdrawal from study 
(early withdrawal from treatment visit, see Appendix 1).
Central reading of endoscopi[INVESTIGATOR_335479], and a detailed 
charter will address the standardization of endoscopic procedures, video recordings, and 
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2068Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
67/Protocol GA29102, Version 7equipment, as well as the criteria for endoscopic assessment.  For each patient, video 
recording of the entire endoscopic procedure will be performed as spec ified in the Video 
Submission Guidelines .  All video recordings will be edited by [CONTACT_781268] (rectum, sigmoid, and descending colon).  The video clips will be 
read centra lly for mucosal lesions and endoscopic severity by [CONTACT_781269]’s clinical activity and 
treatment allocation.  The MCS endoscopic subscore is to be determined both locally (at 
the investig ator site) and centrally as described above.  Each segment of the colon up to 
the splenic flexure (rectum, sigmoid, and descending colon) will be assigned an 
endoscopic subscore . The score from the worst affected segment up to the splenic 
flexure is to be used for the MCS calculation for study conduct, except at post -baseline 
time points, when the sigmoid colon MCS endoscopic subscore will be used if the 
baseline sigmoid colon MCS endoscopic subscore is 2 3.
In the event that there is a discrepancy betwee n the endoscopic subscore obtained by 
[CONTACT_335563], a third read ( by a second central reader) is to be 
conducted. From these three endoscopic MCS subscores, the score with which two 
readers agree will be reported as the final overal l MCS endoscopic subscore.  If no two 
readers agree on an MCS endoscopic subscore, the median score of the three 
completed reads (i.e., local read, central read #1, and central read #2) will be chosen as 
the final reported overall MCS endoscopic subscore.
In all cases the video recordings are to be taken prior to biopsy .
Each patient entered into the study will have colonic biopsy samples obtained during 
flexible sigmoidoscopy/full colonoscopy as follows.
At Screening
A total of five to six paired biopsy samples (10 to 12 samples) will be taken at screening.
Four paired biopsy samples (8 samples) from the most inflamed area of the colon 
within 2040cm from the anal verge (sigmoid colon) .  Two pairs (4 samples) will go 
into formalin, and two pairs ([ADDRESS_1073948] es) will be placed in stabilization buffer (such as 
RNAlater or a similar buffer) and be shipped to a central laboratory for storage 
at80C.
One paired biopsy sample (2 samples) from the most inflamed area of the worst 
affected segment (descending, sigmoid, or rectum).  This biopsy pair (2 samples) 
will go into formalin.
ONLY if there is suspi[INVESTIGATOR_781229], one biopsy sample 
should be taken from the base of an ulcer to evaluate for histological presence of 
CMV but otherwi se is not necessary for inclusion in the study.  Analysis should be 
performed locally if possible or can be sent to a central laboratory if necessary.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2069Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
68/Protocol GA29102, Version 7ONLY if histopathologic confirmation of UC is needed to meet study eligibility, an 
additional biopsy sample can be used for histopathologic confirmation of UC, if 
necessary (analysis should be performed locally if possible or can be sent to a 
central laboratory, if necessary).
If neither CMV testing nor histopathologic confirmation of UC is needed, these 
additional 2 biopsy samples should not be obtained.
At Weeks 10 and 62 and/or at early  withdra wal from treatment visit 
A total of four paired biopsy samples (8 samples) will be taken at W eeks 10 and 62 as 
specified in Appendix 1.
Two paired biopsy samples (4 samples) to be taken from the most inflamed area of 
the colon within 20 40 cm from the anal verge (sigmoid colon, approximately at the 
same endoscopic depth of the original screening endoscopy).  If there is no clearly 
inflamed area, a blind biopsy sample should be taken.  One pair will go into formalin, 
and one pair will be placed in stabilization buffer (such as RNAlater or a similar 
buffer) and shipped to a central laboratory for storage at 80C.
One paired biopsy sample (2 samples) to be taken from the most inflamed area of 
the rectum.  If there is no clearly inflamed area, a blind biopsy sample should be 
taken.  This paired biopsy sample will go into formalin.
One paired biopsy sample (2 samples) to be taken from the most inflamed area of 
the descending colonic segment.  If there is no clearly inflamed area, a blind biopsy 
sample should be taken.  This paired biopsy sample will go into formalin.
Necrotic areas of ulcerated mucosa should be avoided during biopsy.  Original location 
(colonic segment and endoscopic depth) of biopsy specimen should be clearly indicated. 
Samples will all initially be sent to the laboratory vendor (unles s analysis is to be 
performed locally, as indicated).
Progressive Multifocal Leukoencephalopathy Assessment
Study site personnel and patient will be educated regarding the signs and symptoms of 
PML.  Close monitoring during the course of the study for any new symptoms or signs 
suggestive of PML will be performed with regular neurologic examinations (including 
evaluation of cranial nerves, motor and sensory function, coordination, and mental 
status) per the Schedule of Assessments (see Appendix 1).  The PML Subjective 
Checklist (symptom assessment) and the PML Objective Checklist (neurologic 
evaluation) will be administered by a qualified HC P and will be performed at screening 
and as indicated on the Schedule of Assessments.
During the in- clinic visits, patients will undergo PML monitoring assessments.
If a patient has a positive finding on the PML Subjective Checklist that is accompanied 
by a positive finding on the PML Objective Checklist or if there is strong clinical suspi[INVESTIGATOR_335488], the event should be expeditiously reported as an adverse event of special 
interest within 24 hours (see Section 5.2.3 )(see Appendix 6for the Algorithm for 
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2070Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
69/Protocol GA29102, Version 7Evaluation of Progressive Multifocal Leukoencephalopathy).  If PML is suspected, 
dosing with study treatment for that patient will be suspended and the patient should be
promptly referred to a neurologist.  Following formal evaluation by a neurologist, further 
work -up may include brain magnetic resonance imaging (MRI) performed with and 
without contrast.  If PML cannot be ruled out, the case will be referred to an expert PML 
adjudication committee. If there remains any suspi[INVESTIGATOR_335482], the PML adjudication 
committee may recommend performing a lumbar puncture with cerebrospi[INVESTIGATOR_872] (CSF) 
analysis for John Cunningham virus (JCV) by [CONTACT_940] (PCR).  If JC V 
is detected, the patient should be treated as a PML case, permanently discontinue study 
drug, and transfer to safety follow -up.
Dosing with study treatments can be resumed only in patients where PML has been 
ruled out.  See Appendix 6for the Algorithm for Evaluation of Progressive Multifocal 
Leukoencephalopathy.
After completing this study, patients not enrolling in Part 1 (OLE) of Study GA28951 to 
receive treatment with open- label etrolizumab will enter the 12 -week safety follow -up in 
this study (see Appendix 2).  The PML neurologic examination is to be performed at 
Week 12 of this safety follow -up.
Following 12- week safety follow -up, all patients will be requested to continue to be 
monitored for PM L for an additional 92 weeks by [CONTACT_760515] 2 (SM) of Study 
GA28951 ; thus, providing a total of [ADDRESS_1073949] dose of study 
medication.  During the SM portion of Study GA2895 1,patients will not be administered 
study drug.
[IP_ADDRESS] Laboratory  Assessments
Laboratory assessments will be performed as indicated on the Schedule of 
Assessments; see the Study Flowchart in Appendix 1.  All laboratory investigations will 
be sent to one or more central laboratories for analysis with the exception of CMV.  If 
there is suspi[INVESTIGATOR_335480], a colonic biopsy sample should be 
sent for CMV evaluation, which may be conducted locally depending on local 
requirements for the timing of the test result .  Urine pregnancy testing will be conducted 
locally or in the home setting.  If a full colonoscopy is required at screening, laboratory 
samples should be drawn prior to the initiation of bowel preparation.
On days of study drug administration, laboratory samples should be drawn before the 
administration of study drug.  Laboratory assessments will include the following:
Hematology (hemoglobin, hematocrit, platele t count, RBC count, WBC count, 
absolute count [neutrophils, eosinophils, lymphocytes, monocytes, basophils , other 
cells] , mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular 
hemoglobin concentration, and RBC distribution width)
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2071Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
70/Protocol GA29102, Version 7Serum che mistries (sodium, potassium, chloride, bicarbonate, glucose, blood urea 
nitrogen, creatinine, calcium, phosphorus, magnesium, total and direct bilirubin, total 
protein, albumin, alanine aminotransferase, aspartate aminotransferase, lactate 
dehydrogenase, alk aline phosphatase, creatine phosphokinase, and uric acid)
Urinalysis
Tuberculosis
The [COMPANY_003] skin test and QuantiFERON -TB Gold are acceptable screening 
assays for latent Mycobacterium TB infection.
A positive [COMPANY_003] tuberculin skin test reaction is considered 5 mm.
Patients with a history of bacille Calmette -Guérin (BCG) vaccination should be 
screened using the QuantiFERON -TB Gold test only.
An indeterminate QuantiFERON -TB Gold test should be repeated .  The 
follow -up test can be either a repeat of the previous test or a [COMPANY_003] tuberculin 
skin test in patients who are eligible to have a [COMPANY_003] tuberculin skin test 
performed .
The patient is considered to have a positive diagnostic test for TB if at least 
one of the following circumstances applies:
–A positive QuantiFERON -TB Gold test
–Two successive indeterminate QuantiFERON -TB Gold tests
–A positive [COMPANY_003] tuberculin skin test
The patient is considered to have a negative diagnostic test for TB if at least 
one of the following circumstances applies:
–A negative QuantiF ERON- TB Gold test
–A negative [COMPANY_003] tuberculin skin test
If a negative TB screening test has been documented within [ADDRESS_1073950] is needed.
C-reactive protein (CRP)
C. difficile toxin assay in stool, stool culture and sensitivity testing, stool ova and 
parasites analysis
Pregnancy test:  All women of childbearing potential (including those who have had 
a tubal ligation) will have a serum pregnancy test at screening.
Urine pregnancy tests will be performed at specified subsequent vi sits.  If a 
urine pregnancy test result is positive, it must be confirmed by a serum 
pregnancy test.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2072Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
71/Protocol GA29102, Version 7Viral serology and detection
HBV (HBsAg, anti -HBc, and HBV DNA)
HCV antibody
HCV RNA:  Measurement of HCV RNA with use of the Amplicor assay is only 
requir ed when the patient has a known history of HCV antibody positivity with 
past documentation of undetectable HCV RNA, either with or without history of 
anti-viral treatment.  Patients with newly diagnosed HCV antibody positivity are 
not eligible for this stu dy and, therefore, do not require measurement of HCV 
RNA.
HIV
Flow cytometry (fluorescence -activated cell sorting subsets)
Whole blood samples w ill be collected to determine B -cell counts (CD19 )
T cell counts (CD3+, CD4+, CD8+) and natural killer cell co unts (CD16 , 
CD56 ) by [CONTACT_4133]
ATA assays
Serum samples will be collected for the detection and characterization of 
antibodies against etrolizumab in all patients.  Samples will be analyzed using 
validated assays.  For ATA samples without matched PK determinations, 
etrolizumab concentrations may be measured for the purpose of helpi[INVESTIGATOR_335483].  ATA samples may also be utilized for exploratory PD 
biomarkers.
JCV antibodies 
A blood sample to test for antibodies to JCV will be taken and sto red for 
possible later assessment of how widespread the JCV infection is in the study 
population.  Sample testing for the presence of JCV antibodies is not helpful in 
predicting risk for PML or for evaluating neurologic symptoms.  The sample 
may be tested if there is a strong belief that this information will be helpful in 
managing a patient's condition.
PK assays
Serum samples will be collected for determination of etrolizumab 
concentrations in all patients during the Induction Phase and in all patients who 
were randomized into the Maintenance Phase.  Samples will be analyzed using 
a validated ELISA.
CMV testing of colonic biopsy sample, if there is suspi[INVESTIGATOR_335484] (to be obtained at the base o f the ulcer) will be 
analyzed for histologic presence of CMV
Fecal c alprotectin testing
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2073Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
72/Protocol GA29102, Version 7Exploratory diagnostic biomarker assays
Peripheral blood, serum, stool, and colon biops y samples will be assessed 
using qualified methods (including ,but not limited to, ELISA, IHC, and/or qPCR) 
for exploratory diagnostic biomarker analysis.
Exploratory PD biomarker assays
Peripheral blood, serum, stool, and colon biopsy samples will be collected and 
qualified methods (including ,but not limited to ,ELISA, IHC, bacterial culture, 
and/or qPCR) will be utilized for exploratory PD biomarker analysis for samples 
that are assessed.  Biopsy tissue may also be used for exploratory 
determination of drug concentration.  Stool samples may be used for 
assessments that include, but a re not limited to, analyses of the microbiota and 
bacterial cultures .
Histology
Colon biopsy samples will be collected and evaluated for histologic changes .  
Histologic activity on colon biopsies will be categorized using the Nancy 
histological index (see Appendix 12) . 
Unless the patient gives specific consent for his or her leftover samples to be stored for 
optional exploratory research (see Section [IP_ADDRESS] ), biological samples will be 
destroyed when the final Clinical Study Report has been completed, with the following 
exceptions:
Serum samples collected for PK or immunogenicity analysis may be needed for 
additional immunogenicity characterization and for PK or immunogenicity assay 
development and validation; therefore, these samples will be destroyed no later than 
5 years after the final Clinical Study Report has been completed.
Blood samples (RNA Paxgene, serum for exploratory PD) and stool samples 
collected for biomarker research will be destroyed no later than 5 years after the 
final Clinical Study Report has been completed.
Colon biopsy samples (formalin and RNA later) will be destroyed no later than 
5years after the final Clinical Study Report has been completed.
[IP_ADDRESS] Chest X -Ray
A chest X -ray will be performed at screening.  If a chest X -ray has been documented 
within the previous [ADDRESS_1073951] X -ray is required.
[IP_ADDRESS] Electrocardiograms
ECGs for each patient should be obtained from the same machine whenever possible.  
To minimize variability, it is important that pati ents be in a resting position for 
10minutes prior to each ECG evaluation.  Body position should be consistently 
maintained for each ECG evaluation to prevent changes in heart rate.  Environmental 
distractions (e.g., television, radio, conversation) shou ld be avoided during the pre -ECG 
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2074Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
73/Protocol GA29102, Version 7resting period and during ECG recording.  ECGs should be performed prior to meals and 
any scheduled vital sign measurements and blood draws.
For safety monitoring purposes, the investigator or designee must review, sign, an d date 
all ECG tracings.  Paper copi[INVESTIGATOR_141868]'s permanent study file 
at the site.  ECG outputs will be stored at site.
[IP_ADDRESS] Patient -Reported Outcomes
Patient -reported outcomes (IBDQ, UC -PRO/SS, EQ -5D, and the stool frequency and 
rectal bleeding components of the MCS and pMCS) and physician -reported outcomes 
(PGA of the MCS and pMCS) and the endoscopic component of MCS data will be 
collected to help characterize the clinical profile of etrolizumab.  The instruments will be 
translated as required in the local language.
In order to ensure instrument validity and that data standards meet health authority 
requirements, the PROs completed at the sites (IBDQ, EQ -5D, and the stool frequency 
and rectal bleeding components of the MCS and pMCS) should be administered at the 
investigational site prior to the completion of non -PRO assessments and before the 
patient receives any disease- status information or study drug during that visit.  At 
Week0(Day 1), however, IBDQ and EQ -5D do not have to be performed prior to
non-PRO assessments. Patients will complete the UC -PRO/SS measure for at least 
912 days consecutive days around the time of each scheduled visit,as programmed in 
the e -diary .
PRO data will be collected electronically using electronic patient -reported outcome 
(ePRO) devices (i.e., e-diary or tablet ).  The format of the questionnaires may change 
when they are converted to electronic format.  Electronic data captured by [CONTACT_335565].  
ePRO data will be collected and assessed at visits according to the Schedule of 
Assessments in Appendix 1.
Ulcerative Colitis Patient -Reported Outcomes Signs and Sy mptoms 
Measure 
The UC -PRO/SS measure will be used to assess patient -reported UC signs and 
symptoms.  The 14 -item questionnaire (some que stions contain supplementary 
questions regarding severity/frequency) contains three domains:  bowel movement signs 
and symptoms, abdominal symptoms, and systemic symptoms.  The UC -PRO/SS 
assesses the presence of UC symptoms and in some cases the severity o r frequency of 
the symptoms.  The UC -PRO/SS measure has a recall specification of 24 hours.  A copy 
of the UC PRO/SS measure is provided in Appendix 9.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2075Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
74/Protocol GA29102, Version 7Inflammatory  Bowel Disease Questionnaire 
The IBDQ will be used to assess patients’ health -related QOL ( Guyatt et al. 1989 ; 
Irvine 1999 ).  The 32 -item questionnaire contains four domains:  bowel symptoms 
(10items), systemic symptoms (5 items), emotional function (12 items), and social 
function (5 items).  The items are scored on a 7 -point Likert scale with a higher score 
indicating better health- related QOL.  The IBDQ has a recall specification of 2 weeks.  
Acopy of the IBDQ is provided in Appendix 10.
Mayo Clinic Score and Partial May o Clinic Score
The MCS is a composite of four assessments, each rated from 0 3:  stool frequency, 
rectal bleeding, endosc opy, and PG A (Schroeder et al. 1987).  The en doscopy subscore 
of the MCS is derived from an evaluation of findings on endoscopy and as determined 
by [CONTACT_335566] [IP_ADDRESS].  The pMCS is a 
composite of three assessments, each rated from 0 3:  stool frequency, rectal bleeding, 
and PGA.  The MCS has a range of 0 12 and the pMCS has a range of 0 9.  Higher 
scores indicate more severe disease.  Copi[INVESTIGATOR_781230] 4.
EuroQoL 5 -Dimension Questionnaire
The EQ -5D is a generic preference- based health -related QOL questionnaire that 
provides a single index valu e for health status ( Rabin and deCharro 2001 ).  This tool 
includes questions about mobility, self -care, usual activities, pain/discomfort, and 
anxiety/depression that are used to build a composite of the patient’s health status.  The 
EQ-5D questionnaire wi ll be utilized in this study for economic modeling.  A copy of the 
assessment is provided in Appendix 11.
[IP_ADDRESS] Medication Use and Compliance
Following each home administration of study medication, the patient is to record the 
location of each injection and whether the injection was successfully administered.  
Thee-diary will automatically collect date and time information for when the patient 
completes the study medication administration report.  Note that details of the study 
medication administration are to be entered directly into the eCRF following 
clinic administrations.
[IP_ADDRESS] Samples for [COMPANY_002] Clinical Repository
Overview  of the [COMPANY_002] Clinical Repository
The [COMPANY_002] Clinical Repository (RCR) is a centrally administered group of facilities for 
the long -term storage of human biologic specimens, including body fluids, solid tissues, 
and derivatives thereof (e.g., DNA, RNA, proteins, peptides).  The c ollection and 
analysis of RCR specimens will facilitate the rational design of new pharmaceutical 
agents and the development of diagnostic tests, which may allow for individualized drug 
therapy for patients in the future.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2076Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
75/Protocol GA29102, Version 7Specimens for the RCR will be coll ected from patients who give specific consent to 
participate in this optional research.  In addition, any residual colonic biopsy and blood 
samples for biomarkers left over at the end of the study and analyses will be transferred 
to the RCR in consenting p atients.  RCR specimens will be used to achieve the 
following objectives:
To study the association of biomarkers with efficacy, adverse events, or disease 
progression
To increase knowledge and understanding of disease biology
To study drug response, includ ing drug effects and the processes of drug absorption 
and disposition
To develop biomarker or diagnostic assays and establish the performance 
characteristics of these assays
Approval by [CONTACT_781270] R CR is contingent upon the review and approval of the exploratory 
research and the RCR portion of the Informed Consent Form by [CONTACT_25733]'s Institutional 
Review Board or Ethics Committee (IRB/EC) and, if applicable, an appropriate 
regulatory body.  If a site has not been granted approval for RCR sampling, this section 
of the protocol will not be applicable at that site.
Sample Collection
Whole blood (DNA) will be collected for genetic analysis from consenting patients 
(RCR ICF).
Samples that are obtained for exploratory analysis of biomarkers (listed below) but were 
not utilized or were not entirely consumed will be transferred to the RCR.
Specimen types include the following:
Blood collected in RNA Paxgene tubes (for exploratory pharmacodynamics; see 
Appendix 1for specific collection timepoints)
Serum for exploratory pharmacodynamics (see Appendix 1for specific collection 
timepoints )
Stool samples may be used for exploratory biomarker analyses (see Appendix 1for 
specific collection timepoints)
Colon biopsy samples (formalin and stabilization buffer [such as RNAlater or a 
similar buffer]; see Appendix 1for specific collection timepoints)
Potential applications of RCR samples include these samples being assayed for 
mRNA expression, genetic variation, and other biomarker(s) that predict response or 
toxicity to etrolizumab.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2077Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
76/Protocol GA29102, Version 7For all samples, dates of consent and specimen collection should be recorded on the 
associated RCR page of the eCRF.  For sampling procedures, storage conditions, and 
shipment instructions, see the Reference Manual or Labor atory Manual.
RCR specimens will be destroyed no later than 15 years after the date of final closure of 
the associated clinical database.  The RCR storage period will be in accordance with the 
IRB/EC -approved Informed Consent Form and applicable laws (e.g. , health authority 
requirements).
The dynamic biomarker specimens will be subject to the confidentiality standards 
described in Section 8.4.  The genetic biomarker specimens will undergo additional 
processes to ensure confidentiality, as described below.
Confidentiality
Given the sensitive nature of genetic data, [COMPANY_002] has implem ented additional processes 
to ensure patient confidentiality for RCR specimens and associated data.  Upon receipt 
by [CONTACT_25736], each specimen is "double -coded" by [CONTACT_70144] a new independent number.  Data generated from the use of these 
specimens and all clinical data transferred from the clinical database and considered 
relevant are also labeled with this same independent number.  A "linking key" between 
the patient identification number and this new independent number is stored in a secure 
database system.  Access to the linking key is restricted to authorized individuals and is 
monitored by [CONTACT_25738].  Legitimate operational reasons for accessing the linking key are 
documented in a standard operating procedure.  Acce ss to the linking key for any other 
reason requires written approval from the Pharma Repository Governance Committee 
and [COMPANY_002]'s Legal Department, as applicable.
Data generated from RCR specimens must be available for inspection upon request by 
[CONTACT_781271], and [COMPANY_002] monitors, 
representatives, and collaborators, as appropriate.
Patient medical information associated with RCR specimens is confidential and may only 
be disclosed to third parties permitted by [CONTACT_255906] (or separate 
authorization for use and disclosure of personal health information) signed by [CONTACT_102], 
unless permitted or required by [CONTACT_2371].
Data derived from RCR specimen analysis on individual patients will generally not be 
provided t o study investigators unless a request for research use is granted.  The 
aggregate results of any research conducted using RCR specimens will be available in 
accordance with the effective [COMPANY_002] policy on study data publication.
Any inventions and resulting patents, improvements, and/or know -how originating from 
the use of the RCR data will become and remain the exclusive and unburdened property 
of [COMPANY_002], except where agreed otherwise.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2078Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
77/Protocol GA29102, Version 7Consent to Participate in the [COMPANY_002] Clinical Repository
The Informed Cons ent Form will contain a separate section that addresses participation 
in the RCR.  The investigator or authorized designee will explain to each patient the 
objectives, methods, and potential hazards of participation in the RCR.  Patients will be 
told that they are free to refuse to participate and may withdraw their specimens at any 
time and for any reason during the storage period.  A separate, specific signature [CONTACT_20030] a patient's agreement to provide optional RCR specimens.  
Patient s who decline to participate will not provide a separate signature.
The investigator should document whether or not the patient has given consent to 
participate by [CONTACT_26806].
In the event of an RCR participant 's death or loss of competence, the participant's 
specimens and data will continue to be used as part of the RCR research.
Withdrawal from the [COMPANY_002] Clinical Repository
Patients who give consent to provide RCR specimens have the right to withdraw their 
specimens from the RCR at any time for any reason.  If a patient wishes to withdraw 
consent to the testing of his or her specimens, the investigator must inform the Medical 
Monitor in writing of the patient's wishes using the RCR Subject Withdrawal Form and, if 
the trial is ongoing, must enter the date of withdrawal on the RCR Research Sample 
Withdrawal of Informed Consent eCRF.  The patient will be provided with instructions on 
how to withdraw consent after the trial is closed.  A patient's withdrawal from 
StudyGA29102 does not, by [CONTACT_5071], constitute withdrawal of specimens from the RCR.  
Likewise, a patient's withdrawal from the RCR does not constitute withdrawal from 
Study GA29102.
Monitoring and Oversight
RCR specimens will be tracked in a manner consistent with Good Clinical Practice by a 
quality -controlled, auditable, and appropriately validated laboratory information 
management system, to ensure compliance with data confidentiality as well as 
adherence to authorized use of specimens as specified in this protocol and in the 
Informed Consent Form.  [COMPANY_002] monitors and auditors will have direct access to 
appropriate parts of records relating to patient participation in the RCR for the purposes 
of verifying the data provided to [COMPANY_002].  The site will permit monitoring, audits, IRB/EC 
review, and health authority inspections by [CONTACT_26807].
4.5.2 Timing of Study  Assessments
[IP_ADDRESS] Screening and Pretreatment A ssessments
Written informed consent for pa rticipation in the study must be obtained before 
performing any study -specific screening tests or evaluations. Informed Consent Forms 
for enrolled patients and for patients who are not subsequently enrolled will be 
maintained at the study site.  
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2079Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
78/Protocol GA29102, Version 7All scre ening tests and evaluations will be performed within 35 days prior to Day 1 
except for flexible sigmoidoscopy/colonoscopy ,which should be performed 416days 
prior to Day 1 (see Figure 4).  The screening period will not exceed 35 calendar days.
Laboratory samples should be collected from the patient early in the screening period to 
allow time for the laboratory results to be available for review by [CONTACT_335567]
(seeSection [IP_ADDRESS]).   The ECG and chest X -ray can be obtained any time before Day 1 
(seeSection [IP_ADDRESS] and Section [IP_ADDRESS] for additional details on the chest X -ray and 
ECG).  Colon biopsy specimen collection is detailed in Section [IP_ADDRESS] .
A blood sample to test for antibodies to JCV will be taken and stored for possible later 
assessment of how widespread the JCV infection is in the study population.  Sample 
testing for the presence of JCV antibodies is not helpful in predicting risk for PML or for 
evaluating neurologic symptoms.  The sample may be tested if there is a strong belief 
that this information will be helpful in managing a patient's condition.
The screening endoscopy for MCS should be performed 4 16 days prior to Day 1 
(i.e., Day16 to Day 4).  The endoscopy score from the worst affected segment up to 
the splenic flexure (rectum, sigmoid, and descending colon) is to be used for the MCS 
calculation (see Section [IP_ADDRESS] ).
The symptoms of UC must be recorded during the screening period.  The e -diary entries 
will be reviewed by [CONTACT_335560].  Because the colonoscopy/flexible 
sigmoidoscopy and 
bowel cleansing preparations can interfere with the assessment of 
patient -reported symptoms, e- diary entries used to calculate the complete MCS should 
not correspond to days of bowel preparation or endoscopy or the day following the 
endoscopy.  Further details and examples of stool frequency and rectal bleeding 
subscore derivation are provided in Appendix 4.
Theendoscopy and the stool frequency and rectal bleeding subscores willbe 
considered, along with other PGA components, when determining the PGA for the MCS 
calculation at Day 1 (i.e., prior to initiation of study drug) , as described in detail in 
Appendix 4.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2080Etrolizumab —F.Hoffmann -La [COMPANY_002] Ltd
79/Protocol GA29102, Version 7Figure 4Overview  of Screening A ctivities
Note:  Endoscopy should be performed 4 [ADDRESS_1073952] reasons for 
screening failur e, as applicable.
[IP_ADDRESS].[ADDRESS_1073953] time, he or she will be considered a 
screen failure.  
Laboratory testing that is repeated because of administrative or technical issues 
(e.g., breakage of a sample vial during transit to the central laboratory or degradation of 
a sample during transportation) is not considered to be re -screening.
[IP_ADDRESS].2 Re-Screening
Re-screening is required if a patient has not met all the eligibility criteria within 35 days 
after the original screening visit.  Patients who are found to be ineligible for entry into the 
study may be re -screened once only for example, if th e patient develops additional 
manifestations of UC, a worsening of existing manifestations at a later time, if patients’ 
clinical status has changed such that the abnormal laboratory value may be directly 
affected (e.g., transfusion) .  Each patient must be re-consented before re -screening 
occurs.

Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2081Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
80/Protocol GA29102, Version 7Re-screening is not required for t he HIV preliminary and confirmatory tests, HCV 
antibody test, and hepatitis B assessment (i.e., HBsAg, HBcAb, and, if required, HBV 
DNA), provided that the following criteria are met:
Test results are available from the initial screening 
Eligibility criteria for the assessments are satisfied
Date of the initial screening assessment was 6 weeks prior to Day 1 following the 
second screening
In the investigator’s judgment, the pati ent is notdeemed to have been at risk for HIV, 
hepatitis C, or hepatitis B infection (based on medical history, or geographical or 
social circumstance)
As described in Section [IP_ADDRESS] , if a negative TB screening test result has been 
documented within [ADDRESS_1073954] is required.
The screening endoscopy and colonic biopsies do not need to be repeated during 
re-screening provided that all of the following criteria are met:
All endoscopy -related inclusion criteria have been met
The initial endoscopy has been performed within 28 days prior to Day 1 following 
the second screening
Colon biopsies a s specified by [CONTACT_760517], the 
endoscopy and protocol -specified colon biopsies should be repeated 4 16 days prior 
toDay 1 .
Re-Screening in the Event Of Sc reen Failure due to C. Difficile or CMV 
Infection
Patients who are classified as screen failures due to the presence of C.difficile or CMV 
infection may be re -screened 60 days after successful treatment.  For patients who 
screen failed due to CMV infectio n, laboratory analysis of CMV from colon biopsy 
sample is required during re -screening evaluation to rule out CMV infection .
See Appendix 1for the schedule of screening and pretreatment assessments.
[IP_ADDRESS] Assessments during Treatment
All assessments will be performed on the day of the specified visit, except where a time 
window is specif ied.  Assessments scheduled on the day of study drug administration 
should be performed prior to dosing, unless otherwise noted.  When study drug 
administration in the home is required on the same day as a clinic visit, drug is to be 
administered at hom e AFTER the clinic visit.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2082Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
81/Protocol GA29102, Version 7For induction ( Week 10) and maintenance (W eek 62) visits that are associated with an 
MCS requiring endoscopy, every effort should be made to schedule the endoscopy on 
the same day as the clinic visit.  If this is not possible, end oscopy should be performed 
as close to the clinic visit as possible, with a maximal window of 3 days prior to and 
5days after the visit.  The endoscopy score should be considered when determining the 
PGA (as applicable), a component of the MCS (see Appendix 4).
On a number of occasions during the Maintenance Phase (see Appendix 1and Figure 3), 
patients will be contact[CONTACT_760518], rather than 
making a clinic visit.  During these telephone visits, data will be collected as for a clinic 
visit with the exception of blood sample and in clinic PRO assessments (see Appendix 1, 
Schedule of Assessments).  All adverse events and conc omitant medications will be 
recorded and the patient questioned regarding a potential clinical relapse.  An 
unscheduled visit is to be conducted as required (see Section [IP_ADDRESS]).
All patients will receive hands -on training in use of the e -diary and tablet.  Patients will 
also be instructed to contact [CONTACT_335569] e- diary during screening or at any time during the study.
See Appendix 1for the schedule of assessments performed during the treatment period.
[IP_ADDRESS] Assessme nts at Study Completion/Early  Withdrawal from 
Treatment Visit
The completion of study treatment period is defined as the Week 62 visit. Patients who 
complete the treatment medication will be asked to visit the clinic for Week62 
assessments.  Eligible patients who consent to receive open -label etrolizumab in 
Part1(OLE) of Study GA28951 are to receive their first dose of open -label etrolizumab 
[ADDRESS_1073955] dose of etrolizumab in Part 1 (OLE) of Study GA28951 cannot be administered in 
accordance with these requirements, the first dose of etrolizumab is to be administered 
with a maximum delay of 2 weeks from the scheduled dosing day in Study GA2895 1. 
If a patient leaves the study prior to Week 62, an early withdrawal from treatment visit is 
to be conducted at his or her next scheduled visit, including for those patients who are 
enrolling in Study GA28951 (OLE -SM).  Assessments are specified in the Schedule of 
Assessments in Appendix 1.  Following completion of assessments at this early 
withdrawal from treatment visit, eligible patients are to receive their first dose of open -
label etrolizumab in Part 1 (OLE) of Study GA28951 [ADDRESS_1073956] dose of 
study medication in this study, with a maximum delay of 2 weeks from the scheduled 
dosing day in Study GA28951.
At any timepoint , patients who are not eligible or who choose not to enroll i n Part 1 (OLE) 
of Study GA28951 are to enroll in Part 2 (SM) of Study GA28951 for extended PML 
follow -up after completion of the 12 -week safety follow -up in this study.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2083Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
82/Protocol GA29102, Version 7Patients who were treated with prohibited medication are to have their early withdrawal 
from treatment visit at their next scheduled visit followed by [CONTACT_941] 12- week safety follow -up 
phase of this study (telephone call at Week6 and clinic visit at Week 12; see 
Appendix 2).  Patients areto enroll in Part 2 (SM) of Study GA28951 for extended 
PML monitoring.
[IP_ADDRESS].1 Eligibility  for Entry to Open -Label Extension and Safety  
Monitoring Study
The OLE -SM (Study GA28951) study will be conducted under a separate protocol and 
eligible patients as described below (also see Table 4) will need to be willing and able to 
provide separate informed consent to enter this study. 
Note:  Patients who are not eligible or who do not wish to receive open -label etrolizumab 
in Part 1 (OLE) of Study GA28951 will be requested to enroll in the 92-week extended 
PML monitoring (Part 2 [SM] of Study GA28951) after completing the 12 -week safety 
follow -up in this study.
The follo wing patients may  be eligible to enroll in Part 1 (OLE) of Stud y GA28951 :
In the Induction Phase, any patients who requires initiation of an 
immunosuppressant (ASA, 6- MP, MTX), corticosteroid, or oral or topi[INVESTIGATOR_2855] 5-ASA, or 
increase in dose of these medications over baseline levels for treatment of 
worsening disease sym ptoms may enroll in Part 1 (OLE) of Study GA28951 after 
the Week 10 assessment, if eligible.
Patients who do not achieve a clinical response at Week 10
Patients who meet the criteria for relapse (see Section [IP_ADDRESS] for definition) at any 
time between W eek 10 and W eek 62 
Patients who were not receiving corticosteroids at baseline and patients who have 
completed the steroid taper may be eligible for Part 1 (OLE) of Study GA28951 if 
they receive oral corticosteroids at a dose greater than [ADDRESS_1073957] awal.
Patients who use IV or topi[INVESTIGATOR_11930] ,who u setopi[INVESTIGATOR_2855] 5 -ASA, or who initiate 
or escalate dose of oral 5 -ASA to treat worsening symptoms of UC in the 
Maintenance Phase
Patients who require initiation of or an increase in the dose of immunosu ppressants 
during the Maintenance Phase 
All remaining patients at end of W eek 62
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2084Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
83/Protocol GA29102, Version 7The follo wing patients are NOT eligible to enroll in Part 1 (OLE) of Study  GA28951 :
Patients who discontinue study treatment prior to W eek 10 or do not perform the 
Week 10 visit
Patients who require rescue medications that are prohibited in conjunction with 
etrolizumab (see Section [IP_ADDRESS] )
Patients with severe hypersensitivity reactions (see Section [IP_ADDRESS]), specific 
malignancies, specific de novo or reactivated serious viral infections, PML, or other 
life-threatening infections during the study (see Table 5and Sections [IP_ADDRESS]
and5.1.5 )
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number [PHONE_16302]
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
84/Protocol GA29102, Version 7Table 4Eligibility  for Enrollment into Part 1 (OLE) of Study G A28951 or Transfer to 12 -Week Safety  Follow -Up
Time Period RationaleMay Enroll in Part 1 (OLE), if 
Eligible (from W eek [ADDRESS_1073958])Must Transfer to 12 -Week 
Safety Follow -Up of this 
Study
Day 1 to W eek 10 Initiation of an immunosuppressant (AZA, 6 -MP, MTX) oral or 
topi[INVESTIGATOR_2855] 5 -ASA, or corticosteroid, or increase dose in these 
medications over baseline levelsYes (may enroll at the 10 -week 
timepoint)Yes (must transfer to SFU if 
patient does not 
choose OLE)
Week 10 Did not achieve a clinical response at W eek 10 Yes
Week 10 to Week 62 Met criteria for clinical relapse (see Section 4.4.3 ) at any time 
between W eek 10 and W eek 62Yes
Yes(must transfer to SFU if 
patient does not choose to 
receive study medication in 
Maintenance Phase or to 
participate in OLE)Day [ADDRESS_1073959] completed the 
steroid taperYes
Day 1 to W eek 62 Use of IV or topi[INVESTIGATOR_760451] 5 -ASA, or 
increase in dose of oral 5 -ASA over baseline levelYes
Week 62 End of treatment period (all remaining patients) Yes Yes (must transfer to SFU if 
patient does not 
choose OLE)
Day 1 to W eek 10 Discontinuation of study treatment or missing the W eek 10 visit No
Yes (after dosing 
termination visit)Day 1 to W eek 62 Patients requiring rescue medications that are prohibited 
(see Section [IP_ADDRESS] )No
Day 1 to W eek 62 Occurrence of severe hypersensitivity reactions (see 
Section [IP_ADDRESS] ), specific malignancies, specific de novo or 
reactivated serious viral infections, PML or other life -threatening 
infections during the study (see Table 5and Sections [IP_ADDRESS] and 
5.1.5 )No
5-ASA 5-aminosalicylic acid; 6 -MP6-mercaptopurine; AZAazathioprine; IV intravenous; MTXmethotrexate; OLEopen -label extension; 
PMLprogressive multifocal leukoencephalopathy; SFU safety follow -
up.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2086Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
85/Protocol GA29102, Version [IP_ADDRESS] Safety  Follow -Up A ssessments
Safety follow -up will be conducted in this study for a period of 12 weeks for patients not 
enrolling in Part 1 (OLE) of Study GA28951 (see Table 4 for patients who should enter 
the 12 -week safety follow -up phase within this protocol, Appendix 2).  Patients will be 
assessed at [ADDRESS_1073960] dose 
of study drug (e.g., the Week [ADDRESS_1073961] 
dose of study drug).   Patients enrolling in Part 1 (OLE) of Study GA28951 will not enter 
the 12 -week safety follow -up period in this study.   Adverse events should be followed as 
outlined in Section 5.4.
Following the 12 -week safety f ollow-up period, patients should enroll in Part 2(SM) of 
Study GA28951 where they will be monitored for PML for an additional 92 weeks.  
Patients enrolling in Part 2 (SM) f or the extended PML monitoring will NOT receive 
treatment with open- label etrolizumab .  During the extended PML follow -up period in 
Study GA28951, patients will have telephone assessments every [ADDRESS_1073962] dose 
of study drug.
Patients who discontinue from the study prior to completion of the 12 -week safety 
follow -up will be asked to return to the clinic within 30 days ( 7 days) after the last dose 
of study drug or last scheduled visit for an early termination visit (see Appendix 2).
See Appendix 1for the schedule of assessments performed at the study 
completion/early withdrawal from treatment visit.
After the study completion adverse events should be followed as outlined in Sectio ns5.5
and 5.6.
See Appendix 2  for the schedule of 12- week Safety Follow -Upassessments.
[IP_ADDRESS] Assessments at Unscheduled Visits
An unscheduled visit may occur at any time during the study, (i.e., due to relapse of 
disease or an adverse event).  Patients who are seen by [CONTACT_82295] a 
timepoint not required by [CONTACT_781272]:
Review of e -diary data
Recording of concomitant medicati ons and procedures
Collection of adverse events and serious adverse events
Clinical chemistry, hematology, and CRP, if indicated
Stool sample collection, if indicated
Partial or complete MCS, if indicated
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2087Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
86/Protocol GA29102, Version 7Flexible sigmoidoscopy, if indicated
Colonic biopsy to evaluate for CMV, if clinically indicated
Collection of PK and ATA sample, if indicated
See Appendix 1for assessments that are required to be performed in case of an 
unscheduled visit. 
4.[ADDRESS_1073963] the right to voluntarily 
discontinue study drug or withdraw from the study at any time for any reason.  Reasons 
for discontinuation of study drug or withdrawal from the study may include ,but are not 
limited to, the following:
Patient withdrawal of consent at any time
Any medical condition that the investigator or Sponsor determines may jeopardize 
the patient’s safety if he or she continues in the study
Investigator or Sponsor determines it is in the best interest of the patient
Patient non -compliance, specifically defined as missing scheduled visits or 
non-adherence with background medications
[IP_ADDRESS] Discontinuation from Study  Drug
Patients must dis continue study drug if they experience any of the following:
Pregnancy
Anaphylaxis or other severe hypersensitivity reaction
Develop colonic mucosal dysplasia
Malignancy (with the exception of local and resect edbasal or squamous cell 
carcinoma of the skin ) or cervical Pap test with AIS, HSIL, or CIN of Grade 1
Specific serious infection (see Table 5 for details on serious infection):
Any patient who experiences a de novo or reactivated serious viral infection, such 
as HBV, HCV, HIV, should discontinue study medication.
Any patient who de velops life- threatening infecti onsduring the st udy should 
discontinue study medication.
Any medicatio
n for rescue outside defined limits of the protocol (see Section 4.3.2)
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2088Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
87/Protocol GA29102, Version 7Patients who discontinue study drug prematurely for the reasons listed above will be 
asked to return to the clinic for a study drug completion/early withdrawal from treatment
visit (see Section [IP_ADDRESS] ) and will continue to undergo safety follow -up assessments for 
12weeks wit hin this study.  Patients should then enroll in Part 2 (SM) of Study GA28951
for 92 weeks of monitoring for PML (see Section [IP_ADDRESS] ).  The primary reason for 
premature study drug discontinuation should be documented on the appropriate eCRF.  
Patients who discontinue study drug prematurely will not be replaced.
[IP_ADDRESS] Withdrawal from Study
Every effort should be made to obtain information on patients who withdraw from the 
study.  The primary reason for withdrawal from the study should be documented on the 
appropriate eCRF.  Patients will not be followed for any reason after consent has been 
withdrawn.  Patients who withdraw from the study will not be replaced.
4.6.2 Study and Site Discon tinuation
The Sponsor has the right to terminate this study at any time.  Reasons for terminating 
the study may include ,but are not limited to ,the following:
The incidence or severity of adverse events in this or other studies indicates a 
potential healt h hazard to patients.
Patient enrollment is unsatisfactory.
The Sponsor will notify the investigator if the study is placed on hold or if the Sponsor 
decides to discontinue the study or development program.
The Sponsor has the right to replace a site at a ny time.  Reasons for replacing a site 
may include ,but are not limited to ,the following:
Excessively slow recruitment
Poor protocol adherence
Inaccurate or incomplete data recording
Non-compliance with the International Council for Harmonisation (ICH) guideline for 
Good Clinical Practice
5. ASSESSMENT OF SA FETY
5.1 SAFETY PLA N
The safety plan for this study is designed to ensure patient safety and mitigate potential 
risks. The principles of the safety plan include education of investigators and patients 
regarding all identified and potential safety risks, specific eligibility criteria to screen out 
at-risk patients, monitoring to ensure timely identification and management of a safety 
event, and management strategy such as guidelines for treating an event an d for 
withholding or discontinuing study treatment, as appropriate.  These principles are to be 
applied for all safety risks in the clinical program. 
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2089Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
88/Protocol GA29102, Version 75.1.1 Potential Risks for Etrolizumab
Etrolizumab is an investigational drug that demonstrated a safety profile similar to 
placebo in the Phase II study, EUCALYPTUS.  Given the relatively limited size of 
Phase II studies, the full safety profile is not known at this time and will be further 
characterized during the etrolizumab Phase III program.  
The potential and/or hypothetical risks for etrolizumab are based on its mechanism of 
action, available nonclinical and clinical data, data from other anti -integrin drugs, and 
general risks associated with biologic agents.  
Investigators should refer to the Etrolizumab Investigator's Brochure for a complete 
summary of safety information.
5.1.2 Progressive Multifocal Leukoencephalopathy
PML is a potentially fatal neurological condition linked to reactivation of a polyomavirus 
(JCV) and active viral replication in the brain.
Cases of PML have been reported in patients with CD and multiple sclerosis who 
received concomitant treatment with the anti -4 integrin natalizumab and 
immunosuppressives.   
Integrin 41, which is inhibited by [CONTACT_25763], is a pleiotropic integrin that is bel ieved 
to facilitate T cell migration into the CNS.  Inhibition of integrin 41 is thought to reduce 
(CNS) immune surveillance and facilitate development of PML.
PML has not been attributed to vedolizumab, which selectively impedes lymphocyte 
trafficking into gut tissue by [CONTACT_335572] 47integrin and not the 41 
integrin, despi[INVESTIGATOR_335486] (Dotan 2017).
Etrolizumab targets cells expressing th e 7 integrin ( 47 and E7 cells), and not 
41cells.  Despi[INVESTIGATOR_335487] a specific role of 
7integrins in leukocyte homing to the CNS, given the observation of PML risk with 
natalizumab, the Sponsor will cont inue to conduct extensive risk -monitoring procedures 
during the Phase III trials.
[IP_ADDRESS] Screening and Patient Selection
No known interventions can reliably prevent PML or adequately treat PML, if it occurs; 
therefore, it is important to exclude patients with a perceived higher baseline risk for 
PML.  At study screening, patients with a history of demyelinating disease, PML, or 
clinically significant abnormalities noted on baseline neurologic examination will be 
excluded from the study.  Patients who have received natalizumab, efalizumab, or 
rituximab will also be excluded.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2090Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
89/Protocol GA29102, Version 7A blood sample to test for antibodies to JCV will be taken and stored for possible later 
assessment of how widespread the JCV infection is in the study population.  Sample 
testing for the presence of JCV antibodies is not helpful in predicting risk for PML or for 
evaluating neurologic symptoms.  The sample may be tested if there is a strong belief 
that this information will be helpful in managing a patient's condition.
[IP_ADDRESS] Monitoring and Management
Study site personnel and patient participants will be educated regarding the signs and 
symptoms of PML and provided with alert cards.  Close monitoring during the course of 
the study for any new signs or symptoms suggestive of PML will be performed with 
regular neurologic examinations (including evaluation of cranial nerves, motor and 
sensory function, coordination, an d mental status) per the Schedule of Assessments 
(see Appendix 1).  The PML Subjective Checklist (symptom assessment) and the PML 
Object ive Checklist (neurologic evaluation) will be administered (see Appendix 5) by a 
qualified HCP and will be performed at screening and as indicated on the Schedule of 
Assessments (see Appendix 1).
During the in- clinic visits, patients will undergo PML monitoring assessments .
If a patient has a positive finding on the PML Subjective Checklist that is accompanied 
by a positive finding on the PML Objective Checklist or if there is strong clinical suspi[INVESTIGATOR_335488], the event shou ld be expeditiously reported as an adverse event of special 
interest within 24 hours (see Section 5.2.3 and Appendix 6for the Algorithm for 
Evaluation of Progressive Multifocal Leukoencephalopathy).  If PML is suspected, 
dosing with study treatment for that patient will be suspended and the patient should be
promptly referred to a neurologist.  Following formal evaluation by a neurologist, if PML 
cannot be ruled out, the case will be referred to an expert PML adjudication committee 
for further work -up,which may include brain MRI with and without contrast.  I f there 
remains any suspi[INVESTIGATOR_335482], the PML adjudication committee may recommend 
performing a lumbar puncture with CSF analysis for JCV by [CONTACT_954].  If JCV is detected, 
the patient should be treated as a PML case and the patient should permanently 
discontinue study drug and enter safety follow -up.  Dosing with study treatments can 
only be resumed in patients where PML has been ruled out.  See Appendix 6for the 
Algorithm for Evaluation of Progressive Multifocal Leukoencephalopathy.
There is no known effective treatment for PML.  Plasmapheresis has been employed in 
some patients where the event has been thought to be due to administration of a drug 
(Tan et al. 2011 ).
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2091Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
90/Protocol GA29102, Version 75.1.3 Monitoring for Other Serious Infections
Patients will also be monitored closely for other serious infections during the study 
(see Table 5 for details).  Patients and investigators will be informed of the possibility 
ofincreased susceptibility to infectious pathogens.  Investigators will be encouraged to 
promptly evaluate and a ggressively treat any signs and symptoms consistent with an 
infection.
5.1.4 Monitoring for Hypersensitivity Reactions
In addition, throughout the study, patients will be monitored closely for hypersensitivity 
reactions (see Table 5 for details).  Patients should be instructed to recognize the 
symptoms of any anaphylactic, anaphylactoid, or hypersensitivity reaction and to contact 
[CONTACT_760521].  Patients will be 
provided with alert cards to remind them and a caregiver or partner of the symptoms.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number [PHONE_16303]
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
91/Protocol GA29102, Version 75.1.5 Management of Specific A dverse Events
Table 5Guidelines for Managing Specific A dverse Events
Action to Be Taken
Serious Infections Patients who experience a serious infection event (i.e., an infection that is a serious adverse event) should not 
receive further study drug until the event has completely resolved and treatment with anti -infective medications 
has been completed.
All efforts should be made to ident ify the infectious agent.
For those patients who recover from a serious infection, study medication may be restarted following 
consultation with the Medical Monitor.
Any patient who experiences a de novo or reactivated serious viral infection such as HBV, HCV, HIV, should 
immediately discontinue study drug.
Any patient who develops CMV colitis should not receive further study drug until the event has resolved and 
treatment with appropriate anti -viral medication has been completed.  Re -initiation of therapy requires 
consultation with the Medical Monitor.
Patients who develop life -
threatening infections during the study should discontinue study drug.
Signs and symptoms of possible 
PMLIf a patient has a positive finding on the PML Subjective Checklist that is accompanied by a positive finding on the 
PML Objective Checklist, or if there is strong clinical suspi[INVESTIGATOR_335482], then the investigator is required to follow the 
process described in the PML algorithm (see Appendix 6).  If PML is suspected, a neurology consultation should be 
promptly arranged.  Based on this evaluation, brain magnetic resonance imaging and cerebral -spi[INVESTIGATOR_781231] (see Appendix 6).
The following are signs and symptoms that may potentially indicate PML:
Alteration in mental status (cognitive cha nges, including confusion, difficulty concentrating, memory loss) and 
altered behavior (including personality changes)
Higher cortical dysfunction, including impaired comprehension and/or formulation of language (aphasia), loss of 
ability to recognize obje cts, persons, sounds, shapes, or smells (agnosia)
Visual changes, including loss of visual fields (homonymous hemianopsia), double vision (diplopia)
Motor deficits, including weakness (hemiparesis, monoparesis), seizures, (generalized or partial), difficul ties with 
speech (dysarthria,) or swallowing (dysphagia)
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number [PHONE_16304]
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
92/Protocol GA29102, Version 7Table 5Guidelines for Managing Specific A dverse Events (cont.)
Action to Be Taken
Signs and symptoms of possible 
PML (cont.)Sensory deficits, including sensory loss (paresthesia)
Coordination deficits, including difficulty walking and maintaining balance (ataxia), lack of voluntary coordination 
of limb movement (limb ataxia)
If PML is suspected then all investigational treatment should be withheld in that patient and may only be restarted if it 
is confirmed that the patient does not have PML .
Vaccinations For [ADDRESS_1073964] dose of study medication, patients should not receive live 
vaccines.
Malignancies Any signs or symptoms that could be suggestive of malignancy should be promptly and aggressively evaluated 
and reported to the Sponsor.  Incident hematologic abnormalities (e.g., new or worsening neutropenia, anemia, 
thrombocytopenia, macrocytosis, or atypi[INVESTIGATOR_760453] W BC differential) should be c arefully evaluated.
If any dysplasias or abnormalities are noted that could be consistent with malignancy, an oncologist or 
appropriate specialist should be consulted and no further doses of investigational product should be 
administered until a thorough c linical evaluation has been completed.
Patients who develop a malignancy (with the exception of local and resect edbasal or squamous cell carcinoma 
of the skin), or who develop adenocarcinoma in situ, high -grade squamous intraepi[INVESTIGATOR_12184], or cervica l 
intraepi[INVESTIGATOR_760454] [ADDRESS_1073965] not receive additional doses of study drug.
Hepatic effects Liver toxicity has been reported wit h other drugs that target 4 integrins (natalizumab) and 47 integrins 
(vedolizumab).  Therefore, this potential risk is being monitored in all etrolizumab studies.  In nonclinical chronic 
toxicology studies, no abnormalities indicating liver toxicity wit h etrolizumab were observed.  The risk in humans is 
currently unknown.
Patients with significant liver function test abnormalities should be excluded from the etrolizumab clinical 
studies.
Patients should receive guidance on reporting liver problems if the y occur.
Liver function tests should continue to be monitored according to the Schedule of Assessments and as clinically 
indicated.
Significant hepatic events should be evaluated promptly and managed accordingly.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number [PHONE_16305]
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
93/Protocol GA29102, Version 7Table 5Guidelines for Managing Specific Adverse Events (cont.)
Action to Be Taken
Hypersensitivity reactions In completed Phase I/II clinical trials of etrolizumab, one serious adverse event of hypersensitivity (Grade 2) has 
been reported, no anaphylactic, anaphylactoid, or severe hypersensitivity reactions were observed; however, 
anaphylaxis and hypersensitivity reactions will be closely monitored during the study.
Patients with a history of moderate or severe allergic or anaphylactic/anaphylactoid reactions to chimeric, 
human, or humanized antibodies, fusion proteins, or murine proteins are excluded from study participation.
The first four injections will be administered in the clinic.  After the first four injections, the patient must be 
monitored for 60 minutes after each injecti on.
Health care professionals administering the study medication in the clinic must be trained in the appropriate 
administration procedures and be able to recognize the symptoms associated with potential anaphylactic, 
anaphylactoid, or hypersensitivity rea ctions and should be familiar with Sampson’s criteria for defining 
anaphylaxis ( Sampson et al. 2006 ; see Appendix 8).
Investigators and H CPs should also be trained to accurately and appropriately report these events immediately 
to the Sponsor as adverse events of special interest and as serious adverse events, if appropriate 
(see Section 5.2).
Medicinal products for the treatment of hypersensitivity reactions (e.g., epi[INVESTIGATOR_238], antihistamine
s, and 
glucocorticoids . Epi[INVESTIGATOR_760455]. 
Adjunctive medications such as parenteral diphenhydramine and inhaled bronchodilators may be used IN 
ADDITION to epi[INVESTIGATOR_760445].   Resuscitation equipment should also be available .  Site personnel must 
be able to detect and treat such reactions.
If a patient has symptoms of anaphylaxis or severe hypersensitivity, the administration of etrolizumab must be 
discontinued permanently.
HCPs should also instruct patients how to recognize the symptoms of any anaphylactic, anaphylactoid, or 
hypersensitivity reaction and to contact a HCP or seek emergency care in case of any such symptoms.
Subsequent injections can be administered at home.  The patient will be advised to seek emergency care in 
response to any potential sympto
m of hypersensitivity and will receive two alert cards to remind them and a 
caregiver or partner of the symptoms.
Detailed information regarding anaphylactic, anaphylactoid, or hypersensitivity reactions that occur during the study 
will be collected, rega rdless of whether the events are serious (see Section 5.2.2 ) or non -serious (see Section 5.2.3 ).
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number [PHONE_16306]
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
94/Protocol GA29102, Version 7Table 5Guidelines for Managing Specific A dverse Events (cont.)
Action to Be Taken
Local injection -site reactions A local injection -site reaction is any local reaction occurring at the site of injection following study drug 
administration.  In completed Phase I/II studies in patients with UC, injection -site reactions were reported at a 
rate of 10%, all of which were of mild intensity. In the clinic setting, patients will be monitored for signs of 
injection -site reactions in the period immediately following injections.  Patients will be given guidance on reporting 
injection -site reactions when administering drug at h ome or after patient leaves clinic.
Pregnancies Patients who become pregnant should be withdrawn from study drug and followed -up for the duration of the 
pregnancy (see Section 5.4.3 for details).
CMVcytomegalovirus; HBVhepatitis B virus; HCP health -care professional; HCV hepatitis C virus; JCV John Cunningham virus; PML progressive 
multifocal leukoencephal opathy.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2096Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
95/Protocol GA29102, Version 75.[ADDRESS_1073966]; performing 
protocol specified safety laboratory assessments; measuring protocol specified vital 
signs; and conducting other protocol specified tests that are deemed critical to the 
safety evaluation of the study.
Certain types of events require immediate reporting to the Sponsor, as outlined 
inSection 5.4.
5.2.[ADDRESS_1073967], regardless of causal attribution.  An adverse event can 
therefore be any of the following:
Any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a m edicinal product, 
whether or not considered related to the medicinal product
Any new disease or exacerbation of an existing disease (a worsening in the 
character, frequency, or severity of a known condition) (see Section s [IP_ADDRESS]
and5.3.5.9 )
Recurrence of an intermittent medical co ndition (e.g., headache) not present at 
baseline
Any deterioration in a laboratory value or other clinical test (e.g., ECG, X -ray) that is 
associated with symptoms or leads to a change in study treatment or concomitant 
treatment or discontinuation from stu dy drug
Adverse events that are related to a protocol mandated intervention, including 
those that occur prior to assignment of study treatment (e.g., screening invasive 
procedures such as biopsy sample collection)
5.2.2 Serious A dverse Events (Immediately  Repor table to the 
Sponsor)
All serious adverse events are required to be reported by [CONTACT_25741] (i.e., no more than 24 hours after learning of the event; see Section 5.4.2 for 
reporting instructions).  A serious adverse event is any adverse event that meets any of 
the following criteria:
Is fatal (i.e., the adverse event actually causes or leads to death)
Is life threatening (i.e., the adverse event, in the view of the investigator, places the 
patient at immediate risk of death)
This does not include any adverse event that had it occurred in a more severe 
form or was allowed to continue might have caused death.
Requires or prolongs inpatient hospi[INVESTIGATOR_059] (see Section [IP_ADDRESS])
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2097Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
96/Protocol GA29102, Version 7Results in persistent or significant disability/incapaci ty (i.e., the adverse event 
results in substantial disruption of the patient’s ability to conduct normal 
lifefunctions)
Is a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to 
study drug
Is a significant medical event in the i nvestigator's judgment (e.g., may jeopardize the 
patient or may require medical/surgical intervention to prevent one of the outcomes 
listed above)
The terms “severe” and “serious” are notsynonymous.  Severity refers to the intensity of 
an adverse event ( e.g., rated as mild, moderate, or severe or according to National 
Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE ]criteria; 
see Section 5.3.3 ); the event itself may be of relatively minor medical significance (such 
as severe headache without any further findings).
Severity and seriousness need to be independently assessed for each adverse event 
recorded on the eCRF.
5.2.[ADDRESS_1073968] (Immediately  Reportable to 
the Sponsor)
Adverse events of special interest are required to be reported by [CONTACT_33473] (i.e., no more than 24 hours after learning of the event; see 
Section 5.4.2 for reporting instructions).  Adverse events of special interest for this study 
include the f ollowing:
Cases of potential drug- induced liver injury that include an elevated ALT or AST in 
combination with either an elevated bilirubin or clinical jaundice, as defined by 
[CONTACT_25742]’s Law (see Section [IP_ADDRESS] ) 
Suspected transmission of an infectious agent by [CONTACT_335577] :
Any organism, virus, or infectious particle (e.g., prion protein transmitting 
transmissible spongif orm encephalopathy), pathogenic or non -pathogenic, is 
considered an infectious agent.  A transmission of an infectious agent may be 
suspected from clinical symptoms or laboratory findings that indicate an 
infection in a patient exposed to a medicinal produ ct.  This term applies only
when a contamination of the study drug is suspected.
Adverse events of special interest specific to etrolizumab:
Systemic hypersensitivity reactions and anaphylactic and anaphylactoid 
reactions (see Section 5.1.5 and Sampson’s Criteria in Appendix 8)
Neurological signs, symptoms, and adverse events that may suggest possible 
PML, on the basis of a positive finding on the PML Subjective Checklist that is 
accompanied by a positive finding on the PML Objective Checklist or if there is 
strong clinic al suspi[INVESTIGATOR_335482] (see Appendix 6andTable 5 )
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2098Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
97/Protocol GA29102, Version 75.3 METHODS A ND TIMING F OR CA PTURING A ND ASSESSING 
SAFETY PARAMETERS
The investigator is responsible for ensuring that all adverse events (see Section 5.2.1 for 
definition) are recorded on the A dverse Event eCRF and reported to the Sponsor in 
accordance with instructions provided in this section and in Sections 5.4, 5.5, and 5.6.  
The i nvestigator is also responsible for reporting medical device complaints 
(see Section 5.4.4 ).
For each adverse event recorded on the Adverse Event eCRF, the investigator will make 
an assessment of seriousness (see Section 5.2.2 for seriousness criteria), severity 
(see Section 5.3.3 ), and causali ty (see Section 5.3.4 ).  
5.3.1 Adverse Event Reporting Period
Investigators will seek information on adverse events at each patient contac t.  All 
adverse events, whether reported by [CONTACT_25743], will be 
recorded in the patient’s medical record and on the Adverse Event eCRF.
After informed consent has been obtained but prior to initiation of study drug , only 
seriou s adverse events caused by a protocol mandated intervention (e.g., serious 
adverse events related to invasive procedures such as biopsies , discontinuation of 
medications ) should be reported (see Section 5.4.2 for instructions for reporting serious 
adverse events).
After initiation of study drug, all adverse events, regardless of relationship to study drug, 
will be reported until the patient completes his or her last study visit.  After this period, 
patients who enter the GA28951 study should follow the adverse event reporting 
requirements of tha t study.
If the patient does not enter the GA28951 study, the Sponsor should be notified if the 
investigator becomes aware of any post -study serious adverse event sthat are believed 
to be related to prior study drug treatment.  In addition, the Sponsor should be notified if 
the investigator becomes aware of any post -study events of confirmed or suspected 
PML, regardless of relationship to study drug, for up to 2 year s after the patient’s last 
dose of study drug (see Section 5.6).
5.3.2 Eliciting A dverse Ev ent Information
A consistent methodology of non -directive questioning should be adopted for eliciting 
adverse event information at all patient evaluation timepoints.  Examples of non -directive 
questions include the following:
“How have you felt since your last clinic visit?”
“Have you had any new or chan ged health problems since you were last here?”
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2099Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
98/Protocol GA29102, Version 75.3.3 Assessment of Severity  of A dverse Events
The adverse event severity grading scale for the NCI CTCAE (v4. 0) will be used for 
assessing adverse event severity.  Table 6 will be used for assessing severity for 
adverse events that are not specifically listed in the NCI CTCAE. 
Table 6Adverse Event Severity Grading Scale for Events Not Specifically 
Listed in NCI CTCA E
Grade Severity
1 Mild; as ymptomatic or mild sy mptoms; clinical or diagnostic observations only; 
or intervention not indicated
2 Moderate; minimal, local, or non -invasive intervention indicated; or limiting 
age-appropriate instrumental activities of daily livinga
3 Severe or medically significant, but not immediately life -threatening; 
hospi[INVESTIGATOR_3111]; disabling; or 
limiting self-care activities of daily livingb,c
4 Life-threatening consequences or urgent intervention indicatedd
5 Death related to adverse eventd
NCI CTCAE =National Cancer Institute Common Terminology Criteria for Adverse Events .
Note:  Based on the most recent version of NCI CTCAE (v4. 0), which can be found at:  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
aInstrumental activities of daily living refer to preparing meals, shoppi[INVESTIGATOR_19640], using the telephone, managing money, etc.
bExamples o f self -care activities of daily living include bathing, dressing and undressing, 
feeding one's self, using the toilet, and taking medications, as performed by [CONTACT_25744].
cIf an event is assessed as a "significant medical event," it mu st be reported as a serious 
adverse event (see Section 5.4.2 for reporting instructions), per the definition of serious 
adverse event in Section 5.2.[ADDRESS_1073969] be reported as serious adverse events (see Section 5.4.2 for 
reporting instructions), per the definition of serious adverse event in Section 5.2.2 .
5.3.4 Assessment of Causality  of Adverse Events
Investigators should use their knowledge of the patient, the circumstances surrounding 
the event, and an evaluation of any potential alternative causes to determine whether an 
adverse event is considered to be related to the study drug, indicating "yes" or "no" 
accordingly.  The following guidance should be taken into consideration:
Temporal relationship of event onset to the initiation of study drug
Course of the ev ent, considering especially the effects of dose reduction, 
discontinuation of study drug, or reintroduction of study drug (where applicable)
Known association of the event with the study drug or with similar treatments
Known association of the event with t he disease under study
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2100Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
99/Protocol GA29102, Version 7Presence of risk factors in the patient or use of concomitant medications known to 
increase the occurrence of the event
Presence of non -treatment -related factors that are known to be associated with the 
occurrence of the event
Table 7Causal A ttribution Guidance
Is the adverse event suspected to be caused by [CONTACT_25745], evidence, 
science -based rationales, and clinical judgment?
YES There is a plausible temporal relationship between the onset of the adverse event and 
administration of the study drug, and the adverse event cannot be readily explained by 
[CONTACT_102]’s clinical state, intercurrent illness, or concomitant therapi[INVESTIGATOR_014]; and/or the 
adverse event follows a known pattern of response to the study drug; and/or the 
adverse event abates or resolves upon discontinuation of the study drug or dose 
reduction and, if applicable, reappears upon re -challenge.
NO An adverse event will be considered related, unless it fulfillsthe criter ia as specified 
below. 
Evidence exists that the adverse event has an etiology other than the study drug 
(e.g., preexisting medical condition, underlying disease, intercurrent illness, 
orconcomitant medication); and/or the adverse event has no plausible t emporal 
relationship to administration of the study drug (e.g., cancer diagnosed 2 days after 
firstdose of study drug).
5.3.[ADDRESS_1073970] medical terminology/concepts when recording adverse 
events on the Adverse Event eCRF; the use of colloquialisms and abbreviations should 
be avoided.
Only one adverse event term should be recorded in the event field on the Adverse 
Event eCRF.
[IP_ADDRESS] Diagnosis versus Signs and Sy mptoms
Injection- Site Reactions
Local cutaneous adverse events that occur at or around the injection site during or within 
24 hours following study drug injection should be separately captured as individual signs 
(e.g., erythema, induration/swelling at injection site) or symptoms (e.g., pain, prurit us at 
injection site) rather than a diagnosis of allergic reaction or injection -site reaction.
Other A dverse Events 
For adverse events other than injection -site reactions, a diagnosis (if known) should be 
recorded on the Adverse Event eCRF rather than ind ividual signs and symptoms 
(e.g., record only liver failure or hepatitis rather than jaundice, asterixis, and elevated 
transaminases).  However, if a constellation of signs and/or symptoms cannot be 
medically characterized as a single diagnosis or syndrome at the time of reporting, each 
individual event should be recorded on the Adverse Event eCRF.  If a diagnosis is 
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2101Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
100/Protocol GA29102, Version 7subsequently established, all previously reported adverse events based on signs and 
symptoms should be nullified and replaced by [CONTACT_601374] e vent report based on the 
single diagnosis, with a starting date that corresponds to the starting date of the first 
symptom of the eventual diagnosis.
[IP_ADDRESS] Adverse Events Occurring Secondary  to Other Events
In general, adverse events occurring secondary to other events (e.g., cascade events or 
clinical sequelae) should be identified by [CONTACT_5252], with the exception of 
severe or serious secondary events.  Medically significant adverse events occurring 
secondary to an initiating event that are separated i n time should be recorded as 
independent events on the Adverse Event eCRF.  For example:
If vomiting results in mild dehydration with no additional treatment in a healthy adult, 
only vomiting should be reported on the eCRF.
If vomiting results in severe dehydration, both events should be reported separately 
on the eCRF.
If a severe gastrointestinal hemorrhage leads to renal failure, both events should be 
reported separately on the eCRF.
If dizziness leads to a fall and subsequent fracture, all three events should be 
reported separately on the eCRF.
If neutropenia is accompanied by [CONTACT_25747], both events should be reported 
separately on the eCRF.
All adverse events should be recorded separately on the Adverse Event eCRF if it is 
unclear as to whether the events are associated.
[IP_ADDRESS] Persistent or Recurrent A dverse Events
A persistent adverse event is one that extends continuously, without resolution, between 
patient evaluation timepoints.  Such events should be recorded only once on the 
Adverse Event eCRF.  The initial severity (intensity or grade) of the event will be 
recorded at the time the event is first reported.  If a persistent adverse event becomes 
more severe, the most extreme severity should be recorded on the Adverse Event eCRF.  
If the event becomes s erious, it should be reported to the Sponsor immediately (i.e., no 
more than 24 hours after learning that the event became serious; see Section 5.4.2 for 
reporting instructions).   The Adverse Event eCRF should be updated by [CONTACT_70156] “non- serious” to “serious,” providing the date that the event became serious 
and completing all data fields related to serious adverse event s.
A recurrent adverse event is one that resolves between patient evaluation timepoints 
and subsequently recurs.  Each recurrence of an adverse event should be recorded 
separately on the Adverse Event eCRF.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2102Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
101/Protocol GA29102, Version [IP_ADDRESS] Abnormal Laboratory Values
Not every laboratory abnormality qualifies as an adverse event.  A laboratory test result 
must be reported as an adverse event if it meets any of the following criteria:
Is accompanied by [CONTACT_4659]
Results in a change in study treatment (e.g., dosage modification, treat ment 
interruption, or treatment discontinuation)
Results in a medical intervention (e.g., potassium supplementation for hypokalemia) 
or a change in concomitant therapy
Is clinically significant in the investigator’s judgment
It is the investigator’s respo nsibility to review all laboratory findings.  Medical and 
scientific judgment should be exercised in deciding whether an isolated laboratory 
abnormality should be classified as an adverse event.
If a clinically significant laboratory abnormality is a sign of a disease or syndrome 
(e.g., alkaline phosphatase and bilirubin 5 ULN associated with cholecystitis), only the 
diagnosis (i.e., cholecystitis) should be recorded on the Adverse Event eCRF.
If a clinically significant laboratory abnormality is not a sign of a disease or syndrome, 
the abnormality itself should be recorded on the Adverse Event eCRF, along with a 
descriptor indicating if the test result is above or below the normal range (e.g., "elevated 
potassium," as opposed to "abnormal potassium").  If the laboratory abnormality can be 
characterized by a precise clinical term per standard definitions, the clinical term should 
be recorded as the adverse event.  For example, an elevated serum potassium level of 
7.0 mEq/L should be recorded as “hyperkalemia.”
Observations of the same clinically significant laboratory abnormality from visit to visit 
should only be recorded once on the Adverse Event eCRF (see Section [IP_ADDRESS] for 
details on recording persistent adverse events).
[IP_ADDRESS] Abnormal Vital Sign Values
Not every vital sign abnormality qualifies as an adverse event.  A vital sign result must 
be reported as an adverse event if it meets any of the following criteria:
Is accompanied by [CONTACT_4659]
Results in a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation)
Results in a medical intervention or a change in concomitant therapy
Is clinically significant in the investigator’s judgment 
It is the investigator’s responsibility to review all vital sign findings.  Medical and scientific 
judgment should be exercised in deciding whether an isolated vital sign abnormality 
should be classified as an adverse event.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2103Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
102/Protocol GA29102, Version 7If a clinically significant vital sign abnormality is a sign of a disease or syndrome 
(e.g., high blood pressure), only the diagnosis (i.e., hypertension) should be recor ded on 
the Adverse Event eCRF.
Observations of the same clinically significant vital sign abnormality from visit to visit 
should only be recorded once on the Adverse Event eCRF (see Section [IP_ADDRESS] for 
details on recording persistent adverse events).
[IP_ADDRESS] Abnormal Liver Function Tests
The finding of an elevated ALT or AST ( 3ULN) in combination with either an elevated 
total bilirubin ( 2ULN) or clinical jaundice in the absence of cholestasis or other 
causes of hyperbilirubinemia is considered to be an indicator of severe liver injury (as 
defined by [CONTACT_25742]'s Law).  Therefore, investigators must report as an adverse event the 
occurrence of either of the following:
Treatment -emergent ALT or AST 3ULN in combination with total bilirubin 
2ULN
Treatment -emergent ALT or AST 3ULN in combination with clinical jaundice
The most appropriate diagnosis or (if a diagnosis cannot be establ ished) the abnormal 
laboratory values should be recorded on the Adverse Event eCRF (see Section [IP_ADDRESS]) 
and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of 
the event), either as a serious adverse event or an adverse event of special interest 
(see Section 5.4.2 ).
[IP_ADDRESS] Deaths
All deaths that occur during the protocol -specified adverse event reporting period 
(see Section 5.3.1 ), regardless of relationship to study drug, must be recorded on the 
Adverse Event eCRF and immediately reported to the Sponsor (see Section 5.4.2 ).  This 
includes death attributed to progression of UC.
Death should be considered an outcome and not a distinct event.  The event or conditi on 
that caused or contributed to the fatal outcome should be recorded as the single medical 
concept on the Adverse Event eCRF.  Generally, only one such event should be 
reported.  If the cause of death is unknown and cannot be ascertained at the time of 
reporting, “unexplained death” should be recorded on the Adverse Event eCRF.  If the 
cause of death later becomes available (e.g., after autopsy), “unexplained death” should 
be replaced by [CONTACT_25749].   The term " sudden death " should not b e 
used unless combined with the presumed cause of death (e.g., "sudden cardiac death").
If the death is attributed to progression of UC, "ulcerative colitis progression” should be 
recorded on the Adverse Event eCRF.
Deaths that occur after the adverse event reporting period should be reported as 
described in Section 5.6.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2104Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
103/Protocol GA29102, Version [IP_ADDRESS] Preexisting Medical Conditions
A preexisting medical condition is one that is present at the screening visit for this study.  
Such conditions should be recorded on the General Medical History and Baseline 
Conditions eCRF.
A preexisting medical condition should be recorded as an adverse event only if the 
frequency, severi ty, or character of the condition worsens during the study.  W hen 
recording such events on the Adverse Event eCRF, it is important to convey the concept 
that the preexisting condition has changed by [CONTACT_9672] 
(e.g., “more frequent he adaches”).
[IP_ADDRESS] Lack of Efficacy  or Worsening of Ulcerative Colitis
Medical occurrences or symptoms of deterioration that are anticipated as part of UC 
should be recorded as an adverse event if judged by [CONTACT_319080].  W hen recording an unanticipated worsening UC on the Adverse Event eCRF, 
it is important to convey the concept that the condition has changed by [CONTACT_188215] (e.g., “acce lerated ulcerative colitis” or “worsening of ulcerative 
colitis”).
[IP_ADDRESS] Hospi[INVESTIGATOR_781232] a serious adverse event (per the definition of serious 
adverse event in Section 5.2.2 ), except as outlined below.  The duration of 
hospi[INVESTIGATOR_335490].
An event that leads to hospi[INVESTIGATOR_781233] e event or a serious adverse event:
Hospi[INVESTIGATOR_25678]
Planned hospi[INVESTIGATOR_33402] (e.g., for study drug administration 
or insertion of access device for study drug administration)
Hospi[INVESTIGATOR_272] a preexisting condition, provided that all of the following criteria 
are met:
The hospi[INVESTIGATOR_781234].
The patient has not suffered an adverse event.
An event that leads to hospi[INVESTIGATOR_33405] a serious adverse event, but should be reported as an adverse
event instead:
Hospi[INVESTIGATOR_781235]: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2105Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
104/Protocol GA29102, Version [IP_ADDRESS] Adverse Events A ssociated with an Ove rdose or Error in Drug 
Administration
Study drug overdose is the accidental or intentional use of the drug in an amount higher 
than the dose being studied.  An overdose or incorrect administration of study drug is not 
an adverse event unless it results in untoward medical effects.
Any study drug overdose or incorrect administration of study drug should be noted on 
the Study Drug Administration eCRF.
All adverse events associated with an overdose or incorrect administration of study drug 
should be recorded o n the Adverse Event eCRF.  If the associated adverse event fulfills 
seriousness criteria, the event should be reported to the Sponsor immediately (i.e., no 
more than 24 hours after learning of the event; see Section 5.4.2 ).
[IP_ADDRESS] Patient -Reported Outcome Data
Adverse event reports will not be derived from PRO data by [CONTACT_1034], and safety 
analyses will not be performed using PRO data.  Site s are not expected to review the 
PRO data for adverse events. 
5.[ADDRESS_1073971] report 
such events to the Sponsor immediately; under no circumstances should reporting take 
place more than [ADDRESS_1073972] report to the Sponsor within 24 hours after learning 
of the event, regardless of relationship to study drug:
Serious adverse events ( defined in Section 5.2.2; see Section 5.4.2 for further
details on reporting requirements )
Adverse events of special interest ( defined in Section 5.2. 3;s
ee Section 5.4.2 for 
further details on reporting requirements )
Pregnancies (see Section 5.4.3 for further details on reporting requirements )
The investigator must report new significant follow -up information for these events to the 
Sponsor immediately (i.e., no more than 24 hours after becoming aware of the 
information).  New significant information includes the follo wing:
New signs or symptoms or a change in the diagnosis
Significant new diagnostic test results
Change in causality based on new information
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2106Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
105/Protocol GA29102, Version 7Change in the event’s outcome, including recovery
Additional narrative information on the clinical course of the e vent
Investigators must also comply with local requirements for reporting serious adverse 
events to the local health authority and IRB/EC.
5.4.[ADDRESS_1073973]
Medical Monitor: , M.B., Ch.B.
Primary: [PHONE_6968]
Secondary: [PHONE_6969]
To ensure the safety of study patients, an Emergency Medical Call Center Help Desk will 
access the Quintiles Medical Emergency List, escalate emergency medical calls, provide 
medical translation service (if necessary), connect the investigator with a Quintiles 
Medical Monitor, and track all calls.  The Emergency Medical Call Center Help Desk will 
be available [ADDRESS_1073974]
After informed consent has been obtained but prio r to initiation of study drug, only 
serious adverse events caused by a protocol -mandated intervention should be reported.  
The paper Clinical Trial Serious Adverse Event/Adverse Event of Special Interest 
Reporting Form provided to investigators should be c ompleted and submitted to the 
Sponsor or its designee immediately (i.e., no more than 24 hours after learning of the 
event), either by [CONTACT_249177].
After initia tion of study drug, serious adverse events and adverse events of special 
interest will be reported until the patient completes his or her last study visit.  
Investigators should record all case details that can be gathered immediately (i.e., within 
24 hour safter learning of the event ) on the Adverse Event eCRF and submit the report 
via the EDC system.  A report will be generated and sent to [COMPANY_002] Safety Risk 
Management by [CONTACT_27950].

Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2107Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
106/Protocol GA29102, Version 7In the event that the EDC system is unavailable, the paper Clinical Trial Serious Adverse 
Event /Adverse Event of Special Interest Reporting Form provided to investigators should 
be completed and submitted to the Sponsor or its designee immediately (i.e., no more 
than 24 hours after learning of the event), either by [CONTACT_70160].  Once 
the EDC system is available, all information will need to be entered and submitted via 
the EDC system.
Instructions for reporting serious adverse events that occur after the final dose of study 
treatment are provided in Section 5.6.
5.4.3 Reporting Requiremen ts for Pregnancies
[IP_ADDRESS] Pregnancies in Female Patients
Female patients of childbearing potential will be instructed to immediately inform the 
investigator if they become pregnant during the study or within 24 weeks after the final 
dose of study drug.  A paper Clinical Trial Pregnancy Reporting Form should be 
completed and submitted to the Sponsor or its designee immediately (i.e., no more than 
24 hours after learning of the pregnancy), either by [CONTACT_123565] .  Pregnancy 
should not be recorded on the Adverse Event eCRF.  The investigator should 
discontinue study drug and counsel the patient, discussing the risks of the pregnancy 
and the possible effects on the fetus.  Monitoring of the patient should continue until 
conclusion of the pregnancy.  Any serious adverse events associated with the 
pregnancy (e.g., an event in the fetus, an event in the mother during or after the 
pregnancy, or a congenital anomaly/birth defect in the child) should be reported on the 
Adverse Event eCRF.  
In addition, the investigator will submit a paper Clinical Trial Pregnancy Reporting Form 
when updated information on the course and outcome of the pregnancy 
becomes available.
[IP_ADDRESS] Pregnancies in Female Partners of Male Patients
Male patients will be instructed through the Informed Consent Form to immediately 
inform the investigator if their partner becomes pregnant during the study or within 
24weeks after the final dose of study drug.   A paper Clinical Trial Pregnancy Reporting 
Form should be completed and submitted to the Sponsor or its designee immediately 
(i.e., no more than 24 hours after learning of the pregnancy), either by [CONTACT_162492] .  Attempts should be made to collect and report details of the course and 
outcome of any pregnancy in the partner of a male patient exposed to study drug.  When 
permitted by [CONTACT_779], the pregnant partner would need to sign an Authorization for Use 
and Disclosure of Pregnancy Health Information to allow for follow -up on her pregnancy .  
If the authorization has been signed, the investigator should submit a paper Clinical Trial 
Pregnancy Reporting Form when updated info rmation on the course and outcome of the 
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2108Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
107/Protocol GA29102, Version 7pregnancy becomes availabl e. An investigator who is contact[CONTACT_249179], to support an i nformed decision in cooperation with the 
treating physician and/or obstetrician.
[IP_ADDRESS] Abortions
Any abortion should be classified as a serious adverse event (as the Sponsor considers 
abortions to be medically significant), recorded on the Adverse Event eCRF, and 
reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the 
event; see Section 5.4.2 ).
[IP_ADDRESS] Congenital Anomalies/Birth Defects
Any congenital anomaly/birth defect in a child born to a female patient exposed to study 
drug or the female partner of a male patient exposed to study drug should be classified 
as a serious adverse event, recorded on the Adverse Eve nt eCRF, and reported to the 
Sponsor immediately (i.e., no more than 24 hours after learning of the event; 
seeSection 5.4.2 ).
5.4.[ADDRESS_1073975] to 
follow -up, or the patient w ithdraws consent.  Every effort should be made to follow all 
serious adverse events considered to be related to study drug or trial -related procedures 
until a final outcome can be reported.
During the study period, resolution of adverse events (with dates) should be 
documented on the Adverse Event eCRF and in the patient’s medical record to facilitate 
source data verification.
All pregnancies reported during the study should be followed until pregnancy outcome.
5.5.[ADDRESS_1073976], and pregnancies, the 
Sponsor or a designee may follow up by [CONTACT_756], fax, email, and/or a monitoring visit 
to obtain additional case details and outcome information (e.g., from hospi[INVESTIGATOR_123444], consultant reports, autopsy reports) in order to perform an independent 
medical assessment of the reported case.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2109Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
108/Protocol GA29102, Version 75.[ADDRESS_1073977]-study , if the patient does not enter the GA28951 study, the Sponsor should be 
notified if the investigator becomes aware of any serious adverse event occurring after 
the end of the adverse event reporting period (defined as the last study visit [see 
Section 5.3.1 ]) if the event is believed to be related to prior study drug treatment.  In 
addition, the Sponsor should be notified if the investigator be comes aware of any 
post-study events of confirmed or suspected PML, regardless of relationship to study 
drug, for up to 2 years after the patient’s last dose of study drug.
The investigator should report these events directly to [COMPANY_002] or its designee eithe r by 
[CONTACT_571853]/Adverse Event of Special Interest Reporting Form with use of the fax number or 
email address provided to investigators.
5.[ADDRESS_1073978] experience to identify and expeditiously 
communicate possible new sa fety findings to investigators, IRBs, ECs, and applicable 
health authorities based on applicable legislation.
To determine reporting requirements for single adverse event cases, the Sponsor 
willassess the expectedness of these events for etrolizumab using thefollowing 
reference document:
Etrolizumab Investigator's Brochure
Within the Investigator’s Brochure, the reference safety information is provided 
inSection 6 .4(Identified Risks and Adverse Drug Reactions [Reference Safety 
Information]).
The Sponsor will compare the severity of each event and the cumulative event 
frequency reported for the study with the severity and frequency reported in the 
applicable reference document.
Reporting requirements will also be based on the investigator's assessm ent of causality 
and seriousness, with allowance for upgrading by [CONTACT_25753].
All serious related (as assessed by [CONTACT_1755]/or Sponsor) adverse events 
occurring in a patient administered etrolizumab at any  time during the study and 
assessed as unexpected per the reference safety information will be considered 
Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) for the purpose of 
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2110Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
109/Protocol GA29102, Version 7regulatory reporting to all health authorities, with the exception of the U.S. Food and 
Drug Administrat ion (FDA).  For the FDA, S[LOCATION_003]Rs will be submitted as Investigational 
New Drug Application (IND) Safety Reports, in line with the FDA guidance “Safety 
Reporting Requirements for INDs and BA/BE Studies” dated December 2012.
The Sponsor will report all S[LOCATION_003]Rs into the EudraVigilance database in accordance 
with the ”Detailed guidance on the collection, verification, and presentation of adverse 
event/reaction reports arising from clinical trials on medicinal products for human use 
(‘CT-3’).”
To satisfy local reg ulatory reporting criteria while maintaining the blind, investigators will 
be informed of all unexpected serious adverse events regardless of study drug 
assignment (i.e., they may also receive reports of patients on placebo).
6. STATISTICA L CONSIDER ATIONS AND ANAL YSIS PLA N
The analysis of data from the [ADDRESS_1073979] been cleaned and verified.
Whereas Sponsor personnel will be unblinded to treatment assignment to perfo rm the 
primary W eek-62 analyses, patients and study site personnel will remain blinded to 
individual treatment assignment during the Maintenance Phase until after the study is 
completed (after all patients have either completed the safety follow -up period or 
discontinued early from the study) and the database is locked.
Detailed specifications of the statistical methods will be described in the Statistical 
Analysis Plan (SAP).
6.1 DETERMINA TION OF SA MPLE SIZE
The study sample size was selected so that sufficient patients are enrolled to evaluate 
the primary endpoint in the Maintenance Phase.  Approximately 350 patients will be 
enrolled in the open -label Induction Phase. 
Under the assumption of clinical response at Week 10 of approximately 60% (based on 
the Phase II Week 10 response results for the TNF -naive subgroup), the planned size of 
350 patients in the open -label Induction Phase would provide approximately 210patient s 
randomized in tothe Maintenance Phase.   A sample size of approximately 105patients 
per arm is required in the Maintenance Phase to achieve 90% power to detect a 25% 
absolute difference in remission rates between the etrolizumab and placebo arms, for a 
2test at the two -sided 5% significance level, under the assumption of a placebo true 
remission rate of 30% 45%.  If clinical response rates at Week 10 are lower than 
projected, the total enrollment in the open -label induction cohort may be increased to 
ensure that a sufficient number of Week-10 clinical responders are rando mized into the 
Maintenance Phase.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2111Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
110/Protocol GA29102, Version 76.[ADDRESS_1073980] OF STUDY
The number of patients enrolled in the open -label induction and the number of patients 
randomized into the Maintenance Phase will be tabulated by [CONTACT_1606], study site, and 
treatment arm (for th e Maintenance Phase).  Patient disposition (the number of patients 
enrolled, randomized, treated, and completing each study period) will be tabulated by 
[CONTACT_2939].  Reasons for premature study drug discontinuation or withdrawal from 
study, any eligibil ity criteria deviations, and other major protocol deviations will be 
summarized by [CONTACT_2939].
6.3 SUMMA RIES OF TREA TME NT GROUP COMPA RABILITY
Demographic and baseline characteristics such as age, sex, race, region, use of 
corticosteroids and immunosuppressants, duration of disease, and MCS and its 
subscores will be summarized for all enrolled patients as well as for patients randomized 
into the Maintenance Phase by [CONTACT_781273].  
Exposure to open -label etrolizumab/study drug (number of study treatments and 
duration of treatment) will be summarized.
6.4 EFFICA CY ANAL YSES
Analyses of the efficacy endpoints will inc lude all patients randomized into the 
Maintenance Phase (i.e., patients who achieved a clinical response at Week 10 in the 
open -label Induction Phase) with patients grouped according to the treatment assigned 
at randomization (intent -to-treat population).
To manage the overall type I error, the primary and secondary endpoints in the 
Maintenance Phase will be tested sequentially.  Each endpoint will be tested at a 
two-sided 5% significance level.  The testing hierarchy for the secondary endpoints will 
be des cribed in the SAP.
Patients who are non -evaluable for efficacy at a specific timepoint (e.g., because of 
missing data or transfer to the OLE treatment protocol) will be considered 
non-responders for all response/remission type endpoints.  In addition, for the 
Maintenance Phase, patients who initiated an agent not allowed in combination with 
etrolizumab (see Section 4.4.2 ), an immunosuppressant or corticosteroid (administered 
for the treatment of UC), or who had an increase in dose over baseline levels for 
treatment of worsening disease symptoms will be considered non -responders thereafter.  
In the Induction Phase, initiation of an agent not allowed in combination with etrolizumab, 
an immunosuppressant, oralortopi[INVESTIGATOR_2855] 5-ASA, orcorticosteroid, or an increase in dose 
over baseline levels will lead to non -responder classification.
For continuous outcomes (e.g., IBDQ, UC -PRO/SS), scores afte r the first use of rescue 
medication will be imputed using the worst post -baseline score from the following 
assessments:  the last score available prior to the start date of first rescue medication 
and all scores available after the start date of rescue medication use.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2112Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
111/Protocol GA29102, Version 7In addition to the analyses described herein and in Section 6.4.1 and Section 6.4.2 , the 
following analyses will be performed for the primary efficacy endpoint and key secondary 
efficacy endpoints.  Details of these analyses will be described in the SAP :
Sensitivity analyses to evaluate the robustness of results to the primary analysis 
methods (e.g., handling of dropouts)
Subgroup analyses to evaluate the consistency of results across prespecified 
subgroups (e.g., based on age, sex, race/ethnicity, basel ine UC medications, 
baseline corticosteroid dose)
Further details, including additional missing data handling rules, and further definitions 
of exploratory endpoints will be provided in the SAP.
6.4.1 Primary  Efficacy  Endpoint
The primary endpoint for the Maintenance Phase is W eek 62 remission among patients 
with a clinical response at Week 10. Patients who are randomized into the 
Maintenance Phase (i.e. ,clinical responders at Week 10) will be evaluated. The 
difference in rem ission rates between the etrolizumab and placebo arms will be 
compared using the Cochran -Mantel -Haenszel test statistic stratified by [CONTACT_781274] (yes/no), concomitant treatment with 
immunosuppressants after W eek 10 (yes/no), and baseline disease activity (MCS 9, 
MCS 10).  The absolute difference in remission rates and 95% CIs for the point 
estimate will be provided.
6.4.2 Secondary  Efficacy Endpoints
The secondary efficacy endpoints for the Maintenance Phase are as follows :
Proportion of patients inclinical remission at W eek 62 among patients in clinical 
remission at Week 10 
Proportion of patients in clinical remission at W eek 62
 Proportion of patients in remission at Week 6 2among patients in remission at 
Week 1 0
Proportion of patients with improvement in endoscopic appearance of the mucosa at 
Week 62
Proportion of patients in endoscopic remission at W eek 62
Proportion of patients in histologic remission at Week 62
 Change from baseline in rectal bleed subscore at W eek 6
 Change from baseline in stool frequency subscore at Week 6
Proportion of patients in corticosteroid -free remission at Week 62 (off corticosteroids 
for at least 24 weeks prior to Week 62) in patients who were receiving 
corticosteroids at baseline
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2113Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
112/Protocol GA29102, Version 7Proportion of patients in corticosteroid -free clinical remission at W eek 62 (off
corticosteroids for at least 24 weeks prior to W eek 62) in patients who were
receiving corticosteroids at baseline
Change from baseline to Week 62 in UC bowel movement signs a nd symptoms as
assessed by [CONTACT_335505] -PRO/SS measure
Change from baseline to Week 62 in UC abdominal symptoms as assessed by [CONTACT_781275]-PRO/SS measure
Change from baseline to W eek 62 in health -related QOL, as assessed by [CONTACT_781276].
All the responder/ remitter type secondary endpoints will be analyzed in the same fashion 
as the primary endpoint.  The continuous secondary endpoints will be analyzed using an 
analysis of covariance (ANCOVA) model with W eek 10 remission status, concomitant 
treatment with co rticosteroids, concomitant treatment with immunosuppressants, 
baseline disease activity (MCS 9, MCS 10) as stratification variables, and the 
baseline value of the studied measure as a covariate.
6.4.3 Exploratory  Efficacy  Endpoints 
The exploratory efficacy endpoints are as follows:
 Proportion of patients with a clinical response at Week 62 among patients with  
clinical response at Week 10
 Proportion of patients with remission at Week 62
 among patients in clinical  
remission at Week 10
Proportion of patients in corticosteroid-f ree clinical remission at Week 62 (off  
corticosteroids for at least 12 weeks prior to Week 62) in patients who are receiving  
corticosteroids at baseline
 Proportion of patients with change in histologic disease activity from baseline to 
Week 10 and Week 62
 Proportion of patients with improvement in histologic and/or endoscopic disease  
activity
Proportion of patients with improvement in endoscopic appearance of the mucosa at  
Week 10
Proportion of patients with endoscopic remission at Week 10
Frequency and duration of hospi[INVESTIGATOR_760420] 10 to Week 62
 Proportion of patients with response, remission and corticosteroid-f ree endpoints as  
determined by [CONTACT_781277].
Change in health utilities, as assessed by [CONTACT_20367]-5 D, from Week 10 to Week 62
Change in histologic disease activity, from baseline to Week 10
 to Week 62 
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2114Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
113/Protocol GA29102, Version 7These endpoints will be analyzed using the same statistical methods as the UC/PRO 
and IBDQ continuous endpoints.
6.[ADDRESS_1073981] results (serum chemistry, hematology including complete blood count with 
differential and platelet counts, and urinalysis), and the incidence of antibodies 
toetrolizumab.
Additional details will be provided in the SAP.
6.5.[ADDRESS_1073982] dose of study drug.  In addition, separate 
summaries will be generated for serious adverse events, deaths, and adverse events 
leading to discontinuation of study drug .  Adverse events will be summarized by [CONTACT_335586], appropriate thesaurus level, and toxicity grade.
Analyses will be performed for:
Systemic hypersensitivity events
Specific analyses will be performed for anaphylactic reactions using the 
anaphylactic reaction Samps on’s criteria (see Appendix 8).
Serious infections
The frequency of serious infections, in particular GI infections, will be 
summarized f or each treatment arm.
Opportunistic infections
The occurrence of opportunistic infections will be summarized for each 
treatment arm.
Malignancies
Events that occur in the Neoplasms, Benign, Malignant, and Unspecified 
(Including Cysts and Polyps) System Or gan Class will also be summarized for 
each treatment arm.
Injection -site reactions
The frequency of injection -site reactions will be summarized for each 
treatment arm.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2115Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
114/Protocol GA29102, Version 76.5.2 Laboratory  Tests
Descriptive summaries of laboratory values at baseline and throughout the study will be 
tabulated by [CONTACT_2939].  For selected parameters, changes from baseline and the 
proportion of patients experiencing clinically significant changes relative to baseline will 
be summarized by [CONTACT_2939].
The number and percentage of patients with serum antibodies to etrolizumab at baseline 
and during the study will be tabulated by [CONTACT_2939].
6.6 PHA RMA COKINETIC, PHA RMA CODYNA MIC, A ND 
BIOMA RKER ANAL YSES
For PK assessment, group average serum etrolizumab concentration versus time data 
will be tabulated and plotted.  The serum pharmacokinetics of etrolizumab will be 
summarized with a mean serum concentration at steady state (trough) and at the 
primary endpoint time (Week 62).  Estimates for these parameters will be tabulated and 
summarized (mean, SD, coefficient of variation, median, minimum, and maximum).
Additional PK analyses may be conducted as appropriate.
PD and biomarkers analyses will include examination of changes over time in 
exploratory biomarkers after treatment.  Results will b e summarized descriptively.
7. DATA COLLECTION A ND MANAGEMENT
7.[ADDRESS_1073983] research organization ( CRO), and Data Management vendor will be 
responsible for the data management of this study, including quality checking of the data.  
Sites will be responsible for data entry into an eCRF via the EDC system.  In the event of 
discrepant data, data queries will be issued to the sites and resolved by [CONTACT_335587].  The Sponsor will produce an EDC Study Specification document that 
describes the quality checking to be performed on the data.  In addition, eCRF Help Text 
will be provided to the sites through the EDC system.  eCRFs and correction 
documentation will be maintained in the EDC system’s audit trail.
Central laboratory data will be transferred directly to the Sponsor with use of the 
Sponsor’s standard procedures to handle and process the electronic transfer of 
these data.
7.[ADDRESS_1073984] for appropriate eCRF 
completion.  eCRFs will be submitted electronically to the Sponsor and should be 
handled in accordance with instructions from the Sponsor.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2116Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
115/Protocol GA29102, Version 7All eCRFs should be co mpleted by [CONTACT_25755], trained site staff.  eCRFs should be 
reviewed and electronically signed and dated by [CONTACT_1720] a designee.
At the end of the study, the investigator will receive patient data for his or her site in a 
readable format on a compact disc that must be kept with the study records.  
Acknowledgement of receipt of the compact disc is required.
7.3 ELECTRONIC PA TIENT -REPORTED OUTCOME DA TA
Patient -reported data will be collected electronically through use of electronic devices 
provided by [CONTACT_26829] .  The electronic device (e -diary) is designed for entry of 
data in a way that is attributable, secure, and accurate, in compliance with FDA 
regulations for electronic records (21 Code of Federal Regulations, Part 11).  The data 
will be trans mitted to a centralized database at the ePRO vendor.  The data from the 
ePRO devices are available for view access only via secure access to a Web portal 
provided by [CONTACT_70170].  Only identified and trained users may view the data, and 
their actions b ecome part of the audit trail.  The Sponsor will have view access only.  
Regular data transfers will occur from the centralized database at the vendor to the 
database at the Sponsor.
Once the study is complete, the ePRO data, audit trail, and trial and sys tem 
documentation will be archived.  The Sponsor will receive all data entered by [CONTACT_335588] e -diary and all the study documentation.
Details regarding patient -reported data and the electronic device are available in the 
Study Reference Manual.  System backups for data stored by [CONTACT_70172]’s standard procedures.
7.4 SOURCE DA TA DOCUMENT ATION
Study monitors will perform ongoing source data verification to confirm that critical 
protocol data (i.e., source data) entered into the eCRFs by [CONTACT_26831], complete, and verifiable from source documents.
Source documents (paper or electronic) are those in which patient data are recorded 
and documented for the first time.  They include ,but are not limited to ,hospi[INVESTIGATOR_1097], 
clinical and office charts, laboratory notes, memoranda, PRO questionnaires, evaluation 
checklists, pharmacy dispensing records, recorded data from automated instruments, 
copi[INVESTIGATOR_781236], microfiche, photographic negatives, microfilm or magnetic media, X -rays, 
MRIs, ECGs, patient files, and records kept at pharmacies, laboratories, and 
medico -technical departments inv olved in a clinical trial.
Before study initiation, the types of source documents that are to be generated will be 
clearly defined in the Trial Monitoring Plan.  This includes any protocol data to be 
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2117Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
116/Protocol GA29102, Version 7entered directly into the eCRFs (i.e., no prior written or electronic record of the data) and 
considered source data.
Source documents that are required to verify the validity and completeness of data 
entered into the eCRFs must not be obliterated or destroyed and must be retained per 
the policy for retention o f records described in Section 7.6.
To facilitate source data verification, the investigators and institutions must provide the 
Sponsor direct access to applicable source documents and reports for trial -related 
monitoring, Sponsor audits, and IRB/EC review.  The investigational site must also allow 
inspection by [CONTACT_25756].
7.5 USE OF COMPUTERIZED SYSTEMS
When clinical observations are entered directly into an investigational site’s 
computerized medical record system (i.e., in lieu of original hardcopy records), the 
electronic record can serve as the source document if the system has been validated in 
accordance with health authority requirements pertaining to computerized systems used 
in clinical research.  An acceptable computerized data collection system allows 
preservation of the original entry of data.  If original data are modified, the system should 
mainta in a viewable audit trail that shows the original data as well as the reason for the 
change, name [CONTACT_25773], and date of the change.
7.[ADDRESS_1073985] of this study and the distributi on of 
IMP, including eCRFs, patient data (including PRO), Informed Consent Forms, 
laboratory test results, and medication inventory records, must be retained by [CONTACT_1268] [INVESTIGATOR_25653] [ADDRESS_1073986] 
to local regulations.
No records may be disposed of without the written approva l of the Sponsor.  W ritten 
notification should be provided to the Sponsor prior to transferring any records to 
another party or moving them to another location.
8. ETHICA L CONSIDERA TIONS
8.1 COMPLIA NCE WITH LA WSAND REGULATIONS
This study will be conducted in ful l conformance with the ICH E6 guideline for Good 
Clinical Practice and the principles of the Declaration of Helsinki or the laws and 
regulations of the country in which the research is conducted, whichever affords the 
greater protection to the individual. The study will comply with the requirements of the 
ICH E2A guideline (Clinical Safety Data Management:  Definitions and Standards for 
Expedited Reporting).  Studies conducted in the [LOCATION_002] or under a U.S. IND 
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2118Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
117/Protocol GA29102, Version 7Application will comply with FDA regulations and applicable local, state, and federal laws.  
Studies conducted in the European Union/European Economic Area will comply with the 
E.U. Clinical Trial Directive (2001/20/EC).
8.2 INFORMED CONSENT
The Sponsor’s sample Informed Consent Form (and ancillary sample Informed Consent 
Forms such as a Child’s Assent or Caregiver's Informed Consent Form, if applicable) will 
be provided to each site.  If applicable, it will be provided in a certified translation of the 
local language.  The Sponsor or its designee m ust review and approve any proposed 
deviations from the Sponsor's sample Informed Consent Forms or any alternate consent 
forms proposed by [CONTACT_779] (collectively, the “Consent Forms”) before IRB/EC 
submission.  The final IRB/EC -approved Consent Forms must be provided to the 
Sponsor for health authority submission purposes according to local requirements.
The Informed Consent Form will contain a separate section that addresses the use of 
remaining mandatory samples for optional exploratory research.  The inv estigator or 
authorized designee will explain to each patient the objectives of the exploratory 
research.  Patients will be told that they are free to refuse to participate and may 
withdraw their specimens at any time and for any reason during the storage period.  A 
separate, specific signature [CONTACT_22862] a patient's agreement to allow 
any remaining specimens to be used for exploratory research.  Patients who decline to 
participate will not provide a separate signature.
The Consent Forms m ust be signed and dated by [CONTACT_12718]’s legally 
authorized representative before his or her participation in the study.  The case history or 
clinical records for each patient shall document the informed consent process and that 
written info rmed consent was obtained prior to participation in the study.
The Consent Forms should be revised whenever there are changes to study procedures 
or when new information becomes available that may affect the willingness of the patient 
to participate.  The final revised IRB/EC -approved Consent Forms must be provided to 
the Sponsor for health authority submission purposes.
Patients must be re -consented to the most current version of the Consent Forms (or to a 
significant new information/findings addendum in accordance with applicable laws and 
IRB/EC policy) during their participation in the study.  For any updated or revised 
Consent Forms, the case history or clinical records for each patient shall document the 
informed consent process and that written informe d consent was obtained using the 
updated/revised Consent Forms for continued participation in the study.
A copy of each signed Consent Form must be provided to the patient or the patient’s 
legally authorized representative.  All signed and dated Consent Fo rms must remain in 
each patient’s study file or in the site file and must be available for verification by [CONTACT_33483].
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2119Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
118/Protocol GA29102, Version 7For sites in the [LOCATION_002], each Consent Form may also include patient authorization 
to allow use and disclosure of personal health information in compliance with the U.S. 
Health Insurance Portability and Accountability Act of 1996 (HIPAA).  If the site utilizes a 
separate Authorization Form for patient authorization for use and disclosure of personal 
health information under the HIPAA regulations, the review, approval, and other 
processes outlined above apply except that IRB review and approval may not be 
required per study site policies.
8.[ADDRESS_1073987] be submitted to the IRB/EC by [CONTACT_9532] [INVESTIGATOR_25684]/EC before the study is initiated.  
Inaddition, any patient recruitmen t materials must be approved by [CONTACT_1201]/EC.
The Principal Investigator [INVESTIGATOR_25685]/EC annually or more frequently in accordance with the requirements, 
policies, and procedures establi shed by [CONTACT_1201]/EC.  Investigators are also responsible 
for promptly informing the IRB/EC of any protocol amendments (see Section 9.6).
In addition to the requirements for reporting all adverse events to the Sponsor, 
investigators must comply with requirements for reporting serious adverse events to the 
local health authority and IRB/EC.  Investigators may receive written IND safety rep orts 
or other safety -related communications from the Sponsor.  Investigators are responsible 
for ensuring that such reports are reviewed and processed in accordance with health 
authority requirements and the policies and procedures established by [CONTACT_11577] /EC, and 
archived in the site’s study file.
8.[ADDRESS_1073988] parties only as permitted by [CONTACT_25734] (or separate 
authorization for use and disclosure of personal health information) signed by [CONTACT_102], 
unless permitted or required by [CONTACT_2371].
Medical information may be given to a patient’s personal physician or other appropriate 
medical personnel responsible for the patient’s welfare, for tre atment purposes.
Data generated by [CONTACT_70178], Sponsor 
monitors, representatives, and collaborators, and the IRB/EC for each study s ite, as 
appropriate.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2120Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
119/Protocol GA29102, Version 78.5 FINA NCIA L DISCLOSURE
Investigators will provide the Sponsor with sufficient, accurate financial information in 
accordance with local regulations to allow the Sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate health authorities.  
Investigators are responsible for providing information on financial interests during the 
course of the study and for 1 year after completion of the study (i.e., last patient last visit).
9. STUDY DOCUMENTATION, MONITORING, A ND
ADMINISTRA TION
9.[ADDRESS_1073989] of 
the study to be fully documented, including, but not limited to ,the protocol, protocol 
amendments, Informed Conse nt Forms, and documentation of IRB/EC and 
governmental approval.  In addition, at the end of the study, the investigator will receive 
the patient data, which include an audit trail containing a complete record of all changes 
to data.
9.[ADDRESS_1073990] on patient safety and 
data integrity to the Sponsor and to the IRB/EC in accordance with established IRB/E C 
policies and procedures. The Sponsor will review all protocol deviations and assess 
whether any represent a serious breach of Good Clinical Practice guidelines and require 
reporting to health authorities.  As per the Sponsor's standard operating procedu res, 
prospective requests to deviate from the protocol, including requests to waive protocol 
eligibility criteria, are not allowed.
9.3 SITE INSPECTIONS
Site visits will be conducted by [CONTACT_26833], patients’ medical records, and eCRFs.  The investigator will 
permit national and local health authorities, Sponsor monitors, representatives, and 
collaborators, and the IRBs/ECs to inspect facilities and records relevant to this study.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 [ZIP_CODE].4 ADMINISTRA TIVE STRUC TURE
This trial is sponsored by F. Hoffmann La [COMPANY_002] Ltd.  Approximately 125 international 
study centers will participate in this study to enroll approximately 350 patients.
A CRO will be contracted to manage the study and perform monitoring activities.
Centralized facilities (vendors) will be used to collect QOL data and endoscopy reading 
and interpretation; however, the investigator or a designee will also read the endoscopy 
if required for clinically indicated safety reasons.
A central laboratory (i.e., [COMPANY_002] or a vendor) will be used for most laboratory 
assessments, including histologic grading of colonic biopsy samples per the laboratory 
manual.  A selected group of assessments will be performed on site or by a local 
laboratory.
The eCRF data will be recorded via a Sponsor -designated EDC system.  An IxRS will be 
used for study drug inventory management and to randomize patients to study drug.
An iDMC will be established to perform regular review of the safety data to ensure the 
ongoing safety of partic ipating patients.  Its composition and a description of its 
responsibilities will be provided in an iDMC charter.
9.5 PUBLICA TION OF DATA  AND PROTECTION OF TR ADE 
SECRETS
Regardless of the outcome of a trial, the Spons or is dedicated to openly providing 
informa tion on the trial to healthcare professionals and to the public, both at s cientific 
congresses and in peer -reviewed journals. The Sponsor will comply with all 
requirements for publication of study results.  For more information, refer to the [COMPANY_002] 
Global Policy on Sharing of Clinical Trials Data at the following 
website:  
http://www.roche.com/roche_global_policy_on_sharing_of_clinical_study_information.pdf
The results of this study may be published or presented at scientific congresses.  For all 
clinical trials in patients involving an IMP for which a marketing authorization application 
has been filed or approved in any country, the Sponsor aims to submit a journal 
manuscript reporting primary clinical trial results within 6 months after the availability of 
the respective clinical study report.  In addition, for all clinical trials in patients involv ing 
an IMP for which a marketing authorization application has been filed or approved in any 
country, the Sponsor aims to publish results from analyses of addi tional endpoints and 
exploratory data that are clinically meaningful and statistically sound.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
120/Protocol GA29102, Version 7
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2122Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
121/Protocol GA29102, Version 7The investigator must agree to submit all manuscripts or abstracts to the Sponsor prior 
to submission for publication or presentation.  This allows the Sponsor to protect 
proprietary information and to provide comments based on information from other 
studies that may not yet be available to the investigator.
In accordance with standard editorial and ethical practice, the Sponsor will generally 
support publication o f multicenter trials only in their entirety and not as individual center 
data.  In this case, a coordinating investigator [INVESTIGATOR_12992].
Authorship will be determined by [CONTACT_14346].  Any formal publication 
of the study in which contribution of Sponsor personnel exceeded that of conventional 
monitoring will be considered as a joint publication by [CONTACT_26834].
Any inventions and resulting patents, improvements, and/or know -how originating from 
the use of data from this study will become and remain the exclusive and unburdened 
property of the Sponsor, except where agreed otherwise.
9.6 PROTOCOL A MENDME NTS
Any protocol amendments will be prepared by [CONTACT_1034].  Protocol amendments will 
be submitted to the IRB/EC and to regulatory authorities in accordance with local 
regulatory requirements.
Approval must be obtained from the IRB/EC and regulatory autho rities (as locally 
required) before implementation of any changes, except for changes necessary to 
eliminate an immediate hazard to patients or changes that involve logistical or 
administrative aspects only (e.g., change in Medical Monitor or contact [CONTACT_33484]).
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2123Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
122/Protocol GA29102, Version 710. REFERENCES
Bradley GM, Oliva- Hemker M. Infliximab for the treatment of pediatric ulcerative colitis. 
Expert Rev Gastroenterol Hepatol 2012;6:659 65.
Cepek KL, Parker CM, Madara JL, etal. Integrin E7mediates adhesion 
ofTlymphocytes to epi[INVESTIGATOR_265731]. J Immunol 1993;150:3459 70.
Chang JT, Lichtenstein GR. Drug insight: antagonists of tumor -necrosis factor -in the 
treatment of inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatology 
2006;3:220.
Chebli LA, Chaves LD, Pi[INVESTIGATOR_335491], et al. Azathioprine maintains long -term steroid -free 
remission through 3 years in patients with steroid -dependent ulcerative colitis. 
Inflamm Bowel Dis 2010;4:613 9.
Dotan, I. Early use of gut -selective therapy in Crohn’s disease for long -term remission. 
Presented at [COMPANY_005]- organized symposium during the 12th Congress of European 
Crohn's and Colitis Organization, 17 February 2017 ( unpublished ).
Faubion W A Jr, Loftus EV Jr, Harmsen W S, et al. The natural history of corticos teroid 
therapy for inflammatory bowel disease: a population -based study. 
Gastroenterology 2001;121:255 60.
Feagan BG, Greenberg GR, W ild G, et al. Treatment of active Crohn's disease with 
MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gast roenterol 
Hepatol 2008;6:1370 7.
Feagan BG, Greenberg GR, W ild G, et al. Treatment of ulcerative colitis with a 
humanized antibody to the α4 7 integrin. N Engl J Med 2005;352:2499 –507.
Feagan BG, Rutgeerts PJ, Sands BE, et al. Induction therapy for ulcerat ive colitis: 
results of GEMINI I, a randomized, placebo- controlled, double -blind, multicenter 
Phase 3 trial. Presented at: Digestive Disease Week 2012; 19 -22 May 2012; San 
Diego, CA. Abstract 943b.
Feagan BG, Rutgeerts PG, Sand BE, et al. Vedolizumab as in duction and maintenance 
therapy for ulcerative colitis. N Engl J Med 2013;369:699 710.
Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in 
inflammatory bowel disease. Gastroenterology 1989;96:804 -810.
Hanauer SB, F eagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s 
disease: the ACCENT I randomised trial. Lancet 2002;359:1541 49.
Holzmann B, McIntyre BW , Weissman IL. Identification of a murine Peyer’s 
patch specific lymphocyte homing receptor as an i ntegrin molecule with an 
-chain homologous to human VLA -4-α. Cell 1989;56:37 46.
Hu M, Crowe DT, W eissman IL, et al. Cloning and expression of mouse integrin p(7): 
a functional role in Peyer's patch– specific lymphocyte homing. Proc Natl Acad Sci
[LOCATION_003] 1992;89:8254 8.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2124Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
123/Protocol GA29102, Version 7Irvine EJ. Development and subsequent refinement of the inflammatory bowel disease 
questionnaire: a quality -of-life instrument for adult patients with inflammatory bowel 
disease. J Pediatr Gastroenterol Nutr 1999;28:S23 –7.
Khan N, Abba s AM, Moehlen M, et al. Methotrexate in ulcerative colitis: a nationwide 
retrospective cohort from the Veterans Affairs Health Care System. Inflamm Bowel 
Dis. 2013; 19:7.
Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with 
severe ulcerative colitis refractory to intravenous steroids: a parallel, open -label 
randomised controlled trial. Lancet 2012; 380:1909– 15.
Lobel EZ, Korelitz BI, Xuereb MA, et al. A search for the optimal duration of treatment 
with 6 -mercaptopurine f or ulcerative colitis. Am J Gastroenterol 2004; 3:462 5.
Mañosa M, García V, Castro L, et al. Methotrexate in ulcerative colitis: a Spanish 
multicentric study on clinical use and efficacy. J Crohns Colitis 2011;5:397 40.
Marchal -Bressenot A, Salleron J, Bo ulagnon -Rombi C, et al. Development and 
validation of the Nancy histological index for UC. Gut 2017;66:43 –9.
Marchal -Bressenot A, Scherl A, Salleron J, et al. A practical guide to assess the Nancy 
histological index for UC. G ut 2016;65:1919 –20.
Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the 
inflammatory bowel diseases with time, based on systematic review. 
Gastroenterology 2012;142:46 54.
Rabin, R, deCharro, F. EQ -5D: a measure of health status from the EuroQol Group. Ann
Med 2001;33:337 43.
Rutgeerts P, Sandborn W J, Feagan BG, et al. Infliximab for induction and maintenance 
therapy for ulcerative colitis. N Engl J Med 2005;353:2462 76.
Sampson HA, Muñoz -Furlong A, Campbell RL, et al. Second symposium on the 
definition and management of anaphylaxis:  summary report —second National 
Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network 
symposium. J Allergy Clin Immunol 2006;117:391 –7.
Sandborn W J, Colombel JF, D’Haens G, et al. One -year maintenance outcomes among 
patients with moderately -to-severely active ulcerative colitis who responded to 
induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment 
Pharmacol Ther 2013;37:204 13.
Sandborn W J, Colombel JF, Enns R, etal. Natalizumab induction and maintenance 
therapy for Crohn's disease. N Engl J Med 2005;353:1912 25.
Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy 
for ulcerative colitis. N Engl J Med 2017;376:1723 36.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2125Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
124/Protocol GA29102, Version 7Schroeder K W, Tremaine W J, Ilstr up DM. Coated oral 5 -aminosalicylic acid therapy for 
mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med 
1987;317:1625– 9.
Tan IL, McArthur JC, Clifford DB, et al. Immune reconstitution inflammatory syndrome in 
natalizumab -associated PML. Neurology 2011;77:1061 77.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number [PHONE_16307]
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
125/Protocol GA29102, Version 7Appendix 1
Schedule of A ssessments
AssessmentsScreening 
Daya
35 to1Study Week (3 day s)
0b48101216202428c32 36c40c4448c52c5660c62Unscheduled 
Visit dEarly 
Withdrawal  
from 
Treatment 
Visit
Informed consent x
Review eligibility criteria x xe
Demographic data x
Pregnancy test fx xexx xxxx x x x x x x xxx x X
Vital signs (BP and 
pulse)x xexx xxxx x x x x X
ECG x x X
Chest X -ray gx
Height x
Weight x
Medical histor y x
Physical examination hx x x x x x x X
PML neurologic 
examinationix x x x x x x x xdX
Hematology x x ex x x x xdxj
Chemistry x x ex x x x xdxj
Urinalysis x x exd
TB screen kx
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2127Appendix 1
Schedule of A ctivities (cont.)
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
126/Protocol GA29102, Version 7AssessmentsScreening 
Daya
35 to1Study Week (3 day s)
0b48101216202428c32 36c40c4448c52c5660c62Unscheduled 
Visit dEarly 
Withdrawal  
from 
Treatment 
Visit
HIV test x
Hepatitis B and C 
serology lx
Hepatitis B DNAmx x x x x x
Hepatitis C RNA 
(Amplicor)nx
Flow cytometry x x x
PK sampling (serum) ox x x x x xdxj
Anti-therapeutic 
antibody sample 
(serum)o, pxx x x x xq x dxj, q
Plasma sampler
(storage for JCV 
antibody testing)x
MCS (includes 
endoscopy) s, tx ux x x dx j
pMCS (excludes 
endoscopy)vx uxx xxxx x x x x dxj
Stool sample xwxxxxxxxdxx
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2128Appendix 1
Schedule of A ctivities (cont.)
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
127/Protocol GA29102, Version 7AssessmentsScreening 
Daya
35 to1Study Week (3 day s)
0b48101216202428c32 36c40c4448c52c5660c62Unscheduled 
Visit dEarly 
Withdrawal  
from 
Treatment 
Visit
Colonic biopsy (CMV if 
required)xyxd
Colonic biopsy 
(histopathological 
confirmation of UC if 
required)x z
Colonic biopsy 
(formalin)xaax bbx bbxd, bbxj, bb
Colonic biopsy (RNA 
later)xaax bbx bbxd, bbxj, bb
Serum sample (CRP) xex x xdxj
Blood sample for 
genetic analysis (DNA) 
(optional )x
Serum sample (future 
exploratory PD)o x x x x x X
Blood sample (RNA 
Paxgene)o, ccx x x x X
UC-PRO/SS measuretxxxxxxxx x x x x x x xxx x
IBDQddx x x
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2129Appendix 1
Schedule of A ctivities (cont.)
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
128/Protocol GA29102, Version 7AssessmentsScreening 
Daya
35 to1Study Week (3 day s)
0b48101216202428c32 36c40c4448c52c5660c62Unscheduled 
Visit dEarly 
Withdrawal  
from 
Treatment 
Visit
EQ-5Dddx x x x
Concomitant 
medicationsxxxxxxxx x x x x x x xxx x x x
Adverse events x xxxxxxxx x x x x x x xxx x x x
Randomization of 
responders to 
Maintenance Phasex ee
Etrolizumab 
administrationxxx
Etrolizumab/ 
etrolizumab placebo 
administration ffxxxx x x x x x x xxx
ATAanti-therapeutic antibody; BP blood pressure; CMV cytomegalovirus ; CRP C-reactive protein; EQ -5DEuroQoL Five-Dimension Questionnaire; 
HBcHBV core antibody total; HBsAg HBV surface antigen; HBV hepatitis B virus; HCVhepatitis C virus; IBDQ Inflammatory Bowel Disease Questionnaire; 
JCVJohn Cunningham virus; MCSMayo Clinic Score; PDpharmacodynamics ; PKpharmacokinetic ; pMCS partial Mayo Clinic Score; PMLprogressive
multifocal leukoencephalopathy; qPCR quantitative polymerase chain reaction; TBtuberculosis ; 
tctelephone call; UC -PRO/ SSUlcerative Colitis 
Patient -Reported Outcome Signs and Symptoms.
Note s:  All study assessments and blood draws are to be conducted prior to study drug administration.   All colonic biopsy samples will be taken during flexible 
sigmoidoscopy/colonoscopy procedure.
aAll assessments must be performed after obtaining informed consent.  Endoscopy should be performed 4 16 days prior to Day 1 (i.e., Day 16 to Day 4).  The 
total screening period is 35 days. Under no circumstances will either window be extended.
bDay 1 of W eek 0.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2130Appendix 1
Schedule of A ctivities (cont.)
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
129/Protocol GA29102, Version 7cTelephone contact [CONTACT_781278]:  Patients requiring in -clinic drug administration throughout the study will have their study 
assessments conducted in clinic or via telephone call after their clinic visit at the sites’ discretion.
dUnscheduled visit represents a visit that is not per Schedule of Assessment sand is required for an adverse event or for potential relapse assessment.  All 
indicated assessments are NOT performed at each unscheduled visit.  Assessments would be symptom driven (e.g., only perform PML neurologic examination if 
patient reports symptoms suspected of PML; for disease worsening, i nfectious etiologies may be investigated if clinically indicated; and confirmation of clinical 
relapse is performed by [CONTACT_781279]).  Assessments corresponding to items noted in this column should be recorded on t he eCRF.
ePerform prior to administ ration of etrolizumab.
fSerum test at screening for all female patients except those who are more than [ADDRESS_1073991] at other visits; if 
urine test result is positive, perform a confirmatory serum test.  Pre gnancy test will be carried out at home once patient starts etrolizumab administration at home.  
Patient is to report the pregnancy test via the e -diary.  Patients must be instructed at screening and reminded throughout the study that in case of positive 
pregnancy test they must stop self -administration of study drug and call the site immediately.  Donot administer etrolizumab unless the serum pregnancy test 
result is negative.
gNot required if normal chest X –ray result within 3 months prior to screening.
hFull physical examination required at screening; symptom-driven physical examination at all other timepoints indicated.
iPML neurologic examination consists of the PML Subjective Checklist and the PML Objective Checklist. Administer before other assessments, per Appendix 5.
jNot required if unscheduled visit leads to withdrawal and assessment previously conducted at unscheduled visit.
kThe following tests are acceptable screening assays for latent TB in this study:  purified protein derivative ( a tuberculin skin test reaction; e.g., Mantoux test), 
INF- based test (e.g., QuantiFERON-TB Gold).
lPatients must undergo screening for HBV and HCV. This includes testing for HBsAg, anti -HBc, and hepatitis C antibod y.
mEnrolled patients who are hepatitis B core antibody positive should have hepatitis B DNA measured at these timepoints.
nMeasurement of HCV RNA with use of the Amplicor assay is required when the patient has a known history of HCV antibody positivity with past documentation 
of undetectable HCV RNA, either with or without history of anti-viral treatment.  Patients with newly diagnosed HCV antibody positivity are not eligible for this 
study and, therefore, do not require measurement of HCV RNA.
oAll sam ples to be collected prior to administration of etrolizumab.  Serum baseline, W eek 4, and blood sample (RNA Paxgene) are to b e collected prior to dose of 
etrolizumab from all patients.  All subsequent samples (serum and Paxgene whole blood) will be collect ed only from those who were eligible to be randomized 
into the Maintenance Phase.
pIf serum sickness or a clinically significant allergic drug reaction is suspected, Sponsor should be
 notified, and serum for etrolizumab level and ATAs should be 
drawn and sent to the central laboratory.  ATA samples may also be utilized for exploratory PD assessments or assessment of drug concentrations.
qCollection of sample for ATA is required at final or early withdrawal visit, unless it coincides with first visit in Part 1 of Study GA28951 (where a sample for ATA 
must be collected).
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2131Appendix 1
Schedule of A ctivities (cont.)
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
130/Protocol GA29102, Version 7rA blood sample to test for antibodies to JCV will be taken and stored for possible later assessment of how widespread the JCV infection is in the 
study population.  Sample testing for the presence of JCV antibodies is not helpful in predicting risk for PML or for evaluating neurologic 
symptoms.  The sample may be tested if there is a strong belief that this information will be helpful in managing a patient's condition.
sEndoscopy recta l bleeding assessment stool frequency assessment Physician’s Global Assessment.  Patients who have not undergone full colonoscopy 
with documented results within 1 year prior to screening should undergo colonoscopy in lieu of sigmoidoscopy at the screening visit to allow for screening for 
cancer/dysplasia (yes/no).
tDuring screening, patients must be trained on the use of the e -diary.  Patients are to complete the e
-diary on a daily basis for the stool frequency and rectal 
bleeding score (for MCS/pMCS) , starting from the first screening visit , andfor at least 912consecutive days around the time of each scheduled visit f or the 
UC-PRO/SS.
uScreening endoscopy (for the MCS) should be performed 4 16 days prior to Day 1 (i.e., Day16 to Day 4).  For baseline measurements, the Physician’s 
Global Assessment will be obtained only once, on Day 1 (prior to enrollment), and the Physician’s Global Assessment score will be used to calculate both the 
baseline (screening) MCS and the baseline (Day 1) pMCS.
vRectal bleeding assessment stool frequency assessment Physician’s Global Assessment.
wFor culture and sensitivity testing; ova, parasites, and Clostridium difficile toxin testing.  
xSample analyses may include, but are not limited to ,analyses o f fecal calprotectin and other exploratory PD biomarker s (such as analyses of the microbiota and 
bacterial cultures) .
yIF REQUIRED:  Only if there is suspi[INVESTIGATOR_335480], one biopsy sample should be obtained from the base of the ulcer to evaluate for 
histological presence of CMV.  Analysis should be performed locally if possible, or can be sent to a central laboratory if necessary. Result must be negative for 
CMV prior to dosing on Day 1.  
zIF REQUIRED:  If patient does not have previously documented histopathologic confirmation of UC as defined in the inclusion criteria, one biopsy sample ca n be 
obtained from the base of the ulcer read locally for histopathologic confirmation of UC.
aaIn addition to the optional biopsy samples noted in footnote “y” and “z” above, five pairs (10 biopsy samples) will be obtained at screening.  These five biops y 
pairs will be sent to the central laboratory for further storage or distribution.  Two pairs (taken from the most inflamed ar ea of colon within 20 40 cm of anal verge 
[sigmoid]) will be placed in stabilization buffer (such as RNAlater or a similar buffer ) and stored at 80C (one pair for diagnostic qPCR and one pair for PD 
biomarkers qPCR).  The other three pairs (two pairs from most inflamed area of colon within 20 40 cm of anal verge [sigmoid] and one pair from the most 
inflamed area of the worst affec ted segment) will be placed in formalin and then paraffin embedded (one pair will be used for histopathology and exploratory PD 
biomarkers and the other two pairs will be used for diagnostic).  Original biopsy location and endoscopic depth should be cle arly indicated.
bbA total of four pairs (8 biopsy samples) will be obtained.  All will be sent to the central laboratory for further storage or distribution.  One pair will be placed in 
stabilization buffer (such as RNAlater or a similar buffer) and stored a t 80C for exploratory PD or diagnostic biomarker qPCR.  The other three pairs, 
representing three different segments (rectum, sigmoid, descending colon), will be placed in formalin and then paraffin embedded; these biopsy samples will be 
used for histopathology, exploratory PD biomarkers, and/or diagnostic biomarker.  Original biopsy location and endoscopic depth should be clearly indicated.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2132Appendix 1
Schedule of A ctivities (cont.)
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
131/Protocol GA29102, Version 7ccPaxgene blood RNA samples must be collected after all other blood and serum samples .
ddWith the exceptio n of W eek0, the IBDQ and the EQ -5D will be completed in -clinic by [CONTACT_760533]-PRO assessments and before the patient receives any disease status information or study drug during that visit.
eeRandomization to occur within [ADDRESS_1073992] be instructed to administer study drug at home within 3 days (maximum) after clinic visit.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2133Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
132/Protocol GA29102, Version 7Appendix 2
12-Week Safety  Follo w-Up 
Assessme ntWeek (3 days)
Unscheduled 
Visitc6a12/Early 
Terminationb
ECG x
PML neurologic examinationdx
PD sampling (serum) x
PK sampling (serum) x
Anti-therapeutic antibody sample 
(serum)ex
Medication changes x x x
Adverse events x x x
ATA anti-therapeutic antibody; ECG electrocardiogram ; PKpharm acokinetic; 
PDpharmacodynamic; PML progressive multifocal leukoencephalopathy.
aWeek [ADDRESS_1073993].  Administer before other assessments per 
Appendix 5
eAt all timepoints indicated and whenever serum sickness is suspected.  ATA 
samples may  be used for PK and/or exploratory PD assessments.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2134Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
133/Protocol GA29102, Version 7Appendix 3
Childbearing Potential, Pregnancy  Testing, and Contraception
All women of childbearing potential (including those who have had a tubal ligation) will 
have a serum pregnancy test at screening and a urine pregnancy test prior to 
administration of study drug at subsequent visits.  If a urine pregnancy test result is 
positive, study drug will not be administered until pregnan cy is ruled out.  The result 
must be confirmed by a serum pregnancy test (conducted by [CONTACT_2237]).  
See Section 5.4.3 of the protocol for management of a patient with a confirmed 
pregnancy.
All female patients are considered to be of childbearing potential unless they meet one 
of the following criteria:
The patient has been postmenopausal ( nontherapy -induced amenorrhea ) for at 
least 12 months
The patient had a surgical bilateral oophorectomy (with or without hysterectomy) 
more than 6 weeks prior to enrollment
The patient had a hysterectomy
Female patients of reproductive or childbearing potential who are unwilling to use a 
highly effective method of contraception or remain abstinent during the treatment period 
and for at least [ADDRESS_1073994] dose of study drug will be excluded from study 
participation.
Abstinence is acceptable only if it is in line with the preferred and usual lifestyle of
the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, or 
postovulation methods) and withdrawal are not acceptable methods of contraception.
Examples of highly effective contraception include the following:
Combined oral contracepti ve pi[INVESTIGATOR_4382]
Contraceptive transdermal patch
Intrauterine device
Implants for contraception
Injections for contraception (with prolonged release)
Hormonal vaginal device
Sterilization, surgical tubal ligation
Sole sexual partner consisting of surgically sterili zed male partner with appropriate 
postsurgical verification of the absence of spermatozoa in the ejaculate
Double -barrier methods:  condom and occlusive cap (diaphragm or cervical/vault 
caps) with spermicidal foam/gel/film/cream/suppository (Note: a female condom and 
male condom should not be used together because friction between the two can 
result in either product failing)
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2135Appendix 3
Childbearing Potential, Pregnancy  Testing,
and Contraception (cont.)
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
134/P rotocol GA29102, Version 7Patients may provide verbal confirmation that the partner completed appropriate 
follow -up after vasectomy.  Sites are not required t o obtain partner medical records.
With female partners of childbearing potential or pregnant female partners, men must remain 
abstinent or use a condom during the treatment period and for at least [ADDRESS_1073995] refra in from donating sperm during this same period.
For men and women:  The reliability of sexual abstinence should be evaluated in relation to the 
duration of the clinical trial and the preferred and usual lifestyle of the patient.  Periodic 
abstinence (e.g., calendar, ovulation, sy mptothermal, or postovulation methods) and withdrawal 
are not acceptable methods of contraception.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2136Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
135/Protocol GA29102, Version 7Appendix 4
Mayo Clinic Score Measurement
Mayo Clinic Scor
e is a composite e ndpo intwith fo urcomponen ts.The score ranges from
0 to12with higher scores indicatingmore se veredisease.
The Mayo Clinic components are as follows:
1.STOOL FREQ UENCY
0Normal numb erof stools for this patient
11 to2 stools m orethan normal
23 to4 morestoolsthan normal
35ormore stools than normal
Subscore 03
2.RECTAL BLEE DING
0No bl oodin stool
1Streaksof bloodwithstool lessthan half the t ime
2Obvio usbloodwith stool most of the time
3Blood al one passed
Subscore 03
3.ENDOSCOPY
0Normal orinactive disease
1Mild d isease (erythema, decreased vascu lar pattern, mild fria bility)
2Moderate disease ( marked erythema, lackof vascula r pattern, friability, 
erosio ns)
3Severedisease (spontan eous bleedin g, ulceration ) 
Subscore 03
4.PHYSICI ANGLOB AL
0Normal (Subscores are0)
1Mild disease (Subscores a remostly 1s)
2Moderatedisease (Su bscores a re1to2)
3Severedisease (Subscor esare2to3) 
Subscore 03
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2137Appendix 4
Mayo Clinic Score Measurement (cont.)
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
136/P rotocol GA29102, Version 7DATACOLLEC TIONREQUI REMENTS
Data
willbe co llected on e-diary and other ele ctronicmedia;during conversion t o 
these me diathe format of the questio nsmay c hange.
A CRITICAL D ATA POINT TAKEN AT BA SELINE I S THEPATIENT’S NORMAL
NUMBER OF S TOO LS.  This isdefined as the n umberofstool pass edwhena
patientis inremissio n/notinflare.  This istobetakenfrom th e most recent available
datainthe pa tient’s medical no tesor tak enduringpatient interview at screenin g.
Thisvalue will rema instable throu ghout the study.
Normal num berof stools istoberounded up (e.g., nor mal num berof stools12
wouldberounded to2)
The NORMAL n umber of s toolsistoberecordedon the e- diaryandmade visibleto
the pa tient toassist withtheirscoringrelativetothisnumber
NOTE:Datarecorded duringbowelpreparation procedu resand day of endoscopy is
tobeignored (bowelpreparation and endoscopy procedu redays a retobeloaded
ontothe e- diaryby[CONTACT_781280] S calculation)
1.Stoolfrequency
Stoolfrequency istoberecorded daily from sta rtof screening tothe e ndof the study
inthe e- diary
The stoolfrequency istobecompa redwiththepatient’s normalstool frequency and
entered asa scorebetween 0 and3 (see1 above)(e.g., a pa tient normally has
[ADDRESS_1073996] ools mo re
than “normal, ” which y ieldsa value of 2 for that day.)
The stoolfrequency willbedefined as the passage of sol idor liquidfecal material.
Epi[INVESTIGATOR_335492].  A non-productive triptothe bathr oom or the
simple passage of gas DOES NOT COUN T as st ool.
The baseline stool frequency value will be taken from patient e- diary recordings that 
are entered between Day 22 (inclusive) and bowel preparation for the screening 
endoscopy and will be calculated as the average (rounded to the nearest integer) 
from the three most recent stool frequency scores that were entered just prior to the 
day of bowel preparation .  However, up to three post -endoscopy scores, starting 
with the score recorded 2 days after the endoscopy , may be used to calcu late 
baseline stool frequency, but ONLY when fewer than three scores are available 
between Day 22 and bowel preparation (see Figure 1below) .  The days selected 
for this calculation are intended to prevent the use of stool frequency recordings 
during the screening period that are impacted by [CONTACT_335594], 
including the day immediately following the endoscopy .
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2138Appendix 4
Mayo Clinic Score Measurement (cont.)
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
137/P rotocol GA29102, Version 7The post -baseline stool frequency value for endpoint assessment will be calculated 
as the average (rounded to the nearest integer) from the three most recent stool 
frequency scores that were entered in the e- diary within the 7 days prior to the clinic 
visit and prior to the days devoted to bowel preparation and endoscopy. 
2.Recta
l blee ding
Rectal bl eeding istoberecorded daily from scr eening totheendof the stu dyin the
e-diary
Therectal bl eeding scoreistobecategorizedfrom 0 3 acco rding tothe def inition
givenin2 abo ve
Patients aretobeinstruc tedtoignoreanyblood which iscaused by [CONTACT_781281]
The baseline value for the rectal bleeding score will be taken from patient e -diary 
recordings that are entered between Day 22 (inclusive) and bowel preparation for 
the screening endoscopy and will be determined by [CONTACT_335595].  
However, up to three post -endoscopy scores, star ting with the score recorded 2 
days after the endoscopy , may be used to calculate baseline rectal bleeding, but 
ONLY when fewer than three scores are available between Day 22 and bowel 
preparation (see Figure 1below).  The days selected for this calculation are 
intended to prevent the use of rectal bleeding recordings during the screening 
period that are impacted by [CONTACT_335594], including the day 
immediately following the endoscopy .
The post -baseline rectal bleeding value for endpoint assessment will be determined 
by [CONTACT_781282] 
e-diary within the 7 days prior to the clinic visit and prior to the days devoted to 
bowel preparation and endoscopy. 
3.Endos
copySubscore
Thisscoreisprovided by[CONTACT_781283] a subscor e of 0 to 3.
Findin gs on endoscopy willbedocum ented by[CONTACT_335598] (centr al
reading ofendoscopy videos)
The sco rewillbebasedupon the worst a ffected segm ent(ifmucosal a ppearance 
varies)for study conduct, except at post -baseline time points, when the sigmoid 
colon MCS endoscopic subscore will be used if the baseline sigmoid colon MCS 
endoscopic subscore is 2 3.
Note:  The time window for performing endoscopy during the screening is 416 days
prior to Day 1 (i.e., Day16 toDay4).
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2139Appendix 4
Mayo Clinic Score Measurement (cont.)
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
138/P rotocol GA29102, Version 74.PhysicianGlob
alAssessment
Thephysician’s global assessme ntWILL:
Be bas edon the pa tient’s overall status
Reflect how the pa tient isdoingat present.  Assessm entSHOULD NOT reflect past
disease severity or complexity or the number/kinds of medicines the patient is 
receiving
Be bas edon th e:
Rectal bl eeding score,stoolfrequency sco re,and endoscop icevaluation
Patient’srecollection of a bdom inaldiscomfo rtandgeneral sense o f well- being
Patient’s performance status, fecalincontinence a ndmood
Physician’s obs ervationsand phy sical examfindings
Reflectdisease activity NOT disease s everity (e.g.,donotautomatically givea high
PGA to pa tients withpancol itisor severe /complica teddisease or pa tients requiring
multiple medica tions
Thephysician’s global assessment will be provided by [CONTACT_5256] a score of 0 to 
3 and entered into the tablet.
CALC ULATION OF THE MAYO C LINIC SCORE
Timepoints for M CSassessments can be fou ndinthe protocol Sche dule of Assessments.
Eligibility for Enro llment
Moderatelytosevere ly active ulcerativecolitisasdetermined by a Mayo Clinic 
Scoreof 612withanendoscop icsubscore 2,arectal bl eeding subsco re1, 
anda stoolfrequency subscore  1
Achievement of Clinical Response at Week 10
MCS with3-pointdecre ase a nd30%reduction from basel ineaswell as 
1-pointdecre aseinrectal bl eedingsubsco reor an abso lutescoreof 0 or 1
Identification o f ClinicalRelapse
Clinicalrelapseisdefinedas an increaseinpMCS 3 pointscompa redto 
inductiontimepo int(Week10) AND abso lute pMCS of 5 AND a n end oscopy
subsco reof2
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2140Appendix 4
Mayo Clinic Score Measurement (cont.)
Etrolizumab —F.Hoffmann -La [COMPANY_002] Ltd
139/Protocol GA29102, Version 7Figure 1Derivation of Stool Frequency  and Rectal Bleeding Subscores at Screening

Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2141Appendix 4
Mayo Clinic Score Measurement (cont.)
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
140/P rotocol GA29102, Version 7Figure 1 Derivation of Stool Frequency  and Rectal Bleeding Subscores at Screening (cont.)
Endo endoscopy; MCS Mayo Clinic Score; prep preparation; RBrectal bleeding ; SFstool frequency.
Notes:
If 3 days of e -diary data are available between Day 22(inclusive) and bowel preparation, use e-diary data from the [ADDRESS_1073997] 
recent days prior to the bowel preparation day .
Up to [ADDRESS_1073998] -endoscopy e -diary data, starting 2 days after the endoscopy, may be used, but ONLY when 3 days of 
e-diary data are available between Day 22 and bowel preparation .
If 2 days of e -diary data are available between Day [ADDRESS_1073999] available e -diary entry after the endoscopy , starting 2 da ys after the endoscopy .
If 1 day of e -diary data is available between Day [ADDRESS_1074000] two available e -diary entries after the endoscopy , starting 2 days after the endoscopy .
If 0 days of e-diary data are available between Day [ADDRESS_1074001] three available e -diary 
entries after the endoscopy , starting 2 days after the endoscopy .
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2142Appendix 4
Mayo Clinic Score Measurement (cont.)
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
141/Protocol GA29102, Version 7PARTIALMAYO C
LINIC SCO RE
The partial Mayo Cl inicScoreisidenti caltotheMayo Cl inicScoreBUT EXCLUDE S THE
ENDOS COPY SUBS CORE
Timepoints for pa rtial Mayo ClinicScore can be fou ndin the protoco l Sche duleof 
Assessm ents
PartialMCS isalso required at t imeof suspect edclinical relapse . Ifpartial MCS 3
points com pared to induction t imepointAND abso lute pa rtial MCS 5 an endoscopy
wouldbe co nducted a ndendoscopy subscore a ndfull MCS calcul ated
E-DIARY MA LFUNCTION OR LOSS
The help desk for the e -diary vendor (CRF Health) should be contact[CONTACT_187678] 
e-diary malfunction or loss.  Until a working e -diary can be provided to the patient, site 
staff should , after the e -diary malfunction or loss, retrospectively collect the previous 
day's stool frequency and rectal bleeding subscores from the patient via telephone 
interview within the next working day following the e -diary failure or loss .  Thesedata will 
then be transcribed into a data clarification form within CRF Health’s Trial Manage r
system for approval .
REFERENCE
SchroederKW, Tre maineWJ, Ilstr upDM.Coated oral 5-ami nosalicylic acid t herapy f or
mildlyto moderately active ulcerat ive colitis: a ran domizedstudy. N En glJMed
1987;317:1625– 9)
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2143Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
142/Protocol GA29102, Version 7Appendix [ADDRESS_1074002]
ive a ndObjective Check lists ofneurologic a ssessment s to monit or
forprogressive multif ocal leukoencephalopat hy(PML)in theEtrolizumab Phase III
Studies
PML usually man ifestswith su bacut e,progressiveneurologic deficits i ncluding:
Neurologic Domain Signs/Sympt oms Releva nt PML
Subjectiv e/Objective
Checklist Questi on
Altered menta l status C anencompa ssa variety of pres entin g 
signs and symptoms including cogniti ve 
changes (c onfusion, difficult y 
concentrating, memory lo ss) and altere d 
behavior (including persona lity change s)Q2, Q5, Q6
Higher cortical dysf unctio n Im paired comprehension and/o r 
formulation of lang uage (ap hasia), lo ssof 
ability to reco gnizeobject s,person s, 
sounds, shape s,or smells (ag nosia)Q2, Q5, Q6
Visual chan ges Loss of v isual fields (homonymou s 
hemianopsia), do uble vision (diplopia)Q1
Moto r deficits Weakne ss(hem iparesis o r mono paresis) , 
seizures (ge neralized or partial), difficultie s 
with sp eech (d ysarthr ia) or swallowing 
(dysphagia)Q2,Q3
Sensory deficits Sensory lo ss(i.e. p aresthesia) Q7
Coordi nation Diffic ulty walki ngandmaintaining balance 
(ataxia), lackof voluntary coordi nationof 
limb m ovement(limb at axia)Q4
In orderto monitor pati ents f orPML,a neurol ogicexam (includingevaluationof cranial
nerves, mot orand s ensory f unction, coordinati on,andment al status) will beperfo rmed as
perthe Sche dules o f Assess ments (see Appendix 1and Appendix 2). This n eurolo gic
exam will cons ist of administration of t hePML Subjective Ch ecklistand t hePML
Objective Check list.
At scr eening, the PML S ubjectiveCheck list and the PML Objecti veChecklist(including
the components listed as optio nal, e.g. mu scle group strength testing, recal l of 3 objects
in 1 minute , and sensory testing ) should be perfo rmed.
At all other visits , the PML S ubjecti veChecklistand the PML Objecti veChecklist
(bolded items ) should be perfo rmed, and th e optio nal items should only b e perfo rmed 
when there is an abno rmal finding on the co rresponding PML S ubjective C heck list(i.e.,
complaints of foca l weakness or focal s ensory change would prompt a more detailed
objecti veneurol ogic evaluati on).
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2144Appendix 5
Worksheet for the PML Neurologic Examination (cont.)
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
143/P rotocol GA29102, Version 7PML Su
bjective Che cklist
Symptoms “Compare d to how
you u sually f eel, 
have y ou h ad a
signifi cant change
in any ofthe 
following?”If theanswer i s “Yes”,
obtain a descripti on of
the symptom(s ) with 
examplesAppli cable
Objectiv e Test(s):
Docume ntresul t 
on PML Objectiv e 
Checklist
Worksheet
YES NO
1. Ha veyou bee n 
experi en
cing an y persistent
difficulty with your v ision su ch
as lo ss of vision o r doubl e 
vision? Have you bee n having
trouble with reading?Testvisual fields
and ocula r motility
2. Ha veyou bee n 
experi en
cing an y persistent
difficult y speaking or having
your speechunderstood b y 
other s?Casua l 
observation o f 
spee choutput fo r 
dysarthria o r 
aphasia.
3. Ha veyou bee n 
experi en
cing an y persistent
weakne ssin an ar m or a l eg?Testfor pronato r 
drift (Ba rre
maneuve r).
Assessgait.
Testmuscle
(l if4. Ha veyou notice d yourself
r
egularl y bumpi[INVESTIGATOR_335493]?Observe tan dem
gait an d finge r to
nose.
5. Ha veyou regularl y been
exp
eriencin g difficulty
understa nding other s?Testability to
follow seria l 
commands.
6. Ha veyou ha d persist ent
p
roblems with your memory or
thinking?Recall of 3
objects ove r 1 
minute with
distractio n (only if
7. Ha veyou bee n 
experi en
cing an y persistent
numbne ssor other lossof
sensation?Testsensation
side t o side with
eithe r pi[INVESTIGATOR_781237] (only if
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2145Appendix 5
Worksheet for the PML Neurologic Examination (cont.)
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
144/P rotocol GA29102, Version 7PML O bjec
tive Check list
Neurologi c functi on 
being assessedInstruction s (bold text indicates
parts of exa m required at each
visit, as specified i n Schedule of
Assessments)Abnorma l 
exam?If theanswer i s 
“Yes ”,descri be
the abnormal
o
bjectiv e exam
YES NO
1. Visual fields an d 
ocula r mo
tility Visual Fiel d Testi ng
 Ocular Mot ility Testi ng
2.Speech  Obser ve thepatient’s spe ech 
outpu t fordysarthriaoraphasia.
3. Stre ngth  Pronator drift test (Barr e 
maneuve r)
 Gait testing (normal, heel a nd 
toewalk)
 ONLY if the patient has an y 
subjecti vecomplaints o f weakness,
testmuscle strength o f the relevant
muscle groups
4. Coordi nation  Obs erve tandem gait a nd 
finge r to nose
5. Comprehension  Test abi lity to followseria l 
commands
 “Take a pi[INVESTIGATOR_781238] i n your 
hand, fol d it in half, a nd put it on the
floor.”
6.Memory a nd thinking  ONL Y if the patient has
subjectiv e complaints about t heir 
memory o r thinki ng, test the ab ility
of the patient to recall 3 objects
over 1 minute with distraction
7. Se nsation  ONLY i f the patient has
subjectiv e sensory complaints,
evaluat e relevant areas based on
patient’ s subjecti vecomplaints b y 
comparing left vs. right sid e 
sensation to cold (e.g. alcoho l swab
or cold stet hoscope ) or pi[INVESTIGATOR_29107]
(e.g. broken Q-tip)
Please refer t o the PM L Algorith m in theProtocolAppendix f ordetails.
If there is an ab norm alfindingon thePML Subjecti veChecklist, this should be
appropriatel y documente d on the workshe etand in t heeCRF.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2146Appendix 5
Worksheet for the PML Neurologic Examination (cont.)
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
145/P rotocol GA29102, Version 7If ther
e is an ab normal findingon thePML Obj ectiveChecklist, this sh ould be
appropriatel y documente d on the workshe et and in t heeCRF.
If there are a nyabnorm alitiesfound on the PML S ubjecti veCheck list thatare
accomp anied by [CONTACT_335600] t hePML Obj ectiveCheck list,or if
there is hi ghclinical susp icion for PML (in the opi[INVESTIGATOR_335496]):
  This mus t bereported as an adverse eve nt of special interes t (AESI ) within 
24 hours
  An urg entreferral to a ne urologist shoul d be made.
  Dosingwith studydrug willbesuspende d until PM L can be ruled out.
  Further evaluati on willproceed according to thePML Algorithm i n the 
Protocol Appendi x.
   Any confirme d diagnosis ofPML shoul d be reporte d as a serious advers e 
event(SAE).
Please complete t hePML e CRF.
W
as thePML Subjective Check list administere d? (Yes/No)
If yes, date ofadmi nistration of PML Subjective Check list (Date)
If yes, we rethereanyabnormalities on thePML Subjective Check list? (Yes/N o) 
Was t hePML Objective Check list administere d? (Yes/No)
If yes, we rethereanyabnormalities onthePML Objective Check list? (Yes/N o) 
Is PM L suspecte d? (Yes/No)
More deta iled inst ructions f orthePML O bjective Check list Ne urologic
Evaluations (pl ease refer t o the PM L Neurologic E xam Vide o formore
information):
1.Visual fiel dsand o cular mot ility
Visua l Field Testi ng:
Position y oursel f ap proximately 3 f eetawayfromthepatient , witheyes atthe same
level.
Keepi[INVESTIGATOR_335497],askthepatie ntto cov erone eye and askif all parts of y our
face a nd headare cl earto them. Askthem to rep eat, coveringthe oth er eye.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2147Appendix 5
Worksheet for the PML Neurologic Examination (cont.)
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
146/P rotocol GA29102, Version 7Havethe p
atientcover oneeye a ndstare at your nos e,and then askthem how
many fin gers you areholding up, testi ng eachof the 4 vis ualquadrants. Repe at with
theothereyecovere d.
Ocular Mot ility Testing:
Evaluate t hepatie ntfor con jugate eye movement.
Startingabou t 3feetfrom center , movein a big “H” , pausingat thecenter andat 
lateral gaze, and finishing with co nvergence(finger to theirnose). Watch f or
nystagmusin later al gaze, smooth pursuits,and p upi[INVESTIGATOR_781239].Note:a couple of b eats o f nystagm usupon extreme later al gaze is
considered no rmal.
2.Speech
Observe thepatient’s spe echoutputfordysarthria or aphasia.
Dysarthria is a mot or speech disorder . Findingscaninclude“slurred” speech, 
decreased volume , slow rate o f speech,limitedtongue,lip,andjaw movement,
abnorm al rhythm when sp eaking, chang esinvocalquality,and droo ling o r poor 
contr olof sa liva.
Aphasia is a disor derthat results fr omdamagetoparts o f the brain th at contr ol 
language , and can lead to pr oblems with a nyor all of thefollowin g: speaking, 
listening,reading or writing.
3.Strength
Pronator drift test (Ba rre m aneuve r):
Ask t hepatie nt t o sta ndwith their fe et toget herand exte ndtheir armsoutin frontof 
them at90degrees(parallel to floor) with palms faci ngupwar dstoward the ce iling.
Askthepatie nt to closetheir eyesand ke eptheir a rmsextended f or 15 seconds.
If eitherarm drifts downward, upwar d,or starts to pronate (i. e.thumb tur nsup), this
is consi dered anabnorm al exam.
Gait testing:
Ask the patient to walk across the r oom (~10 f eet ). The patient sh ould ha vea
norma l gait, wit h their left ar m swinging forward when the right foot l eads,and vice
versa. Be certain to not e whether there is symmetric ar m swinging, because a sli ght
decrease in ar m swinging may be a n indicator of up per extremity weakne ss.
Ask the patient to walk on t heir heels across the r oom (~10 feet). Carefu lly obser ve
whether they ha veany di fficulty maintaining thei r toes off the ground o r loss of
balance.
Ask the patient to walk on t heir toes acro ssthe roo m (~10 f eet). Carefu llyobser veif
they ha ve any difficulty maintaining t heir heels off the gr ound o r loss of balance.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2148Appendix 5
Worksheet for the PML Neurologic Examination (cont.)
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
147/P rotocol GA29102, Version 7Additi
onal strength testing (ONLY i f thepatienthasanysubjecti vecomplaints o f 
weakn ess):
Test mu
scle strength of the relev ant muscle groups based on the patient’s
subjectivecomplaints.
General guidelines fo r abasic muscle strength exam:
Upper extremit y:
oFinger grip strength
oFlexion at elbow
oExtensionatelbow
oDeltoid strengt h:Maintai n bentarmsup(perpendicul ar to floor) andresist while 
inves tigator pushesdown
oShould er sh rugagains t resistance
Lower extremit y:(examine wh ile patient is si tting down)
oRaisethigh (wh ilebent)
oStraighten leg
oFlex leg
oFlex foot
oExtend foot
4.Coordination
Tandem gait:
As the patient is l ooking a t his feet, a skthem to walk 8 steps withone f oot touching
in front o f the ot her (demonstrate for the m).
Finger to nose:
Hold y ourfinger out so theyneed to reach o utand lea n.Start nearthe c enter, and
move y our finger slowly so tha t theyreach acrosstheir body. Makesure th ey
alternate touching y our finger andtheir noseata goodspee d.Inability to perfor m 
thisaccurately is c onsidered an abnorm al test.
5.Com prehensi on
Test ability to fo llow serial comman ds
“Takea pi[INVESTIGATOR_781240], fold i t inhalf, and p ut it on t hefloor.”
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2149Appendix 5
Worksheet for the PML Neurologic Examination (cont.)
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
148/P rotocol GA29102, Version 76.Memo
ry and Thinki ng
(ONLY if the patient has s ubjecti vecomplaints about thei r memory o r thinki ng) test
theability o f the patient to recall 3 objects over 1 minute with distraction.
7.Sensati on
(ONLYif thepatien t hassubjectivesensory complaints) evaluate rel evant areas
basedon the pa tient’s subj ective complaints by[CONTACT_335601]. rightside
sensation to cold (e.g . alcohol swabor co ld stet hoscope) or pi[INVESTIGATOR_335500](e.g.broken
Q-tip). Confir m that thepatie nt is able t o feelthe s ensation sy mmetrica lly.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2151Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
150/Protocol GA29102, Version 7Appendix 7
Patient Daily  Diary

Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2152Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
151/Protocol GA29102, Version 7Appendix 8
Clinical Criteria for Diagnosing A naphy laxis
These c
riteria are taken from a su mmary re port fro m the second symposium on th e 
definition and ma nage ment of a naph ylaxis, conducted by [CONTACT_335602] y 
and Infectious Disease/Food A llergy and Anaphylaxis Network.1  Anaphylaxis is highl y 
likely
when any one of the fo llowing three criteria is fulf illed:
1.Acute onsetof anillness (minutest o several hours) with invol vementof the ski n, 
mucosal tissue,or both (e.g. , genera lized hi ves, prurit usorflushin g, swollen
lips-tongue-uvul a)
AND AT LE AST ONE O F THEFOLLOWING:
Respi[INVESTIGATOR_7798] (e.g., dyspnea , wheeze-br onchosp asm, stridor , reduce d 
peakexpi[INVESTIGATOR_10229], hypoxemia)
Reduced blood pr essu reor as sociatedsymptoms o f end-org an dy sfunction (e.g. , 
hypotonia , syncope,incontinence)
2.Two o r more of the follo wing that occu r rapi[INVESTIGATOR_335501] r exposure to a likely a llergen fo r 
that patien t (minutes to s evera l hours):
Involvement of the skin-mucosa l tissue (e.g., genera lized hives, itch-flush, swolle n 
lips-tongue-uvula)
Respi[INVESTIGATOR_7798] (e.g., dyspnea, wh eeze-br onchospasm, stridor, reduce d 
peak expi[INVESTIGATOR_10229], hypoxemia)
Reduced blood pressure or associated symptoms (e.g., hypotonia, syncope , 
incontin ence)
Persiste ntgastrointesti nalsymptoms (e.g. , crampy ab domi nal pai n, vomiti ng) 
3.Reduced blood pr essu re aft er exposure to k nown a llergen f or that patie nt (minutes to
several hours):
Infants and children:  low systolic blood pressure (a ge spe
cific)2or greate r than 30 % 
decrea
se in s ystolic blood pressure
Adults:  systolic blood pressure of less than 90 mmHg or greater than 30% decrease 
from that person’s baseline
                                           
1Sampso n HA,Muñoz-Furl on g A, Cam pbell RL, etal. Sec ond symposium o n the definitio n 
and manag ement of anaph ylaxis : summaryreport—sec ond National Institute of Allergy and 
Infecti ous Dis ease /Food Allergy and Anaph ylaxis Networksymposium. J Allergy Clin
Immunol 2006 ;117:3917.
2Low systo lic blood pr essure for ch ildren is defi ned aslessthan 70 mm Hg from 1 mont h to 
1 year,less t han (70 mmHg + [2 x age]) from 1 to 10 years, and less t han 90 mmHg from
11 to 17 years.
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2153Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
152/Protocol GA29102, Version 7

Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number [PHONE_16308]
Etrolizumab—F. Hoffmann-La [COMPANY_002] Ltd
153/Protocol GA29102, Version 7

Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number [PHONE_16309]
Etrolizumab—F. Hoffmann-La [COMPANY_002] Ltd
154/Protocol GA29102, Version 7

Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number [PHONE_16310]
Etrolizumab—F. Hoffmann-La [COMPANY_002] Ltd
155/Protocol GA29102, Version 7

Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number [PHONE_16311]
Etrolizumab—F. Hoffmann-La [COMPANY_002] Ltd
156/Protocol GA29102, Version 7

Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number [PHONE_16312]
Etrolizumab—F. Hoffmann-La [COMPANY_002] Ltd
157/Protocol GA29102, Version 7

Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number [PHONE_16313]
Etrolizumab—F. Hoffmann-La [COMPANY_002] Ltd
158/Protocol GA29102, Version 7

Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number [PHONE_16314]
Etrolizumab—F. Hoffmann-La [COMPANY_002] Ltd
159/Protocol GA29102, Version 7

Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number [PHONE_16315]
Etrolizumab—F. Hoffmann-La [COMPANY_002] Ltd
160/Protocol GA29102, Version 7

Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2162Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
161/Protocol GA29102, Version 7Appendix 10
Quality  of Life in Inflammatory  Bow el Disease Questionnaire 
(IBDQ)
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2174Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
173/Protocol GA29102, Version 7Appendix 11
EuroQoL Five -Dimension Questionnaire (EQ- 5D)
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number [PHONE_16316]         
Health Questionnaire
   
(English versi
on for the US)
© 1998 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group
Etrolizumab—F. Hoffmann-La [COMPANY_002] Ltd
174/Protocol GA29102, Version 7
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number [ADDRESS_1074003] some problems washing or dressing myself q
I am unable to wash or dress myself q
Usual Activities (e.g. work, study, housework, family or
leisure activities)
I have no problems with performing my usual activities q
I have some problems with performing my usual activities q
I am unable to perform my usual activities q
Pain/Discomfort
I have no pain or discomfort q
I have moderate pain or discomfort q
I have extreme pain or discomfort q
Anxiety/Depression
I am not anxious or depressed q
I am moderately anxious or depressed q
I am extremely anxious or depressed q
© 1998 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group
Etrolizumab—F. Hoffmann-La [COMPANY_002] Ltd
175/Protocol GA29102, Version 7
Clinical Study Report: etrolizumab  - F. Hoffmann-La [COMPANY_002] Ltd
Protocol GA29102     Report Number 1099518 2178Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
177/Protocol GA29102, Version 7Appendix 12
Nancy Histological Index
Histologic activity on colon biopsies will be measured using the Nancy histological 
index (below).  Histologic remission is defined as a Nancy histological index of 0 1 
based on consensus guidelines recommending that histologic remission should be 
defined by [CONTACT_760539].
Nancy Histological Index (NHI)
Marker Assessment NHI Grade
Erosion or ulceration Present 4: Severely active disease
Acute inflammatory 
infiltrateModerate to severe 3: Moderately active disease
Mild 2: Mildly active disease
Chronic inflammatory 
infiltrateModerate or marked 
increase1: Chronic inflammatory infiltrate with no 
acute inflammatory infiltrate
No or mild increase 0: No histologically significant disease
Histologic remission: NHI 1
References
Marchal -Bressenot A, Salleron J, Boulagnon -Rombi C, et al. Development and 
validation of the Nancy histological index for UC. Gut 2017;66:43– 9.
Marchal -Bressenot A, Scherl A, Salleron J, et al. A practical guide to assess the Nancy 
histological index for UC. G ut 2016;65:1919 –20.